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Abstract  
 
The apoptotic pathway plays critical roles in regulating lymphocyte survival 
throughout B cell development, maturation and differentiation. The whole 
process involves clonal expansion. In the normal B lymphocyte population the 
majority of cells and their progenitors derived from each stage die from 
induction of apoptosis under specific mechanisms of control. Failure to do so 
can result in malignant transformation. This project focuses on apoptotic 
pathways and associated survival mechanisms in neoplasms of lymphoid 
provenance with an emphasis on B cell malignancies. The role of galectin-3, 
a molecule implicated in signal transduction and apoptotic pathways, has 
been investigated in both primary CLL cells and cell lines of human B lineage, 
using GCS-100, a novel galectin-3 antagonist. The potential interaction 
between galectin-3 and Bcl-2 and its contribution to cell death have been 
explored in depth. The role of NADPH oxidase and ROS in mitochondria has 
also been examined in the context of apoptosis. PK11195, a small pro-
apoptotic molecule, has been studied in relation to mitochondria-mediated 
apoptosis. The above investigations could contribute to a rationale for 
potential novel strategies in the treatment of B cell malignancies. 
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1.1 Malignancy and apoptosis 
 
Malignant growth is characterised by an increased number of cells often in a 
relatively immature state. This process is brought about by deregulated gene 
expression, the fundamental process by which normal tissue cells become 
neoplastic. By contrast to the hypothesis that a ‘direct hit’ somatic mutation 
leads to the initiation of carcinogenesis, Bignold proposes a non-mutational 
mechanism of genetic instability which involves inhibition of proof-reading 
enzymes by carcinogens in DNA synthesis during local stem cell division as 
the first step in tumour formation (Bignold, Coghlan et al. 2006; Bignold 
2003). Systematic ‘signature’ alterations of gene expression may be found for 
specific tumours. The loss of normal tissue homeostasis, which is a hallmark 
of malignancy, can fundamentally be caused by one or two processes acting 
alone or in concert, namely, deregulation of proliferation genes or disruption 
of apoptosis. Either or both result in increased cell numbers. Disrupted 
apoptosis is widely recognised as the main defect in indolent malignancies, 
e.g. certain types of chronic leukaemia (Caligaris-Cappio, Cignetti et al. 
2002). 
 
Malignant cells typically develop a survival advantage, in which the apoptotic 
cascade is blocked, thereby generating resistance to apoptosis-inducing 
therapies. A plethora of genetic and epigenetic modifications contribute to this 
outcome including translocated chromosomes, activated oncogenes or 
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mutated tumour-suppressor genes, leading to abnormal expression of 
transcription factors, receptors and signalling components. Externally, cells 
receive supportive signals from the extracellular environment which further 
serve as encouragement to proliferation and survival, all of which may 
contribute to oncogenic transformation. 
 
B-cell malignancies comprise a group of neoplasms that involve maturational 
arrest and/or immortalization at specific points of B-cell development. They 
are classified in terms of the developmental stage from which the malignant 
clone appears to derive. Accumulation of malignant B cells can occur in the 
bone marrow or periphery as a consequence of either a lack of apoptotic cell 
death or rapid division of a particular type of B-lineage cell.  
 
The apoptotic pathway plays critical roles in regulating lymphocyte survival 
throughout B-cell development, maturation and differentiation. Strict selection 
and clonal expansion are tightly regulated by homeostatic control. In normal 
lymphocytes the majority of lymphoid progenitors and lymphocytes derived 
from each stage die from induction of apoptosis. Failure to do so can result in 
B-cell malignancies. This thesis focuses on the modification of survival factors 
observed in B-cell malignancies with a view to identifying routes to 
therapeutic intervention based on an understanding of the survival process. 
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1.2 Apoptotic pathways 
 
Apoptosis is a Greek word meaning the falling of leaves from trees or petals 
from flowers in autumn. It is a complicated phenomenon. Over 40 years have 
passed since the process was first described. Kerr describes the discovery of 
the ‘shrinkage necrosis’ of liver cells which occurs after ligation of the portal 
vein branches in rats, a non-degenerative process of cell death that differs 
from typical necrosis in histological appearance (Kerr 2002). He noted that 
only isolated cells were affected and no inflammation accompanied cell death 
in 1962. However, the term “apoptosis” to connote this phenomenon was not 
widely accepted until the 1970s on publication of a landmark paper (Kerr, 
Wyllie et al. 1972). Since then, research in apoptosis has grown rapidly. 
Studying alterations in apoptotic pathways in cancer cells has provided more 
detailed mechanisms for cancer survival and immortalization, leading to new 
strategies for pharmacological intervention. 
 
Apoptosis is a vital, programmed, highly regulated and evolutionarily 
conserved process, which is common to physiological and pathological 
phenomena. A cell that dies by apoptosis ‘commits suicide’ in an ordered and 
controlled way. The cell goes through a series of events in which it is finally 
broken down by enzymes internally, to render small apoptotic particles that 
are removed by phagocytosis. Diverse pro-apoptotic stimuli activate signal-
specific pathways via two conventional apoptotic pathways: the ‘extrinsic’ 
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ATP-independent caspase-8 pathway and the ‘intrinsic’ ATP-dependent 
mithochondria/caspase-9 pathway (Ferrari, Stepczynska et al. 1998). 
However, as there is crosstalk between these two pathways at several points 
and many alternative pathways have been discovered, it is an 
oversimplification to frame apoptosis within this scenario alone (Figure 1.1). 
In addition, as apoptosis is such a complicated phenomenon, detailed review 
of the whole apoptotic pathway is beyond the scope of this thesis. Therefore 
the overview below is just a brief description of the relevant pathways, i.e. 
from receipt of the pro-apoptotic signal to caspase-3 activation. 
 
 
 
Figure 1.1 A diagrammatic representation of apoptotic pathways. Different stimuli 
activate signal-specific apoptotic pathways, including the death receptor-caspase-8 (extrinsic) 
and the mitochondria-caspase-9 (intrinsic) pathways (see 1.2.1 & 1.2.2), leading to the 
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activation of caspase-3 and subsequent DNA fragmentation. Arrows indicate activation, 
points indicate inhibition. 
 
 
1.2.1 TNF superfamily receptors – caspase 8 pathway 
 
Apoptosis can be induced through cell surface receptors that belong to the 
tumour necrosis factor (TNF) superfamily, e.g. Fas/CD95/Apo-1, TNF-related 
apoptosis-inducing ligand (TRAIL), death receptors (DR) and TNF receptors. 
As most of them share a homologous cytoplasmic sequence termed the 
death domain, they are sometimes designated as death receptors. This 
pathway mostly involves binding of cognate ligands/antibodies, receptor 
clustering, formation of death-inducing signalling complex (DISC) and 
subsequent activation of caspase-8 (Ferrari, Stepczynska et al. 1998). The 
negative regulator of this process is the FADD-like interleukin-1-converting 
enzyme (FLICE) inhibitory protein (FLIP) (Siegmund, Mauri et al. 2001) that 
resembles caspase-8, although it has no enzyme activity. 
 
Procaspase-8 exists in two isoforms (55/53 kD). Upon activation, it forms two 
intermediate products of 43/41 kD that are further cleaved into the 18/10 kD 
heterodimer (Ferrari, Stepczynska et al. 1998). Activated caspase-8 can relay 
the upstream signal in two ways: by cleavage of caspase-3 or by cleavage of 
Bid, a Bcl-2 family protein. The former is independent of mitochondria, 
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whereas the latter forms a link between the two conventional apoptotic 
pathways (Fehlberg, Gregel et al. 2003), namely intrinsic (caspase-9) and 
extrinsic (caspase-8) (Figure 1.1). Truncated Bid (tBid) translocates onto 
mitochondria upon cleavage, induces oligomerization of Bax and Bak (Wei, 
Zong et al. 2001) and mediates mitochondrial change and the subsequent 
apoptotic events (Luo, Budihardjo et al. 1998). 
 
 
1.2.2 Mitochondrial pathway 
 
Mitochondria play a pivotal role in apoptosis by acting as a sensor and an 
integrator to receive and amplify signals from diverse upstream signalling 
pathways. They also initiate downstream execution steps. The mitochondrion 
has a double-membrane structure, with an outer membrane permeable to 
solutes <1.5 kD (Degterev, Boyce et al. 2001; Narita, Shimizu et al. 1998), 
and an essentially impermeable inner membrane. Apoptogenic factors, e.g. 
cytochrome c, apoptosis inducing factor (AIF), endonuclease G (Endo G), 
second mitochondria-derived activator of caspase/direct inhibitor of 
apoptosis-binding protein with low PI (SMAC/DIABLO) and pro-caspases, are 
larger than 1.5 kD, and safely sequestered in the mitochondrial 
intermembrane space under normal conditions. The mitochondrial inner 
membrane potential (DeltaPsi(m)) is a voltage and pH gradient created by H+ 
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pumping during electron transfer, and is crucial for mitochondrial functions 
(Fennell and Cotter 2000).  
 
Whether mitochondria control cell death in a dominant (sensing damage and 
initiating death signals) or passive (receiving death signals and passing them 
on) way is still a question of debate (Cristea and Degli Esposti 2004). 
However, the majority of evidence points towards a dominant process 
(Jacobson and McCarthy 2002). 
 
 
1.2.2.a Permeability transition (PT) and DeltaPsi(m) dissipation 
 
The mitochondrial permeability transition (PT) is a critical early event in the 
apoptotic cascade. It is characterized as a Ca2+-dependent increase of the 
inner membrane permeability to molecules <1.5 kD (Beutner, Ruck et al. 
1998; Zamzami, Marchetti et al. 1996). Direct induction of PT is an effective 
trigger of apoptosis (Marchetti, Hirsch et al. 1996). PT is regulated by a 
multiprotein complex located at the contact site between the inner and outer 
mitochondrial membrane, termed the PT pore complex. It comprises the 
mitochondrial peripheral benzodiazepine receptor (mPBR), the voltage-
dependent anion channel (VDAC or porin) (Fennell and Cotter 2000; Hirsch, 
Decaudin et al. 1998), the adenine nucleotide translocator (ANT) (Fennell, 
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Corbo et al. 2001; McEnery, Snowman et al. 1992), cyclophilin D and two 
enzymes, hexo-kinase and creatine kinase (Figure 1.2). 
 
 
Figure 1.2 A diagramatic representation of the mitochondrial membrane, showing the 
putative structure of the PT pore complex. The 18 kD mitochondrial peripheral benzo-
diazepine receptor (PBR) localizes to the outer mitochondrial membrane in close association 
with the voltage-dependent anion channel (VDAC) and the adenine nucleotide translocator 
(ANT). Cyclophilin D is on the inner membrane or matrix-facing side (Zamzami, Larochette et 
al. 2005). 
 
The relationship between PT, DeltaPsi(m) dissipation and apoptosis, although 
not completely clear, is thought to follow the pattern of opening of PT pores, 
causing PT and then DeltaPsi(m) dissipation. The latter leads to an 
immediate shutdown of mitochondrial function, resulting in uncoupling of the 
respiratory chain and failure of ATP synthesis, as well as swelling of the 
mitochondrial matrix. Rupture of the outer membrane and release of 
apoptogenic factors then occur (Tang, Gao et al. 2005). Thus, agents that 
target components of the PT pore complex can interfere with the apoptotic 
Outer membrane 
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Intermembrane space 
Matrix 
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pathway. Bongkrekic acid, a specific ligand for ANT (Marchetti, Hirsch et al. 
1996), and cyclosporin A, an inhibitor of cyclophilin D (Zamzami, Marchetti et 
al. 1996; Zoratti and Szabo 1995), are both characteristic PT inhibitors 
(Narita, Shimizu et al. 1998) with the ability to prevent DeltaPsi(m) dissipation 
(Hirsch, Marzo et al. 1997; Zamzami, Marchetti et al. 1996) and apoptosis.  
 
As well as PT pore ligands, the gating of PT pore is regulated by the redox 
state of some critical vicinal thiols (Fennell and Cotter 2000), in particular, the 
thiol groups on ANT (Halestrap, McStay et al. 2002). Thiol-reactive agents 
that act on ANT can induce PT pore opening (Costantini, Belzacq et al. 
2000). 
 
Recent studies show that DeltaPsi(m) dissipation can be independent of PT. 
As one of the main functions of mitochondria is energy production, ATP 
synthesized in mitochondria and ADP generated in the cytosol need to be 
exchanged to maintain the energy chain. This exchange can be achieved by 
ANT (Martinou 1999), acting alone or together with VDAC, and any 
disturbance in this function may lead to failure of energy production and 
apoptosis (Murphy, Imahashi et al. 2005). Bcl-2 family proteins regulate the 
gating of VDAC and ANT, and the closure of VDAC is induced by Bax-like 
proteins (Lucken-Ardjomande and Martinou 2005). Closure of VDAC results 
in ATP/ADP exchange failure, cytoplasmic acidification, mitochondrial 
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hyperpolarization and DeltaPsi(m) collapse (Gottlob, Majewski et al. 2001). 
Thus, DeltaPsi(m) dissipation is not necessarily downstream of PT. 
 
 
1.2.2.b NADPH oxidase and ROS  
 
Reactive oxygen species (ROS) include superoxide anions, hydrogen 
peroxide, hypochlorite ions, hydroxyl radicals and peroxynitrite (Brandes and 
Janiszewski 2005; Richter, Gogvadze et al. 1995). They are unavoidable 
byproducts of cell respiration as well as an important weapon for killing 
microorganisms during the respiratory burst in phagocytes. They have also 
been implicated in several signal transduction pathways. ROS are produced 
initially by oxygen reduction using NADPH as an electron donor (Babior 
1999). The products, superoxide anions, are precursors of other ROS 
molecules. This reaction is catalysed by NADPH oxidase, the key enzyme in 
ROS generation. 
 
 
NADPH oxidase is a family of enzymes that were originally discovered in 
phagocytes, e.g. neutrophils and macrophages. They play important roles in 
host defence. These enzymes are divided into phagocytic and non-
phagocytic types. They are structurally and functionally homologous, but have 
NADPH oxidase 
2O2 + NADPH  2O2- + NADP+ + H+ 
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different biological distribution. Phagocytic NADPH oxidase comprises three 
groups of components (De Deken, Wang et al. 2000). 
 
i) gp91phox and p22phox transmembrane heterodimer with four NADPH-
binding sites, one FAD and two haems, all together known as cytochrome 
b558, located at the organelle membrane (Banfi, Molnar et al. 2001). 
ii) p40phox, p47phox and p67phox forming a cytosolic trimer complex. 
iii) Two G-proteins: membrane-associated Rap-1A and cytosolic Rac-2. 
 
Upon activation, p47phox is phosphorylated and the trimer complex, together 
with Rac-2, migrate through the cytosol towards the membrane-bound 
cytochrome b558 and Rap-1A to assemble active NADPH oxidase. This 
enables the catalysis of oxygen reduction, the electron transfer reaction, 
generation of superoxide anions and other ROS molecules (Babior 1999). 
 
The major biological process leading to ROS generation is electron transport 
at the mitochondrial membrane. Mitochondria actively and continuously 
generate ROS during cell respiration (Chandra, Samali et al. 2000). These 
molecules are biologically toxic and may damage vital macromolecules such 
as nucleic acids, proteins, carbohydrates and lipids. The principal defences 
against this are the natural antioxidant systems of the cell. Among these 
systems, the glutathione redox cycle is the most rapid and abundant weapon 
against ROS. In mitochondria, H2O2 is converted to H2O, at the expense of 
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GSH oxidation to its disulfide type, GSSG, by the catalysis of glutathione 
peroxidase (Fennell, Corbo et al. 2001). 
 
NADPH oxidase is involved in apoptosis as ROS have been implicated in 
apoptotic pathways. The redox state of the mitochondrial NADPH pool is 
found to be associated with PT (Zoratti and Szabo 1995). Intracellular ROS 
generation has been detected and monitored as an index of apoptotic events. 
A biphasic increase of intracellular ROS has been observed following 
apoptosis induction by mPBR ligands, i.e. an early sharp peak followed by a 
secondary, more sustained increase (Blatt, Bednarski et al. 2002). The late 
increase is accompanied by DeltaPsi(m) collapse and the release of 
cytochrome c, indicating that ROS are implicated in the mitochondrial 
apoptotic pathway. Other evidence suggests that ROS may act as mediators 
of growth factor signal transduction (Finkel 2000). In addition, activation of 
NADPH oxidase can be induced by many pro-apoptotic drugs, e.g. capsaicin 
(Lee, Kang et al. 2004), salicylates (Chung, Bae et al. 2003) and tamoxifen 
(Lee, Kang et al. 2000), indicating that ROS production can be a common 
mechanism of apoptosis. NADPH oxidase has also been activated by H2O2 in 
non-phagocytic cell types,  suggesting the existence of a positive feedback 
loop in ROS production (Li, Miller et al. 2001). 
 
Following the discovery of a variety of non-phagocytic NADPH oxidases with 
different tissue distribution, it has become clear that ROS generation is an 
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ubiquitous, rather than phagocyte-specific, physiological phenomenon. As all 
these enzymes have the homologous catalytic subunit, gp91phox, and share 
the conserved core structure, i.e. six transmembrane domains and a long 
cytoplasmic C terminus (Banfi, Tirone et al. 2004), they are termed the Nox 
family, including Nox and dual domain oxidases (DUOX). Nox-5 is a member 
of the Nox family, and is expressed in lymphoid tissues and testis. Nox-5 has 
an additional N-terminal extension with Ca2+-binding EF-hand domains 
(Krause 2004) and therefore is activated and catalyses generation of 
superoxide anions in response to elevated cytosolic Ca2+ (Banfi, Molnar et al. 
2001). During phagocytosis, NADPH oxidase assembles the cytosolic and 
membrane-bound subunits necessary for its activation. It appears that the 
regulatory and catalytic modules of Nox-5 are combined within one protein. 
The N-terminal part of Nox-5 acts as an intracellular [Ca2+] sensor and 
undergoes conformational changes upon Ca2+-binding. This results in 
activation of Nox-5 and subsequent catalysis of ROS generation (Banfi, 
Tirone et al. 2004). 
 
 
1.2.2.c Apoptogenic factor release 
 
It is understood that DeltaPsi(m) dissipation leads to mitochondrial 
dysfunction, resulting in uncoupling of the respiratory chain. ATP synthesis 
fails and all the other ion pumps shut down resulting in swelling of 
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mitochondrial matrix, rupture of the outer mitochondrial membrane and 
release of apoptogenic factors, e.g. cytochrome c and apoptosis-inducing 
factor (AIF). These factors either activate caspases and nucleases directly or 
neutralise cytosolic inhibitors of the apoptotic process.  
 
However, these observations cannot explain the fact that in some apoptotic 
cells mitochondria do not manifest any major ultrastructural abnormalities 
(Martinou 1999). Furthermore, it has been reported that apoptogenic factors, 
e.g. cytochrome c, can be released before DeltaPsi(m) collapse (Yang, Liu et 
al. 1997), or be unaccompanied by DeltaPsi(m) changes (Kluck, Bossy-
Wetzel et al. 1997). More recently the focus has moved to outer mitochondrial 
membrane permeabilization, a process that can be independent of 
DeltaPsi(m) collapse. The new proposal is that the outer membrane 
permeability transition is more important and happens earlier than the inner 
membrane potential changes, as the latter is a late event that also occurs in 
necrotic cell death (Cristea and Degli Esposti 2004). One possible 
mechanism is that pro-apoptotic Bcl-2 proteins, e.g. Bax or Bak, form large 
conductance pores, either alone or in combination with VDAC, at the outer 
mitochondrial membrane and mediate the release of apoptogenic factors. 
This can be blocked by Bcl-2 via its interaction with either Bax/Bak or VDAC 
(Halestrap, McStay et al. 2002; Lucken-Ardjomande and Martinou 2005; 
Murphy, Imahashi et al. 2005; Wang 2001). 
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Cytochrome c is a key component of the electron transport chain (Murphy, 
Imahashi et al. 2005) and normally resides in the intermembrane space of 
mitochondria. Release into the cytoplasm occurs during apoptosis. Cytosolic 
cytochrome c interacts with apoptotic protease-activating factor 1 (Apaf-1) 
and deoxyadenosine triphosphate (dATP), leading to conformational change 
in Apaf-1 and the exposure of its caspase recruitment domain (CARD) 
(Ferrari, Stepczynska et al. 1998). Caspase-9, having its own CARD at the N-
terminal, binds to it and becomes autoproteolytically cleaved and activated. 
Caspase-9 in turn cleaves and activates caspase-3, the main executioner of 
apoptosis.  
 
Apoptosis-inducing factor (AIF) is a flavoprotein that has oxidoreductase 
activity, an important function in cell respiration when sequestered in the 
mitochondrial intermembrane space. Once released to the cytosol, AIF 
translocates to the nucleus and activates endonucleases, inducing large 
scale DNA fragmentation (Reed 2001). The effect of AIF is independent of 
caspase activation (Tsujimoto 2002; Wang 2001), although it can also 
activate caspase-3 (Kroemer, Dallaporta et al. 1998). AIF can bind to DNA 
and RNA (Vahsen, Cande et al. 2005), but does not have DNase activity 
(Kroemer, Dallaporta et al. 1998).  
 
Second mitochondria-derived activator of caspase/direct inhibitor of 
apoptosis-binding protein with low PI (SMAC/DIABLO) is also released from 
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the mitochondrial intermembrane space to the cytosol where it binds 
inhibitors of apoptosis (IAPs), a group of cytosolic apoptosis inhibitors that 
can inactivate caspases. Inhibition of IAPs by SMAC/DIABLO promotes 
apoptosis (Wang 2001). 
 
Endonuclease G (Endo G) is another apoptogenic factor released in the 
cytosol during apoptosis. Like AIF, it causes DNA fragmentation (apoptosis) 
independent of caspases. Unlike AIF, it acts directly as a nuclease (Wang 
2001). 
 
 
1.2.3 Final common pathway  
 
The two pathways, death receptor–caspase-8 (extrinsic) and mitochondria–
caspase-9 (intrinsic) pathways, are not independent of each other. There are 
cells that mainly follow the death receptor-caspase-8 pathway in response to 
certain stimuli which leads to cell death with minimal involvement of 
mitochondria. They are termed Type I cells. By contrast, cells that need the 
mitochondrial amplification loop to respond to death signals are termed Type 
II cells (Scorrano, Oakes et al. 2003). Both types converge at the caspase-3 
point to induce the final stage of apoptosis (Figure 1.3). 
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Apart from AIF and Endo G, etc, the apoptotic pathways converge on a group 
of caspases that perform the final stage of apoptosis and cause the typical 
apoptotic morphological changes, e.g. cell shrinkage, membrane blebbing, 
exposure of phosphatidylserine, chromatin condensation, DNA fragmentation 
and apoptotic body formation. Caspases are synthesized as inactive pro-
enzymes and become activated upon autoproteolysis or cleavage by other 
caspases at aspartate residues (Ferrari, Stepczynska et al. 1998). There are 
more than 280 types of known caspase substrates (Fischer, Janicke et al. 
2003). Caspase-3 is considered to be the key executioner of apoptosis due to 
its ability to cleave a wide range of vital intracellular substrates including the 
DNA repair enzyme poly(ADP-ribose) polymerase (PARP), actin-regulatory 
protein gelsolin, structural protein fodrin, actin and nuclear lamin (Hajra and 
Liu 2004; Janicke, Ng et al. 1998), and the DNA-dependent protein kinase 
catalytic subunit (Porter and Janicke 1999). Caspase-3 also cleaves the 
inhibitory binding partner of DNA fragmentation factor (DFF), DFF45/ICAD, to 
release the active caspase-activated DNase (CAD) and DFF40/CAD 
endonuclease (Springer, Azbill et al. 1999). Furthermore, Bcl-2 family 
proteins, e.g. Bcl-2, Bcl-xl and Mcl-1 (Weng, Li et al. 2005) are also targets 
for caspase-3 (Fujita, Nagahashi et al. 1998; Fujita and Tsuruo 1998). 
Cleavage of Bcl-2 converts its anti-apoptotic effect to pro-apoptotic and 
amplifies upstream mitochondrial signals by facilitating the release of 
cytochrome c, forming a positive signal loop and hastening the apoptotic 
process (Porter and Janicke 1999). As caspase-3 can be activated via 
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mitochondria-independent signals, Bcl-2 cleavage may activate the 
mitochondrial pathway downstream of caspase-3 activation and form another 
link between these two apoptotic pathways besides Bid. Caspase-3 activity is 
also required for the activation of caspase-8, as knock-out of the caspase-3 
gene causes inhibition of caspase-8 activity (Aouad, Cohen et al. 2004). The 
effect of caspase-3 on Bcl-2 proteins and caspase-8 suggests the existence 
and importance of the mitochondrial amplification loop in apoptosis, i.e. pro-
apoptotic signals after mitochondria-caspase-9-caspase-3 can further feed 
back and amplify the process (Figure 1.3). 
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Figure 1.3  A diagramatic representation of the crosstalk between apoptotic pathways 
and the mitochondrial amplification loop. Caspase-3, activated by caspase-8 and/or 
caspase-9, can directly or indirectly act on Bcl-2 proteins and thus form links between the two 
pathways (see 1.2.3). 
 
 
1.3 Resistance to apoptosis in tumour cells 
 
Resistance to apoptosis is a crucial survival mechanism in tumour cells 
achieved by either downregulation of pro-apoptotic or upregulation of anti-
apoptotic signals. The latter include elevated expression of negative 
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regulators of apoptosis, including Bcl-2, galectin-3 and Akt, the primary topics 
of this investigation. 
 
 
1.3.1 Bcl-2 family proteins 
 
Bcl-2 (B-cell leukaemia/lymphoma gene 2), a critical survival protein, was first 
discovered following the cloning of the t(14:18) chromosomal translocation 
found in 85% of follicular B-cell lymphoma (Tsujimoto 2002). This places the 
immunoglobulin gene enhancer on chromosome 14 alongside the complete 
protein coding region of Bcl-2 on chromosome 18. Thus, the enhancer 
switches on Bcl-2 expression in B-cells, leading to development of lymphoma 
(Kitada, Pedersen et al. 2002). Regulation of Bcl-2 family proteins can be 
obtained by increased synthesis, increased degradation and phosphorylation. 
Following the discovery of other Bcl-2 members, it becomes clear that this is 
a large family of proteins that regulate cell death and cause drug resistance.  
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1.3.1.a Structure of Bcl-2 proteins 
 
Two main structural homologies have been found in Bcl-2 proteins (Figure 
1.4).  
 
i) Bcl-2 homology (BH) domains. These include BH1, BH2, BH3 and BH4 
domains. Both BH1 and BH2 domains are critical for the anti-apoptotic 
function and dimerisation (Yin, Oltvai et al. 1994), in particular the NWGR 
motif in the BH1 domain. BH4 is conserved among anti-apoptotic but not 
pro-apoptotic members with the exception of Bcl-xs and Mcl-1 (Day, Chen 
et al. 2005; Kroemer 1997).  
ii) Transmembrane domain (TM). This is the C-terminal hydrophobic tail that 
is responsible for insertion into intracellular membrane structures, e.g. 
mitochondrial, nuclear and endoplasmic reticulum membranes (Hanada, 
Aime-Sempe et al. 1995).  
 
Bcl-2 family proteins are mainly classified into three sub-families (Figure 1.4), 
based on their structures as well as functions. 
 
i) Bcl-2-like sub-family, e.g. Bcl-2, Bcl-xl, Bcl-w, etc. They share BH1, BH2, 
BH3, BH4 and TM, and are anti-apoptotic. 
ii) Bax-like sub-family, e.g. Bax, Bak, etc. They are pro-apoptotic and share 
BH1, BH2, BH3 and TM, but not necessarily BH4. 
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iii) BH3-only sub-family. They all share BH3 and are pro-apoptotic. Apart from 
BH3, Bik and Bim possess TM, whereas Bid, Bad and Puma do not (Cory, 
Huang et al. 2003; Hutcheson, Scatizzi et al. 2005; Kroemer 1997).  
 
 
Figure 1.4 A diagramatic comparison of the structure of Bcl-2 proteins and galectin-3. 
The BH1 domain shared by Bcl-2-like and Bax-like proteins contains the NWGR motif which 
is also found in the CBD domain of galectin-3 (see 1.3.2 for detailed description). BH, Bcl-2 
homology domain; CBD, carbohydrate-binding domain; TM, transmembrane domain. 
 
There are exceptions to these broad groupings. Bcl-xs is the alternative 
splicing product of bcl-xl gene. It is pro-apoptotic and has only BH3, BH4 and 
TM (Lindenboim, Yuan et al. 2000). Mcl-1 lacks the N-terminal BH4 domain 
(Day, Chen et al. 2005) but is anti-apoptotic.  
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The BH3 domain of pro-apoptotic members, e.g. Bax, Bak, and Bid, is 
normally inactive and folded into the molecule. To become active and to 
heteroligomerize with other Bcl-2 proteins, the N-terminal part around the 
BH3 domain needs to be exposed by either conformational change, e.g. Bax 
and Bak (Griffiths, Dubrez et al. 1999), or N-terminal truncation by caspase-8 
in the case of Bid (Tsujimoto 2002).  
 
Bax is mainly phosphorylated and inactive in healthy cells, forming monomers 
or heterodimers with anti-apoptotic Bcl-2 members, e.g. Bcl-xl, Bcl-2 and Mcl-
1. Akt is thought to be involved in direct phosphorylation of Bax and thus 
keeps Bax inactive (Gardai, Hildeman et al. 2004). Bax is dephosphorylated 
in response to upstream pro-apoptotic signals and undergoes conformational 
changes, i.e. exposure of the N-terminal part and release of the C-terminal 
tail, to become activated (Lucken-Ardjomande and Martinou 2005). Activated 
Bax loses its ability to heteroligomerize and translocates from cytosol to 
mitochondria (Wolter, Hsu et al. 1997) to exert its function.  
 
 
 
 
 
 
                                                                                   Bo Su, 2010. Chapter 1: Introduction 
 
- 44 -
1.3.1.b Function of Bcl-2 proteins 
 
Bcl-2 family proteins predominantly control the fate, i.e. life or death, of a cell. 
Their pro-apoptotic and anti-apoptotic members act independently, syner-
gistically, counter-actively or via interaction with other family molecules. In 
transgenic animal models, Bax promotes apoptosis in Bcl-2-null mice, 
whereas Bcl-2 represses apoptosis in Bax-null mice, suggesting that Bcl-2 
and Bax can act independently (Knudson and Korsmeyer 1997). However, 
the intricate mechanisms for their function are largely unknown. It has been 
hypothesized that Bcl-2 proteins form pores on lipid membrane and interfere 
with ion exchange across intracellular membrane, thus stabilising the PT pore 
and preventing DeltaPsi(m) collapse with subsequent release of apoptogenic 
factors. 
 
i) Pore-forming 
 
The discovery of the structural similarities between some Bcl-2 members, 
bacterial colicins and diphteria toxin leads to the investigation of their pore-
forming function (Lucken-Ardjomande and Martinou 2005). Bcl-2 (Schendel, 
Xie et al. 1997), Bcl-x (Minn, Velez et al. 1997), Bax (Antonsson, Conti et al. 
1997) and Bid (Tsujimoto and Shimizu 2000) can form pore structures in a 
synthetic lipid membrane. These pore structures have different properties. 
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The pore-forming activity of Bax is inhibited by Bcl-2 at physiological pH 
(Antonsson, Conti et al. 1997). 
 
It appears that Bax/Bak as well as other Bcl-2 members can translocate to 
the outer mitochondrial membrane and form pore structures, directly 
mediating the release of apoptogenic factors (see 1.2.2.c). However, this 
theory has been challenged due to the finding that Bax/Bak alone cannot 
induce cytochrome c release from artificial liposomes or isolated 
mitochondria, and the existence of VDAC is necessary for this process 
(Shimizu, Narita et al. 1999).  
 
ii) Interference with mitochondrial ion exchange, PT, DeltaPsi(m) and 
apoptogenic factor release 
 
Bcl-2 resides at the outer mitochondrial membrane (also other organelle 
membranes) and regulates the ion exchange across the membrane (Hajra 
and Liu 2004). It increases the mitochondrial matrix volume and its ability to 
take up cytosolic Ca2+ (Murphy, Imahashi et al. 2005). Thus Bcl-2 plays a 
crucial role in the control of intracellular Ca2+ homeostasis (Burlacu 2003). 
 
Recombinant Bax induces PT and cytochrome c release from isolated 
mitochondria, possibly by direct interaction with the PT pore,  which can be 
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inhibited by exogenous Bcl-xl, Bcl-2 and cyclosporin A (Gardai, Hildeman et 
al. 2004; Jurgensmeier, Xie et al. 1998; Narita, Shimizu et al. 1998).  
 
Although the pathway is not fully elucidated for events downstream of Bcl-2 
inhibition of PT, e.g. the release of cytochrome c (Kluck, Bossy-Wetzel et al. 
1997) and AIF (Susin, Zamzami et al. 1996), it is thought that Bcl-2 (and Bcl-
xl) interacts with the PT pore complex and stabilises it (Marzo, Brenner et al. 
1998). As stated in 1.2.2.a, it is hypothesized that the closure of VDAC, 
induced by pro-apoptotic signals, plays important roles in apoptosis. Bcl-2 
interacts with VDAC to keep it in the open state (Murphy, Imahashi et al. 
2005), whereas Bax-like proteins promote its closure (Lucken-Ardjomande 
and Martinou 2005).  
 
The role of anti- and pro-apoptotic proteins on VDAC is, however, 
contradictory. Bcl-xl, the anti-apoptotic protein, also closes VDAC (essentially 
the opposite effect to Bax). Possibly the role of these molecules on ANT or 
the ANT state at the time of VDAC closure is the important factor (see Figure 
1.2). Greater clarification will be required to determine the full effect of these 
molecules on cytochrome c release.  
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iii) Interactions between Bcl-2 members  
 
The ratio between the anti-apoptotic and pro-apoptotic Bcl-2 family members 
is crucial for the susceptibility of a cell to apoptosis. This “death-life rheostat” 
is mediated, at least in part, by competitive oligomerization between 
antagonists and agonists of apoptosis. One of the classical examples is the 
Bcl-2/Bax heteroligomers (Zhang, Lapolla et al. 2004). When Bcl-2 is in 
excess, Bcl-2 homoligomers dominate and cells are protected from apoptosis. 
When Bax is in excess, Bax homoligomers dominate and cells are 
susceptible to apoptosis. The balance between activated Bax-like proteins 
(forming oligomers at the outer mitochondrial membrane) and inhibitory Bcl-2-
like proteins (stabilising mitochondrial membrane) decides the release of 
apoptogenic factors such as cytochrome c (Zhang, Lapolla et al. 2004).  
 
One of the recent models of how Bcl-2 proteins regulate apoptosis proposes 
that pro-apoptotic signals activate BH3-only proteins, e.g. Bid, which 
translocate to mitochondria and either activate Bax-like proteins directly or 
interact with anti-apoptotic Bcl-2 proteins, e.g. Bcl-xl or Bcl-2. The latter action 
frees Bax-like proteins from heteroligomerizing with Bcl-2/Bcl-xl and leads to 
homoligomerization of Bax/Bak and permeabilization of the outer 
mitochondrial membrane (Hajra and Liu 2004; Li, Zhu et al. 1998; Wei, Zong 
et al. 2001; Zhang, Lapolla et al. 2004). This is not necessarily accompanied 
by DeltaPsi(m) disruption (Katoh, Tomimori et al. 2004). 
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1.3.2 Galectin-3 
 
Lectins, or glycoproteins, are carbohydrate-binding proteins, excluding 
enzymes and antibodies, which have a C-terminal carbohydrate-binding 
domain (Nangia-Makker, Conklin et al. 2002) and an affinity for specific 
oligosaccharides (Krzeslak and Lipinska 2004). The most widely expressed 
family of lectins are galectins (galactoside-binding lectins) with a specific 
affinity for beta-galactosides. Galectin-3  is a member of the galectin family. 
 
 
1.3.2.a Structure of galectin-3  
 
The N-terminal part of galectin-3 has a repetitive sequence of 100-150 amino 
acids rich in proline, glycine and/or tyrosine (Figure 1.4) (Krzeslak and 
Lipinska 2004), and the length of the repeats is species-dependent (Barboni, 
Bawumia et al. 2000; Gong, Honjo et al. 1999; Herrmann, Turck et al. 1993; 
Morris, Ahmad et al. 2004). It contains collagenase-cleavage sites (Hsu, 
Zuberi et al. 1992) and serves as a substrate for matrix metalloproteinases 
(Yoshii, Fukumori et al. 2002).  
 
The C-terminal part of galectin-3 has a globular structure and contains the 
carbohydrate-binding domain (Gong, Honjo et al. 1999). The highly-
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conserved NWGR motif, also shared with Bcl-2 family proteins as part of the 
BH1 domain, is found within the carbohydrate-binding domain (Figure 1.4) 
(Akahani, Nangia-Makker et al. 1997). This motif is crucial for its anti-
apoptotic effect, as substitution of glycine within the motif by alanine 
abrogates its anti-apoptotic effect against genistein (Lin, Moon et al. 2000).  
This is reminiscent of the abolition of the anti-apoptotic effect of Bcl-2 by 
substitution of glycine, the same amino acid  within the same motif (Yin, 
Oltvai et al. 1994). 
 
Several research groups have been trying to distinguish the function of N-
terminal and C-terminal parts using truncated galectin-3. It was found that 
galectin-3-C, with its N-terminal part truncated, has similar affinity for lactose 
and other types of saccharide to intact galectin-3 (Hsu, Zuberi et al. 1992). 
Transfection of galectin-3-positive PEL cells with the N-terminal truncated 
galectin-3 resulted in increased sensitivity to anti-Fas-induced apoptosis 
(Hoyer, Pang et al. 2004). 
 
Galectin-3 shows the ability to form homodimers (Barboni, Bawumia et al. 
2000; Kuklinski and Probstmeier 1998; Yang, Hill et al. 1998). Electron 
microscopy shows that, at a certain concentration, recombinant galectin-3 
exists mostly in a Y-shaped dimer form (Ochieng, Platt et al. 1993).  
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Galectin-3 is post-translationally modified by Met-1 cleavage and Ala-2 
acetylation (Herrmann, Turck et al. 1993). The first twelve amino acids 
contain phosphorylation sites, e.g. Ser6 and Ser12, and are involved in 
cellular compartmentalization (Gong, Honjo et al. 1999). The Ser6 site can be 
phosphorylated by casein kinase ? (Huflejt, Turck et al. 1993), which is 
believed to be an ‘on/off’ switch for some of its important functions, e.g. 
carbohydrate-binding capability (Mazurek, Conklin et al. 2000; Nangia-
Makker, Conklin et al. 2002), exportation from the nucleus to the cytoplasm 
(Takenaka, Fukumori et al. 2004) and anti-apoptotic effect (Yoshii, Fukumori 
et al. 2002). Galectin-3 can also be phosphorylated by glycogen synthase 
kinase-3ß, similar to beta-catenin, and is implicated in the Wnt/beta-catenin 
signalling pathway (Shimura, Takenaka et al. 2005). 
 
 
1.3.2.b Intracellular and extracellular distribution and trafficking 
 
Galectin-3 is synthesized on free ribosomes and mainly found in the 
cytoplasm in its phosphorylated form as a result of its N-acetylation, a marker 
for cytoplasmic proteins (Gong, Honjo et al. 1999; Krzeslak and Lipinska 
2004; Mehul and Hughes 1997). Galectin-3 is also found on the cell surface, 
in the nucleus and extracellular matrix, depending on cell type, cell cycle and 
external stimulus. Phosphorylated galectin-3 is found in both cytosol and 
nucleus, whereas its non-phosphorylated form exists exclusively in the 
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nucleus (Dagher, Wang et al. 1995; Gong, Honjo et al. 1999). Galectin-3 in 
proliferating 3T3 mouse fibroblasts is predominantly localized in the nucleus, 
whereas in quiescent cells it is primarily found in the cytoplasm (Moutsatsos, 
Wade et al. 1987).  
 
It has been reported that galectin-3 translocates to the perinuclear 
mitochondrial membrane following pro-apoptotic stimulation (Yu, Finley et al. 
2002). Galectin-3 is also secreted in vesicles into the extracellular matrix (Zhu 
and Ochieng 2001) via a non-classical export pathway independent of the ER 
and Golgi system, as it lacks the signal sequence for translocation to the ER 
(Hughes 1999; Krzeslak and Lipinska 2004; Mehul and Hughes 1997; Menon 
and Hughes 1999). The trafficking of galectin-3 from free ribosomes to the 
plasma membrane is thought to be the rate-limiting step in its secretion 
(Mehul and Hughes 1997). The first twelve amino acids are crucial for the 
secretion as truncated galectin-3 without this N-terminal part cannot be 
secreted (Gong, Honjo et al. 1999).  
 
 
1.3.2.c Function of galectin-3  
 
Galectin-3 is a multi-functional protein involved in a wide range of cell 
behaviour, but this study has focused on its apoptosis-related functions.  
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Galectin-3 has affinities for a variety of molecules of varied sizes and 
functions. Galectin-3 has an affinity for beta-galactoside-containing sugar 
molecules or glycoconjugates, and acts as a receptor for ligands with sugar 
moieties, e.g. asialofetuin, lactose and N-acetyllactosamine (Castronovo, Van 
Den Brule et al. 1996; Krzeslak and Lipinska 2004). Initially galectin-3 was 
termed IgE-binding protein, suggesting its affinity for IgE (Hsu, Zuberi et al. 
1992).  Some complex carbohydrates, e.g. modified citrus pectin, can bind 
galectin-3 and interfere with its functions (Nangia-Makker, Conklin et al. 
2002). Galectin-3 binds to extracellular matrix molecules such as laminin 
(Castronovo, Van Den Brule et al. 1996; Ochieng, Furtak et al. 2004) and 
fibronectin (Ortega, Behonick et al. 2005). Galectin-3 also binds single-
stranded DNA and RNA with higher affinity than for carbohydrate (Wang, 
Inohara et al. 1995).  
 
Galectin-3 has an anti-apoptotic function. Galectin-3 overexpression shows 
protection in Jurkat T cells against anti-Fas- and stauroporine-induced 
apoptosis (Yang, Hsu et al. 1996) and in breast cancer cell lines against 
genistein- and nitric-oxide-induced apoptosis (Lin, Moon et al. 2000). 
Galectin-3 transfected breast cancer cells show resistance to ROS generation 
and mitochondrial membrane potential collapse induced by TNF-alpha and 
menadione (Matarrese, Tinari et al. 2000). High levels of galectin-3 
expression have been found in B cell malignancies such as diffuse large B-
cell lymphoma (DLBCL), primary effusion lymphoma (PEL) and multiple 
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myeloma (MM) (Hoyer, Pang et al. 2004). Transfection of galectin-3 in 
galectin-3-negative Burkitt lymphoma (BL) cells results in increased 
resistance to anti-Fas-induced apoptosis (Hoyer, Pang et al. 2004). In normal 
B-cell development, galectin-3 expression is low in germinal centre B cells 
and plasma B cells, but high in long-lived  B cells, e.g. memory B cells 
(Hoyer, Pang et al. 2004), suggesting a protective advantage associated with 
galectin-3 levels in B cells. Galectin-3 serum levels are significantly elevated 
in patients with breast, gastrointestinal, lung and ovarian cancer, as well as 
melanoma and non-Hodgkin’s lymphoma (NHL) (Iurisci, Tinari et al. 2000).  
 
How galectin-3 exerts its anti-apoptotic effect is unclear, but its role in the 
PI3K/Akt pathway may explain some of its action. Galectin-3 promotes strong 
activation of PI3K/Akt pathway in bladder carcinoma cells (Oka, Nakahara et 
al. 2005), and the expression of galectin-3 appears to be regulated by the NF-
(kappa)B pathway (Dumic, Lauc et al. 2000; Nakahara, Oka et al. 2005). 
Galectin-3 is implicated in the canonical Wnt signalling pathway. Activation of 
Wnt signalling results in dephosphorylation of beta-catenin and protection 
from its subsequent ubiquitination and degradation. beta-catenin enters the 
nucleus where it binds transcription factors and regulates Wnt-target genes 
such as c-myc and cyclin D1. This process appears to be galectin-3-
dependent, and structurally beta-catenin/galectin-3/transcription-factors 
together form one complex in the nucleus (Shimura, Takenaka et al. 2004). 
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However, galectin-3 can be pro-apoptotic. Many haematopoietic tumour cells 
do not express high levels of galectin-3. Galectin-3 expression is down-
regulated in prostate cancer (Pacis, Pilat et al. 2000). Downregulation of 
galectin-3 has also been observed in relation to progression and invasiveness 
of breast cancer (Castronovo, Van Den Brule et al. 1996). There has been 
increasing evidence that galectin-3 plays different or even opposite roles 
intracellularly and extracellularly. Exogenous galectin-3 induces T cell line 
apoptosis via cell surface CD29/CD7 and the mitochondrial apoptotic 
pathways (Fukumori, Takenaka et al. 2003). This implies a role of galectin-3 
in immune escape (Nakahara, Oka et al. 2005). It is known that many types 
of tumour cells export galectin-3 extracellularly which correlates with the high 
serum level of galectin-3 in breast cancer (Iurisci, Tinari et al. 2000). Galectin-
3-null cells seem to be more sentitive to exogenous galectin-3 than galectin-
3-expressing cells, and there may be a balance between its intracellular anti-
apoptotic effect and extracellular pro-apoptotic effect (Nakahara, Oka et al. 
2005). The effect of galectin-3 on TRAIL-induced apoptosis has been 
controversial, as in bladder carcinoma cells it renders resistance to TRAIL-
induced apoptosis (Oka, Nakahara et al. 2005), whereas in breast cancer 
cells it sensitises them to TRAIL (Lee, Song et al. 2003). 
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1.3.3 Akt and NF-?B 
 
 
 
Figure 1.5 Simplified diagrammatic representation of the PI3K/Akt pathway. Specific 
receptors on the cell membrane receive signals and lead to the activation of PI3K, which 
phosphorylates PIP2 and produces PIP3. PIP3 recruits and activates PDK1, which in turn 
phosphorylates and activates Akt. Akt is a protein kinase involved in a number of 
downstream signalling pathways, including IKK (NF-(kappa)B pathway), Bad (Bcl-2 family 
proteins), caspase-9 pathway, FKHR transcription factors and mTOR. IKK, I(kappa)B 
(inhibitor of NF-(kappa)B) kinase; FKHR, Forkhead (Drosophila) homolog 1 
(rhabdomyosarcoma); PIP2, phosphatidylinositol bisphosphate; PIP3, phosphatidylinositol-
3,4,5-trisphosphate; PTEN, phosphatase and tensin homolog deleted on chromosome ten; 
PI3K, phosphoinositide 3-kinase; PDK1, phosphoinositide-dependent kinase 1; mTOR, 
mammalian target of rapamycin. 
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The PI-3K/Akt pathway (Figure 1.5) is one of the most important signalling 
pathways that regulate cell survival. Akt, also known as protein kinase B, is a 
serine/threonine protein kinase and another major determinant of cell survival 
(Datta, Dudek et al. 1997). Constitutive activation and hyperactivity of Akt 
have been found in many human tumour types (Kitada, Pedersen et al. 2002; 
Nicholson and Anderson 2002). Overexpression of activated Akt in primary 
non-small cell lung cancer (NSCLC) cells is correlated with poor prognosis 
(David, Jett et al. 2004). Elevated levels of Akt activation can also be an 
independent biomarker for biomedical recurrence of prostate cancer (Ayala, 
Thompson et al. 2004). Inhibition of Akt activity induces apoptosis in human 
cell lines that overexpress its activated form (Yang, Dan et al. 2004).  
 
Growth factors signal through the PI-3K/Akt pathway to promote cell survival. 
PI3K is activated via tyrosine kinase and G-protein-coupled receptors, 
generating phospholipids PIP3, secondary messengers for downstream 
signals. Akt binds PIP3 via its pleckstrin homology (PH) domain and 
translocates from cytoplasm to the inner face of the plasma membrane 
(Datta, Brunet et al. 1999; Oka, Nakahara et al. 2005) to become 
phosphorylated by phosphoinositide-dependent kinase 1 (PDK1) and thus 
activated (Kennedy, Kandel et al. 1999; Nicholson and Anderson 2002). 
PTEN and SHIP are lipid phosphatases that dephosphorylate PIP3 at 
different sites and act as negative regulators of the PI3K/Akt pathway (Datta, 
Brunet et al. 1999; Nicholson and Anderson 2002). Mutations and defective 
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function of PTEN are found in NHL and MM (Kitada, Pedersen et al. 2002). 
Enhanced PI3K signalling or impaired PTEN activity leads to enhanced 
activation of Akt and promotes cell survival (Jones, Saibil et al. 2005). 
 
Activated Akt dissociates from the membrane and regulates a variety of cell 
signalling pathways by phosphorylation. It can also enter the nucleus where it 
phosphorylates nuclear proteins (Lawlor and Alessi 2001). At least five major 
pathways have been suggested through which Akt may prevent apoptosis. 
 
i) One of the first and best known substrates of Akt is Bad, the pro-apoptotic 
member of Bcl-2 family. Bad has no mitochondria-targeting sequence and 
translocates to mitochondria in a phosphorylation-dependent manner by 
heteroligomerization with other Bcl-2 proteins, e.g. Bcl-xl (Kennedy, 
Kandel et al. 1999). Dephosphorylated Bad promotes cell death possibly 
via forming heterodimers with Bcl-xl to release Bax and generate Bax 
homodimers. Akt can directly phosphorylate and inactivate Bad (Franke 
and Cantley 1997; Hajra and Liu 2004; Karin and Lin 2002). 
Phosphorylated Bad is sequestered by 14-3-3, the cytosolic phospho-
serine-binding protein, from Bcl-xl and thus promotes cell survival (Datta, 
Dudek et al. 1997).  
ii) Akt directly phosphorylates and inactivates caspase-9, and thus prevents 
apoptosis downstream of the release of cytochrome c from mitochondria 
(Datta, Brunet et al. 1999). 
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iii) Akt can act independently of Bad, upstream of cytochrome c release and 
caspase activation (Kennedy, Kandel et al. 1999), e.g. via preventing Bid 
cleavage (Oka, Nakahara et al. 2005). In the presence of glucose, Akt also 
prevents the closure of VDAC associated with hexokinase, another 
possible mitochondrial effector of Akt-mediated cell survival (Gottlob, 
Majewski et al. 2001). Akt also phosphorylates Bax and suppresses its 
translocation to mitochondria during apoptosis (Gardai, Hildeman et al. 
2004; Tsuruta, Masuyama et al. 2002). 
iv) Akt phosphorylates transcription factors that regulate apoptosis, e.g. 
phosphorylation of Forkhead family transcription factors by Akt sequesters 
them in the cytoplasm from entering the nucleus and therefore prevents 
the transcription of pro-apoptotic genes, e.g. FasL (Datta, Brunet et al. 
1999). 
v) I(kappa)B kinase (IKK), containing two catalytic subunits IKK-alpha and 
IKK-beta (NEMO), and a regulatory subunit IKK-gamma (Karin and Lin 
2002), is another important substrate of Akt (Nicholson and Anderson 
2002). Akt stimulates the signalling pathway that leads to upregulation of 
NF-(kappa)B activity (Madrid, Wang et al. 2000) and it has been 
suggested that IKK is a direct downstream target of Akt. Phosphorylation 
of I(kappa)B-alpha is detected following Akt activation. Akt and IKK-alpha 
constitutively co-immunoprecipitate (Ozes, Mayo et al. 1999; Romashkova 
and Makarov 1999). 
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NF-(kappa)B comprises a group of dimer transcription factors composed of 
Rel family subunits, Rel-A (p65), Rel-B, c-Rel, NF-(kappa)B1-p105 and NF-
(kappa)B2-p100. The latter two are synthesized as big precursors and have 
an I(kappa)B-like C-terminus. Degradation of the  I(kappa)B-like C-terminus 
in response to upstream signal forms the activated p50 and p52 (Karin and 
Lin 2002). Two NF-?B activation pathways have been described.  
 
i) The canonical pathway  
 
NF-(kappa)B dimers, e.g. Rel-A (p65)/p50, are sequestered in the 
cytoplasm by inhibitors of NF-(kappa)B (I(kappa)B). IKK-beta becomes 
phosphorylated and activated by upstream kinases, possibly Akt, and 
phosphorylates I(kappa)B. Phosphorylated I(kappa)B is subjected to 
ubiquitination and degradation via proteasome and releases NF-(kappa)B 
dimers that translocate to the nucleus where they activate the transcription 
of NF-(kappa)B-target genes (Datta, Brunet et al. 1999). 
 
ii) IKK-alpha pathway 
 
Rel-B and NF-(kappa)B2-p100 form dimers in the cytoplasm. Upon 
stimulation, the I(kappa)B-like C-terminus of NF-(kappa)B2-p100 becomes 
phosphorylated by IKK-alpha and degraded, leaving the Rel-B/p52 to 
actvate transcription of target genes (Karin and Lin 2002). 
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Tumour cells that express constitutively active NF-(kappa)B are highly 
resistant to drug or radiation treatment, and inhibition of NF-(kappa)B activity 
increases their sensitivity to such treatment (Karin, Cao et al. 2002). Many 
tumours of lymphoid origin show constitutively activated NF-(kappa)B (Karin 
and Lin 2002). Aberrant NF-(kappa)B activation has also been found in 
association with defective apoptosis in breast cancer cells (Biswas, Shi et al. 
2004). In a similar manner to Bcl-2 proteins, NF-(kappa)B is another major 
regulator of cell death. Unlike Bcl-2, NF-(kappa)B has direct DNA-binding 
activity and binds promoters of a variety of genes involved in host defence, 
inflammatory responses and anti-apoptosis, regulating their transcription 
(Kitada, Pedersen et al. 2002). The anti-apoptotic proteins under NF-
(kappa)B regulation include Bcl-2 proteins, IAPs, FLIP, etc (Karin and Lin 
2002; Kitada, Pedersen et al. 2002).  
 
1.3.4 p53 mutation and apoptosis 
 
The TP53 gene was discovered as a tumour supressor gene, mutations of 
which are found in more than 50% of human cancers (Soussi and Beroud 
2001). It regulates gene expression and cellular response after stress by 
inducing a series of signals leading to DNA repair, cell cycle arrest or 
apoptosis (Soussi and Lozano 2005). Recent studies reveal that it also plays 
roles in regulating longevity and ageing, glycolytic pathways and overall 
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fitness of an organism (Vousden and Lane 2007). More than 1500 p53 
mutants have been described in various types of human tumours and these 
correlate with anti-apoptotic activity and drug resistance (Soussi, Kato et al. 
2005). p53 translocates to mitochondria in apoptotic tumour cells and causes 
permeablization of the outer membrane of mitochondria and release of 
cytochrome c, by forming complex with Bcl-xl and Bcl-2 proteins (Mihara, 
Erster et al. 2003). 
 
 
1.4 Normal B cell development 
 
 
 
A detailed understanding of the molecular basis of normal B-cell development 
helps elucidate defects in B cell malignancies. The life cycle of B cells 
includes development in the bone marrow followed by maturation and 
differentiation in the periphery (Table 1.1). Sequential stages of B-cell 
development are defined by expression of particular molecular markers, 
including the rearrangement status and expression of the immunoglobulin 
genes. In adult life B cell development occurs predominantly in the bone 
marrow. Haematopoietic stem cells (HSC), the pluripotent primitive CD34+, 
CD38- cells in the bone marrow, have self-renewal capacity and differentiate 
into committed precursors of various haematopoietic lineages. These include 
the common lymphocyte progenitor (CLP) cells that further differentiate into 
T, B or natural killer cells (Auer 2003).  
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                         Table 1.1 B cell development 
Pluripotent stem cells 
Both heavy and light Ig genes are germline. 
No surface Ig expression. CD34+ 
Pro-B 
Light chain genes remain germline, heavy 
chain genes rearrange. Cell surface 
expression of Pro-BCR. CD43+ 
Pre-B 
Light chain genes rearrange. Cell surface 
expression of pre-BCR. 
Immature B 
Heavy and light Ig genes are both 
rearranged. IgM is expressed on cell surface. 
Cell surface expression of BCR. 
Mature B Cell surface expression of BCR, IgD 
 
 
B cells at the earliest stage are CD43+ pro-B cells. They have limited self-
renewal capacity and are further divided into early pro-B and late pro-B cells. 
Rearrangement of immunoglobulin heavy chain occurs at this stage, with DH 
to JH joining at early pro-B and VH to DHJH joining at late pro-B stage. 
Productive rearrangement leads to the expression of mu heavy chain in the 
cytoplasm and the next stage, pre-B cells. At early pre-B stage, mu heavy 
chain starts to be expressed on the cell surface, together with a surrogate 
light chain, to form the pre-B receptor. These cells proliferate and differentiate 
into CD43- late pre-B cells when VL to JL rearrangement of light chain begins. 
                                                                                   Bo Su, 2010. Chapter 1: Introduction 
 
- 63 -
Finally intact IgM molecules are expressed on the surface of immature B cells 
(Rudin and Thompson 1998). 
 
Immature B cells undergo a series of negative selections, depending on the 
specificity of their B-cell receptors (BCR). Self-reactive B cells are eliminated 
or rendered tolerant. The latter also die, but take longer than clonally aborted  
cells (Burrows and Kearney 1993). Those survivors of the selection enter the 
periphery and become naïve mature B cells. They express IgD as a second 
surface Immunoglobulin (Janeway, Travers et al. 2001) and are subject to T-
cell-dependent or -independent activation. These cells die within a few days 
in the periphery unless they encounter their cognate antigen and become 
either anergic or activated (Shaffer, Rosenwald et al. 2002). The dramatic 
effects of B cell activation include the formation of germinal centres, IgH 
isotype switching, antibody affinity maturation, plasma cell differentiation, and 
the generation of memory B cells. 
 
Only a small fraction of the newly generated B precursors survive the entire 
development process and enter the periphery. In order to protect themselves 
from all the pro-apoptotic signals and accomplish the whole developmental 
and maturational process, B cells need to receive survival signals or express 
pro-survival proteins once they are selected as the desired clone. These 
include: 
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i) CD40/CD40L: CD40, a 48 kD glycoprotein expressed on mature B cells, 
interacts with CD40L (CD154) on activated CD4+ T cells and delivers 
costimulation and survival signals to B cells (Furman, Asgary et al. 2000; 
Klaus, Choi et al. 1997). CD40 ligation is critical for T-cell-dependent B-
cell activation and evidence shows that it acts via activation of the NF-
(kappa)B pathway (Furman, Asgary et al. 2000). 
ii) Surface immunoglobulins: early pre-B cells express pre-B receptors and 
immature B cells express surface IgM. They are markers of successful 
rearrangement of immunoglobulin heavy and light chain, respectively, and 
prevent B cells from undergoing apoptosis. In mature B cells, surface 
immunoglobulins are the key part of the B-cell receptor (BCR) and 
determine antigen specificity, B cell survival and activation (Rudin and 
Thompson 1998). 
 
Apoptosis is a critical mechanism to eliminate self-reactive cells, attenuate 
immune responses and maintain the crucial state of dynamic homeostasis in 
the lymphoid immune system. It happens at several stages: 
 
i) Early pre-B cells that lack surrogate immunoglobulin, mostly due to non-
productive rearrangement of the heavy chain gene, are deleted by 
induction of apoptosis. 
ii) Late pre-B cells that fail to express functional surface immunoglobulin die 
from apoptosis. 
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iii) Immature B cells that express self-reactive immunoglobulin undergo 
apoptosis within the bone marrow. 
iv) Peripheral naïve B cells are also highly susceptible to apoptosis induction 
unless stimulated by their cognate antigen. 
v) Apart from the differentiation of a minute fraction of the activated B cells 
into memory B cells, the majority of selected, activated and amplified B 
cell clones undergo apoptosis on termination of an immune response. 
 
 
1.5 B cell receptor (BCR) signalling 
 
B cell receptor signalling is required for both B cell development and survival, 
as well as the pivotal role that B cell plays in the immune system. The signal 
transduction through BCR is a complex labyrinth of interconnecting pathways 
and there follows below only a brief description of the main pathways relevant 
to this thesis. 
 
As with most receptor-based signal transduction, BCR signalling begins with 
receptor aggregation initiated by recognition of antigens and activation of an 
array of effector molecules, and ends with phenotypic and/or genotypic 
modifications which determine the cell response to the stimulus. The receptor 
comprises a surface immunoglobulin, non-covalently associated with a 
disulfide-linked CD79a and CD79b heterodimer. The cytoplasmic part of the 
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CD79a/b contains an important motif, the immunoreceptor tyrosine-based 
activation motif (ITAM). At least two major events occur rapidly after BCR 
ligation, ITAM phosphorylation by Src-family kinases, and generation of PIP3 
by PI3K (Gold 2002; Kurosaki 2002). 
 
i) Phosphorylation of the ITAM of CD79a/b leads to the recruitment 
and activation of Syk, the cytosolic tyrosine kinase (Rowley 1995), 
which in turn phosphorylates B cell linker protein (BLNK), the 
adaptor molecule. Phospholipase C(gamma)2 (PLC(gamma)2) is 
recruited via its SH2 domain to BLNK and becomes phosphorylated 
by Syk. 
ii) PI3K catalyses the generation of PIP3, which interacts with PH-
domain containing proteins, including Akt, PLC(gamma)2 as well as 
Btk, which subsequently phosphorylates PLC(gamma)2, like Syk. 
 
The two events converge on the phosphorylation and activation of 
PLC(gamma)2, which cleaves membrane-associated PIP2 into inositol 
trisphosphate (IP3) and diacylglycerol (DAG), the phospholipid-derived 
second messengers. IP3 frees the intracellular Ca2+, whereas DAG mediates 
activation of protein kinase C (PKC) and subsequent activation of mitogen 
activated protein kinase (MAPK) family. Both lead to the activation of 
transcription factors, e.g. NF-(kappa)B and nuclear factor of activated T-cells 
(NF-AT), which modify gene expression and determine the cell response to 
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stimuli. BCR stimulation does not always result in B cell activation and 
proliferation, and how a B cell responds to a signal depends not only on the 
maturational stage and its extracellular environment, but also on properties of 
the relevant antigen and the availability of T cell help (Dal Porto, Gauld et al. 
2004). BCR signalling is also modulated by co-receptors and other accessory 
molecules, including CD19 and CD45, the positive regulators, and CD22, 
Fc(gamma)RIIB, the negative regulators (Dal Porto, Gauld et al. 2004; 
Monroe 2006). 
 
 
1.6 Chronic lymphocytic leukaemia (CLL) 
 
Chronic lymphocytic leukaemia (CLL) involves the abnormal clonal expansion 
of the CD5+ /CD19+/CD23+ B cells that have a prolonged life span (Furman, 
Asgary et al. 2000; von Bergwelt-Baildon, Maecker et al. 2004). These non-
proliferating cells are arrested at the G0/early G1 phase of the cell cycle and 
gradually accumulate in lymphoid tissues, bone marrow and peripheral blood 
(Granziero, Ghia et al. 2001; Kolb, Kern et al. 2003). The prolonged survival 
mechanisms in CLL include defective apoptosis and cell cycle arrest that 
result from both intrinsic and extrinsic factors. 
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1.6.1 Genetic abnormalities and CLL biomarkers 
 
Chromosomal abnormalities and genomic aberrations are frequently seen in 
CLL (Byrd, Stilgenbauer et al. 2004; Kokhaei, Palma et al. 2005; Shanafelt, 
Geyer et al. 2004) and may determine response to therapies and cell survival. 
Although none of these defects are fully unifying (Chiorazzi, Rai et al. 2005), 
reported mutations and altered gene expression patterns include TP53, ATM, 
Tcl-1 and mdm2 (Bentley and Pepper 2000; Kipps 2003; Munk Pedersen and 
Reed 2004). Extended cell survival favours genetic instability and 
accumulation of gene mutations, as well as new and more ‘damaging’ genetic 
abnormalities  that coincide with disease progression. 
 
The mutation status of the variable region of the immunoglobulin heavy chain 
(VH) gene is an important characteristic of CLL, as it divides the disease into 
two prognostic subtypes: VH-unmutated and VH-mutated CLL (Herishanu and 
Polliack 2005; Kokhaei, Palma et al. 2005; Shaffer, Rosenwald et al. 2002;). 
The VH-unmutated CLL is associated with poor prognosis, relative to the VH-
mutated subtype (Damle, Wasil et al. 1999; Hamblin, Davis et al. 1999). Zeta-
associated protein-70 (ZAP-70), a cytoplasmic tyrosine kinase involved in T 
cell receptor signalling, is preferentially expressed in VH-unmutated CLL cells 
(Crespo, Bosch et al. 2003; Kokhaei, Palma et al. 2005; Wiestner 2005). 
CD38 is another surrogate marker associated with VH-unmutated CLL, 
although it is less reliable and expression of CD38 may change through the 
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course of disease (Kharfan-Dabaja, Chavez et al. 2008; Kokhaei, Palma et al. 
2005; Shanafelt, Geyer et al. 2004). 
 
 
1.6.2 Aberrant apoptotic pathway 
 
CLL cells have a survival advantage in vivo in association with defective 
apoptosis. This is reflected in the following mechanisms: 
 
a. CLL cells have consistent overexpression of Bcl-2 and Mcl-1 (Bentley and 
Pepper 2000; Granziero, Ghia et al. 2001). Bcl-2 gene is hypomethylated 
in over 95% of CLL cells, resulting in elevated expression of this anti-
apoptotic protein (Blaise, Masdehors et al. 2001).  
b. Signal transducers and activators of transcription protein 1 and 3 (STAT1 
and STAT3) are constitutively phosphorylated and activated in CLL cells. 
STATs have been implicated in upregulation of Bcl-xl and Mcl-1 and 
downregulation of caspases (Munk Pedersen and Reed 2004). 
c. The PI3K/Akt and NF-(kappa)B signalling pathways are constitutively 
active and play important roles in CLL cell survival (Cuni, Perez-Aciego et 
al. 2004). In normal B cells, T-cell leukaemia/lymphoma 1 (Tcl-1), a 14 kD 
protein, is expressed at early B cell maturation stages and downregulated 
possibly following antigen encounter and transition through the germinal 
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centre. Tcl-1 overexpression is detected in CLL and reportedly binds and 
activates Akt (Kipps 2003; Munk Pedersen and Reed 2004).  
d. CLL cells express defective apoptotic receptors on their surface, e.g. Fas 
and TRAIL. The activities of Fas and TRAIL are impaired, contributing to 
resistance to spontaneous and drug-induced apoptosis (Kolb, Kern et al. 
2003). CLL cells express and secrete Fas ligand and induce apoptosis in 
Fas+ T cells, a possible mechanism for immune escape (Jewell 2002).  
e. The ubiquitin system involved in apoptosis of normal lymphocytes is 
deregulated in CLL cells (Blaise, Masdehors et al. 2001). 
 
 
1.6.3 BCR signalling in CLL cells  
 
In CLL, low expression of surface immunoglobulin has been reported 
(Kokhaei, Palma et al. 2005; Shaffer, Rosenwald et al. 2002). CD79b is 
downregulated (Chiorazzi, Rai et al. 2005) and a truncated form has been 
detected with the extracellular domain absent, resulting from alternative 
splicing of the CD79b gene (Munk Pedersen and Reed 2004). These 
properties may contribute to the unresponsiveness and survival mechanisms 
in CLL.  
 
BCR signalling leads to either cell death or progression into the cell cycle. 
This can be upregulated or downregulated in CLL, depending partly on the 
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surface density of IgM and IgD as well as the levels of CD38 and ZAP70 
(Herishanu and Polliack 2005). Medium-cultured CLL cells show reduced 
responsiveness to IgM stimulation (Wiestner 2005). Crosslinking of surface 
IgM leads to apoptosis or cell survival, whereas crosslinking of surface IgD 
consistently protects CLL cells from apoptosis (Chiorazzi, Rai et al. 2005). As 
IgM and IgD can transduce opposite signals, the final results of BCR 
signalling may depend on the balance between these two types of receptors 
(Zupo, Massara et al. 2000).  
 
 
1.7 Modified citrus pectin – GCS-100 
 
Carbohydrates are  molecules that contain only hydrogen, oxygen and 
carbon. They may have simple structures, e.g. five- and six-carbon sugars, or 
complex polymer chains, i.e. polysaccharides. Carbohydrates play finely-
tuned roles in regulation of cell function. Even minor changes in their 
structures may have a major impact on cell signalling. They interact and form 
conjugates with biologically active molecules such as carbohydrate-binding 
proteins to interfere with their functions.  
 
Citrus pectin, a type of polysaccharide obtained from citrus fruit, is highly 
branched and rich in galactoside residues. In its modified form after 
hydrolysis, it acts as a specific inhibitor of galectin-3, which binds the beta-
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galactoside residues through its carbohydrate binding domain (Inohara and 
Raz 1994; Nangia-Makker, Hogan et al. 2002). As galectin-3 is a multi-
functional protein involved in immune response, cell cycle, apoptosis, cell-cell 
and cell-matrix interaction, tumour metastasis and angiogenesis (Inohara and 
Raz 1994), potentially modified citrus pectin may interfere with a wide 
spectrum of cell functions. Experimentally it can inhibit cell adhesion to 
laminin and, in at least partial consequence of this, tumour metastasis 
(Inohara and Raz 1994; Pienta, Naik et al. 1995). 
 
GCS-100, formerly designated as GBC-590, is a type of modified citrus pectin 
derived by acid/base hydrolysis of citrus pectin isolated from the skin and 
pulp of citrus fruits (GlycoGenesys, Boston). Structurally it is rich in 
galactoside residues and has a high-affinity for galectin-3, which is thought to 
be instrumental in its biological effects. GCS-100 appears to interfere with 
tumour metastasis and inhibit angiogenesis, and has been in Phase II clinical 
trial for pancreatic, prostate and colorectal cancer (Cotter 2004; Daliani, Pratt 
et al. 1999; Grous, Redfern et al. 2006; Gunzburg and Salmons 2001; 
Springgate, Cartwright et al. 2001; Staddon, Bonnem et al. 1999; Stuart, 
Kindler et al. 2001). Recently it has been reported that GCS-100 induces 
apoptosis in multiple myeloma cells without affecting normal lymphocytes 
(Chauhan, Li et al. 2005).  
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The potential anti-cancer role of modified pectin has recently excited 
considerable interest as a dietary component of fruit and vegetables, and as 
an agent used in food processing. The specific binding between the bioactive 
fragments from pectin and human galectin-3 has also been demonstrated 
(Gunning, Bongaerts et al. 2009). 
 
 
1.8 PK11195 
 
PK11195, or 1-(2-chlorophenyl)-N-methyl-N-(1-methyl-propyl)-3-isoquinoline-
carboxamide, is a ligand for the mitochondrial peripheral benzodiazepine 
receptor (mPBR) with high affinity. The mPBR, also designated as the 18 kD 
translocator protein (TSPO), is a  transmembrane protein in mitochondria 
which forms part of the PT pore (see 1.2.2.a). PK11195 binds to mPBR at 
nanomolar concentrations (Fennell, Corbo et al. 2001). Higher doses of 
PK11195 induce apoptosis and have chemosensitisation effects in primary 
CLL, AML and MM cells (Banker, Cooper et al. 2002; Chauhan, Li et al. 2004; 
Santidrian, Cosialls et al. 2007; Walter, Pirga et al. 2005; Walter, Raden et al. 
2004), and B-cell lymphoma cell lines (Muscarella, O’Brien et al. 2003). It has 
also shown pro-apoptotic effects in human glioma and insulinoma (Chelli, 
Salvetti et al. 2008; Park, Cho et al. 2005), and is currently in clinical 
development (Banker, Cooper et al. 2002). 
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The mechanism of the pro-apoptotic effect of PK11195 remains to be fully 
understood. It can induce PT pore opening, cytochrome c release as well as 
mitochondrial memebrane potential collapse (Li, Wang et al. 2007; Park, Cho 
et al. 2005). Anti-apoptotic activity due to Bcl-2 overexpression can also be 
overcome by PK11195 in human B lymphoma cells and other tumour cell 
lines (Hirsch, Decaudin et al. 1998; Muscarella, O’Brien et al. 2003). Based 
on the finding that the dose needed for its pro-apoptotic effects is much 
higher than that required for receptor engagement, and the fact that it induces 
apoptosis in mPBR-negative cells, PK11195-induced apoptosis must have an 
additional mPBR-independent mechanism (Fennell, Corbo et al. 2001; 
Walter, Pirga et al. 2005).  
 
 
1.9 Purpose of investigation 
 
The foregoing two types of drug candidates, GCS-100 and PK11195, 
currently of interest to the Department of Haematology at Queen Mary, 
University of London, of contrasting provenance and putative mechanisms of 
action, both with anti-cancer effects in haematopoietic malignancies and 
currently in clinical development (Banker, Cooper, et al. 2002; Chauhan, Li, et 
al. 2005), were evaluated for their capacity to induce apoptosis in established 
cell lines and primary neoplastic cells of B cell lineage, and the mechanisms 
of apoptosis-induction evaluated at the molecular level. For logistic reasons, 
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access to primary materials (e.g. primary CLL cells) was limited in this project. 
Therefore, for experimental purposes, the emphasis was on malignant cell 
lines of B cell origin for which no prior data on GCS-100 were available. In 
addition, cell lines of non-B-cell origin were included for comparison. The data 
presented have implications for the design of therapeutic strategies targeting 
apoptosis in haematological maliganancies. 
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2.1 General reagents and stock solutions 
 
Table 2.1 General reagents 
 
Products Suppliers and Catalogue No. 
EDTA Promega, V4231 
EPOSIN (etoposide, VP-16) Pharmachemie B.V. 
Galectin-3 inhibitor Organic Chemistry, Lund Uni. 
GCS-100 
GlycoGenesys, Batch.876284-
HO1(unless otherwise indicated). 
Glycine BDH, 10119CU 
HCl BDH, 101254H 
2-Mercaptoethanol Sigma, M6250 
MnTBAP OxisResearch, 26532 
Nonidet P40 Substitute Fluka, 74385 
PBS tablets Fluka, 79382 
PK11195 Sigma, C0424 
2-Propanol (Isopropanol) Sigma, I9516 
Rotenone Aldrich, 477737 
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Sodium chloride BDH, 10241AP 
Triton X-100 Sigma, T8787 
Trizma base (Tris base) Sigma, T6066 
Spectrophotometer  Eppenforf, 6132. 000.008 
 
 
Table 2.2 General stock solutions 
 
Solution Preparation 
1 M Tris pH 7.5 
(1 L) 
 
· 121.14 g  Tris base was dissolved in 900 ml H2O. 
· The pH was adjusted to 7.5 with HCl. 
· The volume was adjusted to 1 L with H2O. 
5 M NaCl (1 L) 
 
· 292.2 g NaCl was dissolved in 900 ml H2O. 
· The volume was adjusted to 1 L with H2O.  
10% SDS (1 L) 
 
· 100 g SDS was dissolved in 900 ml H2O. A mask 
was used when weighing SDS. 
· The volume was adjusted to 1 L with H2O. 
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2.2 Cell culture 
 
2.2.1 Reagents 
 
Table 2.3 Cell culture reagents 
 
Products Suppliers and Catalogue No. 
Dulbecco’s Modified Eagle’s (DME) 
Medium 
Sigma, D5546 
FCS PAA, A11-043 
Ficoll-Paque Plus Amersham Biosciences, 17-1440-03 
L-glutamine (200 mM) PAA, M11-004 
Penicillin & streptomycin PAA, P11-010 
RPMI1640 PAA, E15-039 
Trypsin-EDTA PAA, L11-660 
 
 
2.2.2 Cell lines 
Table 2.4 Cell lines 
 
Designation Cell type Origin Features 
DOHH2 Mature B cell Follicular B-Non-Hodgkins Lymphoma 
High expression of 
Bcl-2 due to t(14;18) 
JURKAT Immature T cell 
Relapsed childhood T-
acute lymphoblastic 
leukaemia 
No galectin-3 
expression, 
CD95+,sensitive to 
various apoptotic 
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signals 
K562 
Erythroid 
leukaemia 
cell 
Myeloid leukaemia 
Ph chromosome 
with bcr-abl b3-a2 
fusion gene 
RAMOS B lymphoma cell 
American Burkitt’s 
Lymphoma p53 mutation 
RPMI8226 B-lineage cell Myeloma; plasmacytoma 
No heavy chain 
production 
SUD4 Mature B cell B lymphoma p53 mutation 
U266 B-lineage cell Myeloma; plasmacytoma Producing IL-6 
HEK293 Epithelial Human embryonic kidney Adherent cells 
 
 
2.2.3 Culture of suspension cell lines  
 
All suspension cells were cultured in RPMI1640 medium supplemented with 
10% FCS (inactivated at 56ºC for 0.5 hr), 2 mM L-glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin unless otherwise stated. Incubation was 
at 37ºC with 5% CO2. 
 
Cells were defrosted at 37ºC, immediately washed with 10 ml PBS, 
transferred to 20 ml medium (20% FCS) and incubated overnight. A further 
20 ml medium (20% FCS) was added the following day. When cells became 
confluent, usually after 2 or 3 days, they were transferred to 40 ml fresh 
medium and kept in culture for 2 weeks. Medium was changed every 2-3 
days during this period and culture volume expanded according to the degree 
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of confluence. The majority (leaving 5 ml in culture) of the confluent cell 
suspension was then resuspended in 3-5 ml (depending on the total cell 
number) of Freezing medium (50% FCS, 30% RPMI 1640 and 20% DMSO), 
aliquoted into 1 ml  freezing vials and immediately stored in a pre-cooled 
(4ºC) Nalgen freezing box at -70ºC overnight before being transferred to a 
liquid nitrogen tank. The remaining 5ml cell suspension was subcultured by 
adding 35 ml fresh medium and maintained in culture as needed for 2 months 
before being discarded. Another vial of freezing stock was then defrosted in 
the same way as stated above. 
 
 
2.2.4 Culture of adherent cell lines  
 
Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% FCS (inactivated at 56ºC for 0.5 hr), 2 mM L-
glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin unless otherwise 
stated, in a cell-culture incubator at 37ºC with 5% CO2. 
 
Cells were defrosted at 37ºC, immediately washed with 10 ml PBS, re-
suspended in 20 ml medium and seeded in a 75 cm2 flask. When the 
confluence reached 80%, cells were detached with Trypsin-EDTA and re-
seeded in two 150 cm2 flasks. When both flasks became 90% confluent, cells 
were collected as much as possible, washed with PBS, resuspended in 10 ml 
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Freezing solution (10% DMSO + 90% FCS), aliquoted into 1 ml freezing vials 
and immediately stored in the pre-cooled Nalgen freezing box (4ºC) at -70ºC 
overnight before being transferred to the liquid nitrogen tank. 40ml fresh 
medium was added to each flask, and the remaining cells were subcultured 
and maintained in culture for 2 months before being discarded. Another vial of 
freezing stock was then defrosted in the same way as stated above.  
 
 
2.2.5 Culture of primary CLL cells and normal lymphocytes 
 
Peripheral whole blood samples were obtained from CLL patients at 
Birmingham Heartlands Hospital, or normal donors, following ethical 
approval. Lymphocytes were freshly isolated using Ficoll as described below. 
 
i) Whole blood samples were diluted with an equal volume of PBS and 
mixed well. 
ii) The Ficoll-Paque Plus bottle was inverted several times to ensure 
thorough mixing and 3.5 ml (2.4 cm of the height) Ficoll was added to a 15 
ml centrifuge tube. 
iii) 4.5 ml (3.0 cm of the height) diluted blood sample was carefully layered on 
top of Ficoll, and centrifuged at 400 g (1660 RPM, r=13 cm) for 40 minutes 
at 18ºC. 
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iv) The lymphocyte layer was transferred using a sterile Pasteur pipette to a 
clean centrifuge tube with 3 volumes of PBS. The lymphocytes were 
resuspended by gently inverting the tube several times and centrifuged at 
100 g (830 RPM) for 10 minutes at 18ºC. 
v) Supernatant was removed and the lymphocytes were resuspended in 8 ml 
PBS and centrifuged at 100 g (830 RPM) for 10 minutes at 18ºC. 
vi) Lymphocytes were then resuspended in a suitable volume (depending on 
the size of cell pellets) of culture medium. 
vii) Lymphocytes were counted and seeded in culture vessels, and treated as 
indicated. 
 
 
2.2.6 Culture of PK11195-resistant cell line 
 
Ramos cells were cultured as described in 2.2.3. At passage 3, cells were 
treated with 10 µM PK11195 and cultured until reaching confluency. Part of 
the cells were then frozen down for future use. Cells were then treated with 
25 µM PK11195 and cultured until reaching confluency. Part of the cells were 
then frozen down for future use. Finally, cells were treated with 50 µM 
PK11195, and kept in culture for about 2 months before being discarded. 
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2.3 Flow cytometry 
 
2.3.1 Fluorescent reagents 
Table 2.5 Fluorescent reagents 
 
Products Suppliers and Catalogue No. 
DHE Sigma, D7008 
DiOC6(3) Molecular Probe, D273 
MC540 Molecular Probe, M24571 
Sphero Rainbow Calibration Particles Pharmingen, 559123 
 
Flow cytometry is a powerful and convenient method to detect apoptotic cells. 
By introducing a potentially fluorescent dye, which either binds to a specific 
protein or membrane or enters a specific cellular compartment, cells at 
certain stages of apoptosis can be detected and quantified. As specific 
probes detect different stages of apoptosis, a kinetic study was performed 
first to determine upon the time point for measurement.  
 
       
i) DiOC6(3) stains the mitochondrial membrane at low concentrations. It has 
been specifically used to detect collapse of the mitochondrial trans-
membrane potential (DeltaPsi(m)) and is regarded as a mitochondria-
selective potentiometric probe (Blatt, Bednarski et al. 2002). Negative 
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DiOC6(3) staining correlates with apoptosis through the mitochonrial 
pathway, and this can be detected on the FL1 channel of the flow 
cytometer. 
 
ii) Merocyanine 540 (MC540) is a polar dye which intercalates in the 
unpacked membrane and detects alterations in membrane symmetry. This 
often reflects a later stage of apoptosis in comparison with DiOC6(3). 
Positive MC540 staining correlates with apoptosis and this can be 
detected on the FL2 channel of the flow cytometer. 
 
iii) Dihydroethidium (DHE) is a redox-sensitive fluorescent dye that reacts 
specifically with O2- (Blatt, Bednarski et al. 2002). It was used to detect 
intracellular ROS production and positive staining was detected on the 
FL2 channel of the flow cytometer. 
 
2.3.2 Sample preparation and FACS analysis 
 
a. Sample preparation 
 
Calibration of the FAScan Machine (Becton Dickinson) was performed prior to 
detection using SPHEROTM Rainbow Calibration particles (8 peaks, 3.0-3.4 
µM). Titration of each fluorescent probe, or combination, was also performed 
to determine optimal concentration for cell types being analysed. 
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i) DiOC6(3)/PI: 100 mg DiOC6(3) was dissolved in 20 ml DMSO to make 
5 mg/ml stock solution. 25 mg PI was dissolved in 5 ml PBS to make 5 
mg/ml stock solution. 100 µl PI stock solution and 1 µl DiOC6(3) stock 
solution were added into 10 ml PBS to make the working solution, of 
which 40 µl/ml was used. The final concentration was 2 µg/ml PI + 20 
ng/ml DiOC6(3). 
 
ii) MC540/7-AAD: 25 mg MC540 was dissolved in 5 ml DMSO to make 5 
mg/ml stock solution. 1:40 substock solution was made by adding 1 ml 
stock solution in 40 ml PBS. 40 µl/ml of substock solution was used to 
achieve the final concentration of 5 µg/ml. 1 mg 7-AAD was dissolved 
in 5 ml PBS to make 200 µg/ml stock solution, and 5 µl/ml of stock was 
used to achieve the final concentration of 1 µg/ml. 
 
iii) DHE: 10 mg DHE (MW. 315.4) was dissolved in 31.7 ml DMSO to 
make 1 mM stock solution. 5 µl/ml was used to achieve the final 
concentration of 5 µM. 
 
b. FACS analysis 
 
Cells were incubated with the fluorescent probe at room temperature in the 
dark for 5-15 minutes, and analysed on the FACScan machine. 10,000 
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events were recorded, and the results were further analysed by WINMDI 
software. 
 
 
2.4 Immunoprecipitation 
 
2.4.1 Reagents and buffers 
 
Table 2.6 Reagents for immunoprecipitation 
 
Products  Suppliers and Catalogue No. 
Dynabeads Pan Mouse IgG DYNAL Biotech, 110.41 
Protease inhibitor cocktail Sigma, P8340 
Protein assay Kit Bio-Rad, 500-0113/4 
Spectrophotometer cuvettes Sigma, C5416-100EA 
 
 
Table 2.7 Buffers for immunoprecipitation 
 
Buffers Preparation 
Washing buffer 1 (WB1, 50 ml) 
 
· 50 mM Tris pH 7.5 (2.5 ml of 1 M 
stock) 
· 150 mM NaCl (1.5 ml of 5 M stock) 
· 1% Nonidet P40 (500 µl) 
· H2O 45.5 ml 
Washing buffer 2 (WB2, 50 ml) · 50 mM Tris pH 7.5 (2.5 ml of 1 M 
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 stock) 
· 500 mM NaCl (5 ml of 5 M stock) 
· 0.1% Nonidet P40 50 µl 
· H2O 42.45 ml 
Washing buffer 3 (WB3, 50 ml) 
 
· 50 mM Tris pH 7.5 (2.5 ml of 1 M 
stock) 
· 0.1% Nonidet P40 50 µl 
· H2O 47.45 ml 
CSH buffer (5×, 200 ml) 
 
· 250 mM Tris pH 7.5 (50 ml of 1 M 
stock) 
· 1.25 M NaCl (50 ml of 5 M stock) 
· 5 mM EDTA (2 ml of 0.5 M stock) 
· H2O 98 ml 
Lysis buffer (2 ml, freshly made) 
 
· CSH (5×) 400 µl 
· Triton 100 2 µl 
· Protease inhibitor cocktail 60 µl 
· H2O 1.538 ml 
 
 
2.4.2 Cell lysate preparation 
 
Cells were washed with PBS twice and the pellet was frozen at -70ºC for at 
least 1 hr before being defrosted on ice. 30-50 µl of lysis buffer (see Table 7), 
depending on cell numbers, was added to the cell pellet and mixed by 
pipetting up and down gently (no air bubbles should be produced). They were 
then incubated on ice for 30 minutes before centrifuging at full speed, 4ºC for 
20 minutes. The supernatant was carefully transferred to a clean pre-cooled 
microcentrifuge tube (on ice) and the amount of protein in the lysate was 
quantified using BioRad protein assay kit. The lysate was stored at -20ºC. 
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2.4.3 Protein quantification  
 
The amount of protein in the lysate was quantified by BioRad Kit. 1 µl of 
lysate was diluted with 40 µl H2O. 20 µl of the diluted lysate (using H2O as 
blank), 100 µl Reagent A and 800 µl Reagent B were mixed together, 
vortexed and incubated at room temperature for 15 minutes before being 
transferred to a cuvette and analysed spectrophotometrically (Eppenforf, see 
2.1), using the Bradford programme set up by BSA standards according to 
the manufacturer’s guide. 
 
 
2.4.4 Immunoprecipitation  
 
i) Pan mouse IgG Dynabeads were mixed well before 50 µl per sample was 
transferred to an eppendorf and washed with 900 µl of WB1 (see Table 7) 
twice. 
ii) The beads were then resuspended in 300 µl WB1 with the appropriate  
first antibody (2 µg/sample) and incubated at 4ºC overnight with agitation. 
iii) The beads were washed with 1 ml of WB1 three times before being 
resuspended in 200 µl of WB1.  
iv) The cell lysate was defrosted on ice. 20 µg protein was removed and set 
aside to save as an input control if immunoblotting was to be performed 
afterwards. An equal amount of protein for each sample (500-1000 µg) 
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was then added to the beads bound with the first antibody. 6 µl Protease 
inhibitor cocktail was added before incubation at 4ºC for 3 hours with 
agitation. 
v) The beads bound with the first antibody and the cognate molecules were 
washed with 1 ml of WB1 for 15 minutes twice, 1 ml of WB2 (see Table 7) 
for 15 minutes twice and finally 1 ml of WB3 (see Table 7) for 15 minutes 
once at 4ºC before loading buffer was added and SDS-PAGE was 
performed (see 2.5). 
 
 
2.5 Immunoblotting (Western blotting) 
 
2.5.1 Reagents and materials 
 
Table 2.8 Reagents and Materials for Western blotting 
 
 
Products  Suppliers and Catalogue No. 
Acrylamide/bisacrylamide National Diagnostics, EC-890 
Ammonium persulfate Sigma, A3678 
Blotting Paper Sigma, P7769 
BSA Sigma, A7906 
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Hyper-film ECL Amersham, RPN3103K 
Protein Marker New England Biolabs, P7702S 
PVDF membrane Sigma, P2813 
Short plates Bio-Rad, 165-3308 
Spacer plates (0.75 mm) Bio-Rad, 165-3310 
SuperSignal Kit PIERCE, 34080 
Tween 20 Sigma, P1379 
 
 
Table 2.9 Antibodies for Western blotting 
 
 
Antibodies Suppliers and Catalogue No. 
beta-actin, mouse Sigma, A5316 
Bax (2D2), mouse Santa Cruz, SC-20067 
Bcl-2, mouse Santa Cruz, SC-509 
Bcl-2, rabbit Abcam, ab7973 
Bcl-x, mouse BD PharMingen, 556499 
Bid, rabbit R&D Systems, AF846 
Caspase-8, mouse Alexis, ALX-804-242 
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Caspase-9, mouse Stressgen, AAM-139 
Fas, mouse Immunotech, 1504 
Galectin-3, mouse R&D Systems, MAB1154 
Galectin-3, mouse BD PharMingen, 556904 
I(kappa)B-alpha, mouse Cell Signaling, 9247 
Mouse IgG HRP, goat BD Pharmingen, 554002 
Penta-His, mouse Qiagen, 34660 
Phospho-Akt (Ser473), rabbit Cell Signaling, 9271 
Phospho-I(kappa)B-alpha (Ser32/36), 
mouse 
Cell Signaling, 9246 
Rabbit IgG HRP, goat BD Pharmingen, 554021 
 
 
Table 2.10 Buffers for Western blotting 
 
 
Buffers Preparation 
1 M Tris pH 6.8 (500 
ml) 
 
· 60.57 g TRIZMA base was dissolved in 350 
ml H2O. 
· The pH was adjusted to 6.8 with HCl. 
· The volume was adjusted to 500 ml with H2O. 
1.5 M Tris pH 8.8 (500 
ml) 
 
· 90.855 g TRIZMA base was dissolved in 400 
ml H2O. 
· The pH was adjusted to 8.8 with HCl. 
·  The volume was adjusted to 500 ml with H2O. 
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Loading buffer (2×, 10 
ml) 
 
· 3%×2 SDS (6 ml of 10% stock) 
· 10%×2 glycerol (2 ml) 
· 50 mM×2  Tris pH 6.8 (1 ml of 1 M stock) 
· 5%×2 2-mercaptoethanol (1 ml) 
· 20 mg bromophenol blue 
· 0.5 ml aliquots were stored at -20ºC 
Running buffer (10×, 1 
L) 
 
· 0.25 M Tris (30.2 g) 
· 1.92 M glycine (144 g) 
· 1% SDS (100 ml of 10% stock, see Table 2) 
· H2O (up to 1 L) 
Transfer buffer (10×, 1 
L) 
 
· 0.25 M Tris (30.2 g) 
· 1.92 M glycine (144 g) 
· H2O (up to 1 L) 
Working transfer 
buffer (3 L, freshly 
made) 
 
 15% Methanol 20% Methanol 
Transfer buffer (10×) 300 ml 300 ml 
H2O 2250 ml 2100 ml 
Methanol 450 ml 600 ml 
 
Semi-dry transfer 
buffer (1 L) 
 
· 48 mM Tris (5.82 g) 
· 39 mM glycine (2.93 g) 
· 1.3 mM SDS (3.75 ml 10% stock) 
· 20% methanol (200 ml) 
· H2O (up to 1 L) 
TBST (0.5% Tween 
20, 2 L) 
 
· 40 ml 1 M Tris pH 7.5 
· 60 ml 5 M NaCl 
· 10 ml Tween 20 
· H2O (up to 2 L) 
TBS (500 ml) 
 
· 10 ml 1 M Tris pH 7.5 
· 15 ml 5 M NaCl 
· H2O (up to 500 ml) 
Washing buffer, 1 L 
 
· 1% skimmed milk powder (10 g) 
· 0.5% BSA (5 g, optional) 
· TBST (up to 1 L) 
                                                                    Bo Su, 2010. Chapter 2: Materials and Methods 
 
- 94 -
Stripping buffer 1 (for 
restaining with 
antibody of a different 
species, 200 ml) 
 
· 3 g glycine (200 mM) was dissolved in ~150 
ml H2O and the pH was adjusted to 2.5 with 
HCl 
· H2O (up to 200 ml) 
· Store at 4ºC 
Stripping buffer 2 (for 
restaining with 
antibody of the same 
species, 250 ml) 
 
· 100 mM 2-mercaptoethanol (1.75 ml) 
· 2% SDS (50 ml 10% stock) 
· 62.5 nM Tris (15.625 ml 1 M Tris pH 6.8) 
· H2O (up to 250 ml) 
· Store at 4ºC 
 
 
2.5.2 SDS-PAGE  
 
a. Casting acrylamide gel 
 
The BioRad gel cassette was assembled and the pre-gel solution (Table 
2.11) was added using a Pasteur pipette. The space for stacking gel was 
filled with water. The resolving gel was left at room temperature for 30 
minutes. The water was removed and the pre-gel solution (Table 2.12) was 
added. The comb was inserted and the stacking gel was left at room 
temperature for 30 minutes. 
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Table 2.11 Resolving gel (10 ml) for SDS-PAGE 
 12% 10% 
1.5 M Tris pH 8.8 2.5 ml 2.5 ml 
H2O 3.3 ml 4 ml 
Acrylamide/bis-acrylamide (30%) 4 ml 3.3 ml 
10% SDS 100 µl 100 µl 
TEMED  4 µl 4 µl 
10% APS (1 ml H2O + 0.1 g APS, freshly made) 100 µl 100 µl 
 
Table 2.12  Stacking gel (5%, 4 ml) for Western blotting 
1 M Tris pH 6.8 0.5 ml 
H2O 2.753 ml 
Acrylamide/bis-acrylamide (40%) 667 µl 
10% SDS 40 µl 
TEMED  4 µl 
10% APS (1 ml H2O + 0.1 g APS, freshly made) 40 µl 
 
b. Sample loading and gel running  
 
i) The gel cassette was assembled into the running tank and running buffer 
(see Table 10) was added to the inner and outer chamber to cover the gel. 
The comb was removed. 
ii) A volume of lysate containing an equal amount of protein (20-50 µg) was 
transferred to a clean and cold eppendorf (on ice) and an equal volume of 
loading buffer (2×, see Table 2.10) was added. 
iii) Final volume was adjusted to 20 µl (for 0.75 mm-thick gel) using loading 
buffer (1×, made by 1:2 dilution of the 2x loading buffer). 10 µl protein 
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marker plus 10 µl loading buffer (1×) was used as a reference for the 
molecular weight. 
iv) Sample solution was heated at 100ºC for 3 minutes and incubated on ice 
for 5 minutes. 
v) Sample solution was briefly centrifuged and loaded into the wells of the 
stacking gel. 
vi) Empty wells were filled with 20 µl loading buffer (1×). 
vii) The gel was run at constant current (voltage 60-70 V) for the stacking gel 
and constant voltage at 110 V for the resolving gel. 
 
2.5.3 Blotting and staining 
 
a. Tank transfer 
 
i) The gel was washed in working transfer buffer (Table 2.10) for 30 
minutes. 
ii) PVDF membrane was cut, 8.5×5 cm for each gel, soaked in methanol for 
20 seconds and washed in working transfer buffer for 15 minutes. 
iii) The gel (close to the cathode) and the membrane (close to the anode) 
were put together in a folder, with blotting paper on each side and 
immersed in the transfer tank filled with cold working transfer buffer. 
iv) Transfer was carried out at 30 V overnight. 
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v) Membrane was blocked with 5% milk TBST (Table 2.10, 100 ml TBST + 5 
g skimmed milk powder) for 1 hour with agitation. 
vi) The first antibody was added to 2 ml 1% milk TBST (100 ml TBST + 1 g 
skimmed milk powder)  at 1:1000 to 1:200 dilution according to the 
supplier’s instructions, and the membrane was stained in a 50 ml tube for 
1 hour at room temperature with agitation. 
vii) Membrane was washed in a small tray with washing buffer for 10 minutes 
× 6 with agitation. 
viii) Secondary antibody (1:10 000) was added to 10 ml 1% milk TBST, and 
the membrane stained in a 50 ml tube for 45 minutes at room temperature 
with agitation. 
ix) The membrane was washed in a small tray with TBST for 10 minutes ×6 
with agitation. 
x) The membrane was finally washed with TBS for 10 minutes ×2. 
xi) The membrane was stained with SuperSignal Kit and exposed to a film 
which was then developed. 
 
b. Semi-dry transfer 
 
i) The PVDF membrane was placed in methanol.  
ii) 6 blotting papers for each gel were placed in semi-dry transfer buffer 
(Table 2.10). 
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iii) The gel (close to the cathode) and membrane (close to the anode) were 
put into a semi-dry transfer chamber, with 3 blotting papers on each side. 
To get rid of air bubbles, rolling was performed between each layer. 
iv) Transfer was carried out at constant current of 400 mA,  maximum voltage 
of 25 V for 1 hour. 
v) Membrane was stained with first antibody in 1% milk TBST at 4ºC 
overnight. The blocking and secondary staining was performed the 
following day as stated  previously. 
 
2.5.4 Stripping and restaining 
 
a. Mild stripping (when using antibody from a different species) 
 
i) Membrane was incubated with stripping buffer 1 (Table 2.10) for 20 
minutes at room temperature with agitation. 
ii) Membrane was equilibrated in 1 M Tris pH 7.5 for 5 minutes. 
iii) Membrane was blocked and restained with the new antibody. 
 
b. Harsh stripping (when using antibody from the same species) 
 
i) Pre-warm stripping buffer 2 (Table 2.10) to room temperature. 
ii) In a fume cupboard, the membrane was placed in 10 ml stripping buffer 2 
in a small tray with a lid. The lid was sealed with parafilm. 
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iii) Membrane was incubated in 50ºC water bath for 5-30 minutes, depending 
on the affinity of the previous antibody. 
iv) Membrane was washed in H2O × 2 (in the fume cupboard). 
v) Membrane was washed with TBST for 10 minutes × 2. 
vi) Membrane was blocked and restained with the new antibody. 
 
 
2.6 Molecular cloning  
 
2.6.1 Reagents 
 
Table 2.13 Reagents for molecular cloning 
 
Products Suppliers and Catalogue No. 
ABI PRISM BigDye Kit Applied Biosystems, 4336915 
Agarose Melford, MB1200 
Ampicillin Sigma, A9393 
Calcium Chloride Dihydrate BDH, 43705 5N 
Calf Intestinal Alkaline 
Phosphatase (CIAP) Kit Promega, M1821 
Ca3(PO4)2.2H2O BDH, 437053L 
pCMV.Tag 4A vector Stratagene, 211174 
DH5a competent cells Invitrogen, 18263-012 
1 kb DNA ladder New England Biolabs, N3232S 
pEGFP-N3 vector Clonetech, 6080-1 
Formamide BDH, 10326 
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Galectin-3 Image Clone 5755882 MRC geneservice, 12795-J11 
HEPES Sigma, H4034 
Kanamycin Sigma, K1876 
LB agar (Lennox L Agar) Gibco-BRL, 22700-041 
NaH2PO4·2H2O BDH, 301324Q 
Na2HPO4 BDH, 102494C 
QIAGEN Plasmid Maxi Kit Qiagen, 12162 
QIAprep Spin Miniprep Kit Qiagen, 27104 
QIAquick Gel Extraction Kit Qiagen, 28704 
PEI Polysciences, 23966 
pfu DNA polymerase Promega, M7741 
Taq DNA polymerase Qiagen, 201205 
Wizard DNA Clean-Up System Promega, A7280 
 
 
 
 
 
Table 2.14 Primers for molecular cloning 
 
Primers Sequence 
Galectin-3 forward HindIII 
 
5’-GAT CAA GCT TGC CAC CAT GGC AGA 
CAA TTT TTC GCT CC-3’ 
Galectin-3 reverse XhoI 
 
5’-GAT CCT CGA GTA TCA TGG TAT ATG 
AAG CAC-3’ 
Bcl-2 forward HindIII 
 
5’-GAT CAA GCT TGC CAC CAT GGC GCA 
CGC TGG GAG AAC AGG-3’ 
Bcl-2 reverse XhoI 
 
5’-GAT CCT CGA GCT TGT GGC CCA GAT 
AGG CAC CCA G-3’ 
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Galectin-3 reverse XhoI 
Stop 
 
5’-GAT CCT CGA GTT ATA TCA TGG TAT 
ATG AAG CAC-3’ 
Bcl-2 reverse XhoI Stop 
 
5’-GAT CCT CGA GTC ACT TGT GGC CCA 
GAT AGG CAC CCA G-3’ 
 
 
Table 2.15 Plates, medium and buffers for molecular cloning 
 
  
Plates or solution Preparation  
Agar plates 
 
32 g LB agar was dissolved in 1 L H2O and autoclaved. 
When cool antibiotic of choice was added (25 µg/ml 
kanamycin, 100 µg/ml ampicillin). The pre-gel mixture 
was poured into 10 cm petri dishes and allowed to set at 
room temperature by a flame. Air bubbles were removed 
using the flame. 
CIAP stop buffer 
(10 ml) 
 
· 10 mM Tris pH 7.5 (100 µl of 1 M Tris pH 7.5) 
· 1 mM EDTA (20 µl of 0.5 M stock) 
· 200 mM NaCl (400 µl of 5 M stock) 
· 0.5% SDS (500 µl of 10% stock) 
· H2O, 8.98 ml, up to 10 ml 
DNA loading buffer 
(6X, 100 ml, for 
agarose gel) 
 
· 50% glycerol, 60 ml 
· 0.5 M EDTA pH8, 12 ml 
· 1 M Tris pH7.5, 6 ml 
· 0.5-1 mg xylenol orange 
· H2O, up to 100 ml  
· Aliquoted and stored at -20ºC. 
DNA sequencing 
buffer (2.5×) 
 
· 200 mM Tris 
· 5 mM MgCl2  
· pH 9 at room temperature 
HBS (2×) stock: 
 
· 280 mM NaCl (1.64 g) 
· 50 mM HEPES (1.19 g) 
· 1.5 mM Na2HPO4·7H2O (400 µl of 1 g in 10 ml) 
or 1.5 mM Na2HPO4·2H2O (400 µl of 0.67 g in 10 
ml) 
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· H2O, up to 60 ml 
· Adjusted to pH 7.05 – 7.1 (exact) using 1 M 
NaOH. 
· H2O, up to 100 ml 
· Aliquoted in 5 ml×20 and stored at -20ºC. 
LB medium (1 L) 
 
· 10 g bactotryptone 
· 5 g yeast extract 
· 5 g NaCl 
· H2O, up to 1 L 
· Autoclaved and stored at 4ºC 
TE buffer (1 L) 
 
· 10 mM Tris (10 ml of 1 M Tris pH7.5)  
· 1 mM EDTA (2 ml of 0.5 M EDTA) 
· H2O was added and pH was adjusted to 8, 
volume to 1 L 
TBE buffer (10×, 1 
L) 
 
· 108 g Tris-Base 
· 55 g boric acid 
· 7.44 g EDTA 
· H2O, up to 1 L 
PCR mix (general, 
10 µl) 
 
· 1 µl Buffer (10×, 15 mM MgCl2) 
· 1 µl Primer 1 (forward) 
· 1 µl Primer 2 (reverse) 
· 1 µl dNTPs (2.5 m? ) 
· 0.05 µl Tag polymerase (5 U/µl) / 0.2 µl pfu 
· H2O, up to 9 µl 
· 1 µl DNA  
· Programme: 95ºC 1’? (94ºC 30”? 55ºC 
30”? 72ºC 2’)×30? 72ºC 10’? 4ºC 
PEI (25 kD) stock 
solution (125 mM) 
This was made assuming  the molecular weight was 
44. 275 mg PEI was dissolved in 40 ml H2O and 
heated in 70ºC water-bath with stirring until all 
dissolved. The pH was adjusted to 7 using HCl. The 
volume was adjusted to 50 ml. The solution was 
aliquoted and stored at -20ºC. 
PEI working 
solution (10 mM)  
1 ml stock (125 mM) was mixed with 11.5 ml H2O, 
aliquoted and stored at -20ºC. 
Sequencing 
reaction mix (10 µl) 
· 0.5 µl (10-20 ng) DNA sample 
· 0.32 µl primer (from 5 µM stock) 
· 2 µl sequencing buffer (2.5×) 
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 · 2 µl BigDye 3 (ABI PRISM BigDye Kit) 
· 5.18 µl H2O 
· Programme: (96ºC 10”? 50ºC 5”? 60ºC 4’) × 24 
?  4ºC 
 
 
 
2.6.2 Galectin-3/Bcl-2 cDNA plasmid preparation 
 
a. Agar stabs of galectin-3 and Bcl-2 cDNA plasmid clones were subcultured 
on ampicillin-containing agar plates at 37ºC overnight. 
b. A single colony from each plate was innoculated in ampicillin-containing 
LB medium and grown in a shaking incubator at 37ºC overnight. 
c. Glycerol stocks were made by adding 500 µl LB culture to 250 µl 50% 
filter-sterilised glycerol, vortexed and stored at -80ºC. 
d. Plasmid DNA was extracted from the bacterial cells using QIAprep Spin 
Miniprep Kit. 
e. DNA from both plasmid clones (galectin-3 and Bcl-2) was sequenced to 
confirm that the expected cDNA inserts were present and correct using 
ABI PRISM BigDye Kit. 
f. Sequencing reactions were cleaned as follows: 
i) 10 µl reaction product, 1 µl 3 M NaOAc and 25 µl cold ethanol (-20ºC) 
were mixed together and incubated on ice for 10 minutes. 
ii) Product was centrifuged at 14,000 RPM, 4ºC for 20 minutes. 
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iii) Product was washed with 125 µl cold 70% ethanol (-20ºC) at 14,000 
RPM, 4ºC for 5 minutes. 
iv) Pellet was air dried at 37ºC for 3 minutes before being re-suspended in 
10 µl Hi-di formamide and denatured at 95ºC for 4 minutes. 
v) Product was analysed on the ABI 3100 sequencing machine (Applied 
Biosystems). 
 
2.6.3 Cloning 
 
a. PCR amplification of galectin-3 and Bcl-2 full length cDNA. 
 
PCR primers were designed to amplify the full length cDNA of galectin-3 and 
Bcl-2 from the plasmid clones. Restriction sites were incorporated into the 5’ 
ends of the forward primer (HindIII) and the reverse primer (XhoI) compatible 
with the cloning sites of the pCMV.Tag 4A vector. The PCR amplification (20 
µlx5) was carried out using pfu polymerase. The PCR products were cut and 
extracted from the gel using QIAquick Gel Extraction Kit. 
 
b. Restriction digestion of galectin-3 and Bcl-2 PCR products of pCMV.Tag 
4A vector.  
 
i) PCR products extracted from the gel and the pCMV.Tag 4A vector were 
digested with the restriction enzymes HindIII and XhoI (New England 
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Biolab, the buffer and BSA were provided with the enzyme kit) at 37ºC 
overnight as follows. 
 
 
Table 2.16 Digestion buffer 
 
 
 DNA extracted from the gel Vector 
DNA 200 ng (24 µl) 5 µg (5 µl) 
Buffer 2  5 µl 1 µl 
BSA 5 µl 1 µl 
Hind??? (20 U/ml) 5 µl 1 µl 
Xho? (20 U/ml) 5 µl 1 µl 
H2O 6 µl (up to 50 µl) 1 µl (up to 10 µl) 
 
ii) Digestion products were purified using Wizard DNA Clean-up System 
(Promega). 
iii) DNA in the purified product was quantified. 
 
c. Dephosphorylation of the vector 
 
i) The total number of 5’- and 3’-ends in the digested vector was calculated 
as follows: 
1 µg 1 kb = 1.52 pmol DNA 
1 µg 4.3 kb (e.g. pCMV.Tag 4A is 4.3 kb) = 1.52/4.3 = 0.353 pmol DNA 
The purified product was 50 µl 330 ng/ul DNA. Therefore the total 
amount of DNA was 0.33 × 50 = 16.5 µg = 5.82 pmol (16.5 × 0.353). 
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The amount of 5’- and 3’-ends in 25 µl (i.e. 2.91 pmol, 5.82/(50/25)), 
was 2.91 × 2 = 5.82 pmol.  
0.01 U/pmol calf intestinal alkaline phosphatase (CIAP kit, Promega) 
was used, i.e. 0.06 U CIAP for 5.82 pmol.  
ii) 1:100 dilution of  the 1 U/µl CIAP stock was made by adding 1 µl stock in 
99 µl 1×buffer (1:10 dilution of the 10x buffer provided with the Kit). 50 µl 
reaction was made by mixing 25 µl vector, 5 µl 10×buffer, 6 µl CIAP 
dilution (0.01 U/µl) and 14 µl H2O, as calculated above. 
iii) The reaction mix was incubated at 37ºC for 30 minutes 
iv) 6 µl of 0.01 U/µl CIAP was added to the reaction. 
v) The reaction mix was incubated at 37ºC for another 30 minutes. 
vi) 300 µl CIAP stop buffer (see Table 15) was added to the reaction. 
vii) The product was purified with Wizard DNA Clean-up System (Promega). 
viii) The amount of DNA in the product was quantified. 
 
d. Ligation 
 
Digested galectin-3 and Bcl-2 products were ligated into the digested and 
dephosphorylated pCMV.Tag 4A vector. Vector:insert ratio of 1:3 was used.  
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Table 2.17 Vector:insert ratio for ligation  
 
 kb ng/µl ratio ng µl 
Vector 4.3 256 1 100 100/256=0.4 
Insert 0.9 36 3 100×0.9×3/4.3=63 63/36=1.75 
 
10 µl reactions were set up by mixing 0.4 µl vector (100 ng), 1.75 µl insert 
(1:3), 1 µl 10×buffer, 1 µl T4 DNA ligase (New England Biolab) and 5.85 µl 
H2O (up to 10 µl). Ligation was carried out at 14ºC overnight. 
 
e. Transformation 
 
i) DH5a competent cells were thawed on ice and gently mixed by tapping. 
ii) 50 µl cells and 10 µl ligation product were incubated on ice for 30 minutes. 
iii) Cells were heat-shocked in 42ºC water bath for 45 seconds without 
shaking. 
iv) Cells were incubated on ice for 2 minutes. 
v) 0.9 ml S.O.C. medium (provided with the competent cells by Invitrogen) 
was added using sterile tips. 
vi) Cells were shaken at 37ºC for 1 hour. 
vii) Cells were centrifuged briefly. Most of the supernatant (leave 100 µl) was 
discarded. 
viii) Cells were resuspended by gentle tapping, transferred to a LB agar plate 
containing ampicillin and spread evenly by a sterile spreader by a flame. 
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ix) Cells were incubated at 37ºC overnight. 
 
 
f. Screening transformation reaction for colonies containing galectin-3 and 
Bcl-2 insert. 
 
i) Colonies were screened by PCR using galectin-3 or Bcl-2 primers (Table 
2.14).  
ii) Positive colonies were inoculated in 5 ml LB medium with ampicillin in a 
shaking incubator at 37ºC overnight. 
iii) A glycerol stock of each positive colony was made by mixing 500 µl LB 
culture and 250 µl 50% glycerol. This was vortexed and stored at -70ºC. 
The rest was mini-preped using QIAprep Spin Miniprep Kit (Qiagen). 
iv) 20 ng plasmid DNA was used in a sequencing reaction (Table 2.15) with 
Sp6 and T7 primer to determine whether or not the expected insert had 
been cloned. 
v) If the sequence was correct, a maxi-prep of the cDNA clone was prepared 
by subculturing from the glycerol stock and using QIAGEN Plasmid Maxi 
Kit  for transfection experiments (see 2.6.4 & 2.6.5).  
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2.6.4 Transfection I  using Ca3(PO4)2 precipitation 
 
i) Hek293 cells were subcultured on 10 cm TC plates from TC flasks at 
appropriate densities, e.g. cells in a 150 cm2 TC flask with 70% 
confluence were seeded on 10 plates. 
ii) Top medium was changed with 10 ml fresh DME medium after 24-hour 
culture and the plates were cultured for additional 2 hours.  
iii) HBS (2×) buffer (Table 2.15) was thawed on ice. 
iv) 10 ml 2 M CaCl2 solution was made in a 10 ml measuring cylinder by 
adding 2.94 g calcium chloride dihydrate (BDH, Table 2.13) and H2O 
slowly to 10 ml. 
v) 10 µg DNA, 68.2 µl 2 M CaCl2 solution and H2O, up to 550 µl, were mixed 
in a 1.5 ml eppendorf and dropped into 550 µl HBS (2×) slowly with 
vortexing. This was incubated at room temperature for 20 minutes before 
being dropped evenly and slowly to cells on the plate. 
vi) Cells were cultured for 24 hours before the medium was refreshed and 
collected at 48-hour after transfection. 
 
 
2.6.5 Transfection II using Polyethyleneimine (PEI) 
 
i) HEK293 cells were subcultured on 10 cm TC plates at appropriate 
densities 24-hour before transfection. One additional plate was made to 
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be transfected with pEGFP-N3 vector as a control for transfection 
efficiency. 
ii) Medium (6 ml/10 cm plate) was refreshed at least 1 hour before 
transfection. 
iii) PEI solution was made by mixing 550 µl 150 mM NaCl and 150 µl 10 mM 
PEI. 
iv) DNA solution was made by mixing 10 µg DNA and 150 mM NaCl (up to 
700 µl). 
v) PEI solution was dropped into DNA solution slowly with vortexing. This 
was incubated at room temperature for 30 minutes. 
vi) The PEI and DNA mix was dropped on cells slowly while shaking the plate 
and cultured for 5 hours before the medium was refreshed.  
vii) GFP expression was checked after 24 hours using a UV-laser microscope 
by the presence of green fluorescence in the transfected cells. 
Transfection efficiency was checked by flow cytometry by analysing the 
percentage of green fluorescent cells. 
viii) Cells were collected after 48-72 hours. 
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2.7 Immunofluorescent imaging 
 
2.7.1 Reagents and materials 
 
 
Table 2.18 Reagents used for immunofluorescent imaging 
 
 
Reagents Suppliers, Catalogue No. / preparation 
Anti-Bcl-2, rabbit  Abcam, ab7973 
Anti-galectin-3, rabbit Abcam, ab2473 
ImmEdge Pen Vector Laboratories, H-4000 
Anti-Mouse-IgG AlexaFluor 
488, donkey Molecular Probe, A-21202 
Anti-Mouse-IgG PE, goat  Sigma, P9287 
Anti-Rabbit-IgG PE, goat Sigma, P9795 
0.1% PBST 1 ml Tween 20 was added to 1 L PBS solution. 
2% PFA (fixative, toxic, 500 
ml) 
 
· 2% PFA (10 g) 
· 100 mM NaCl (50 ml 5 M stock) 
· 300 mM sucrose (51 g) 
· 3 mM MgCl2 (1.5 ml of 1 M stock) 
· 1 mM EGTA (5 ml of 100 mM stock) 
· 10 mM PIPES pH 6.8 (5 ml of 1 M stock) 
· H2O (up to 500 ml) 
· Heated in 60ºC water-bath for 0.5 hour 
to dissolve. 
· Aliquoted and stored at -20ºC. 
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2.7.2 Imaging of suspension cells 
 
i) Slides were labelled for different samples. For each secondary antibody / 
cell line / combination of secondary antibodies and cell line, a non-
specific-binding control with cells stained with only secondary antibody / 
combination of secondary antibodies was labelled and made. The 
fluorescence of this control was to be deducted from the background. 
ii) Cytospin preparations were made. 150-200 µl confluent cells were spun 
onto glass slides at 500 RPM, 5 minutes. 
iii) Cells were air dried for 1-2 minutes at room temperature.  
iv) Cell pellet was circled completely with the ImmEdge pen. 
v) Cells were fixed with 2% PFA (Table 2.18) for 10 minutes. 
vi) Cells were permeabilised with cold 0.1% PBST (Table 2.18) for 5 minutes. 
vii) Cells were blocked with 3% FCS in PBS for 30 minutes, and stained with 
primary antibody at 4ºC overnight. 
viii) Cells were washed with 0.1% PBST 5 minutes × 6, and stained with 
secondary antibody  at room temperature in the dark for 2 hours. 
ix) Cells were washed with 0.1% PBST 5 minutes × 4, and stained with DAPI 
(1:10 000) for 5 minutes. 
x) Cells were washed with 0.1% PBST 5 minites × 2 before mounted and 
and air dried. 
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2.8. Real-time Quantitative PCR 
 
All reagents and primers were purchased from Applied Biosystems unless 
otherwise stated.  
 
Nox-5 primers are PDAR (predeveloped assay reagent, 20x) from Applied 
Biosystems (proprietary-product ID Hs00225846_m1).  
 
The primer/probe sequences for c-ABL were as follows:  
 
c-ABL Forward: 5’-TGGAGATAACACTCTAAGCATAACTAAAGG-3’ 
c-ABL Reverse: 5’-GATGTAGTTGCTTGGGACCCA-3’ 
c-ABL Probe (Eurengentech): FAM5’-CCATTTTTGGTTTGGGCTTCACACCATT-
3’TAMRA.  
 
Total RNA was extracted from 1-10x106 cells using RNeasy Mini Kit (Qiagen), 
and reverse transcribed using Superscript reverse transcriptase (Invitrogen).  
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2.8.1 Reverse transcription 
 
i) 1 µl Random primer (200 ng/µl), 1 µl dNTP mix (10 mM of A, T, C, G type) 
and RNA free H2O (to make up the final volume of 12 µl with the volume 
of RNA samples deducted) were mixed together. 
ii) Total RNA samples (no more than 5 µg)  were added in triplicate. 
iii) One sample was specified as RT-blank control containing all of the above 
reagents with any one of the RNA samples but no Superscript (RT-
enzyme).  
iv) Samples were Incubated at 65ºC for 5 minutes, cooled down on ice and 
flash spun. 
v) 4 µl First-strand Buffer (5x),  2 µl 0.1 M DTT and 1 µl RNase Out (40 U/µl) 
were added to each sample. 
vi) Samples were Incubated at 25ºC for 10 minutes. 
vii) 1 µl Superscript were added to each sample except the RT-blank control. 
viii) Samples were incubated at 42ºC for 50 minutes, 70ºC for 15 minutes to 
inactivate the enzyme and stored at -20ºC. 
 
2.8.2 Quantitative PCR (qPCR) 
 
i) 20 µl qPCR reaction was prepared by mixing 10 µl TaqMan Master Mix 
(2x, containing Taq, dNTP, etc), 1 µl PDAR (predeveloped assay reagent, 
20x), 100 ng cDNA sample and H2O (up to 20 µl).     
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ii) 20 µl c-ABL control reaction (endogenous control) was prepared by mixing 
10 µl TaqMan Master Mix (2x), 0.6 µl c-ABL forward primer, 0.6 µl c-ABL 
reverse primer, 0.4 µl c-ABL probe (final primer/probe concentrations 900 
nM and 250 nM, respectively), H2O (up to 20 µl) and 100 ng cDNA 
sample. 
iii) A standard curve was made by using standardized cDNA samples with 
increasing concentration of 0.1, 1, 10 and 100 ng of cDNA. Negative 
controls with no DNA were also included. Samples were prepared in 
triplicate to reduce the statistical error. 
iv) Thermal cycling was performed on the ABI7700 under the standard 
conditions: 94ºC 10 minutes ?  94ºC 15 seconds ?  60ºC 1 minute, 40 
cycles.  
v) Ct values were normalized relative to c-ABL. 
 
 
2.9 Statistical Analysis 
 
 
Statistical analysis was performed using MINITAP 15.0 software. One-way 
ANOVA was used to evaluate the statistical differences between experiments 
repeated in at least triplicate. When p values <0.05, the differences are 
considered significant. 
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Apoptosis can be induced via many mechanisms. It is known that modified 
citrus pectin can antagonize the anti-apoptotic action of galectin-3 and induce 
apoptosis in tumour cells (see 1.7). GCS-100 is a novel type of modified 
citrus pectin and induces apoptosis in human multiple myeloma cells 
(Chauhan, Li et al. 2005). It has also shown anti-tumour effects in patients 
with colorectal and pancreatic cancers (Cotter 2004; Gunzburg and Salmons 
2001). When these studies were initiated in 1998, GCS-100 was attracting 
interest as a therapeutic agent in clinical trial for cancer treatment. It seemed 
pertinent therefore, to study its effects on apoptosis in human malignant B-
lineage cell lines, primary CLL cells, normal human lymphocytes and certain 
additional human cell lines. The interference of GCS-100 in the mitochondrial 
apoptotic pathway was focused and changes in mitochondrial staining and 
plasma membrane were measured as a correlate of apoptosis. The effects of 
concurrent treatment with GCS-100 and VP-16, a chemotherapeutic drug for 
leukaemia, were also studied in order to determine if they act synergistically 
in leukaemia cells. Caspase activation, one of the major events in the 
apoptotic cascade, was examined in GCS-100- and/or VP-16- treated cells to 
further confirm their pro-apoptotic effects, both alone and in combination. 
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3.1 Effects of GCS-100 in DOHH2 and primary lymphocytes. 
 
As stated above, GCS-100 induces apoptosis in multiple myeloma cells 
(Chauhan, Li et al. 2005). Whether or not it has the same effects in human 
mature B cells has not been investigated. Here the pro-apoptotic effects of 
GCS-100 were examined in DOHH2, a B-lineage cell line, and primary 
lymphocytes, including cells from CLL patients and normal donors. This was 
achieved by measuring changes in mitochondrial transmembrane potential 
(DiOC6(3) staining) and disorders in plasma membrane (MC540 staining), 
both typical events in apoptosis, and widely used for investigations of this 
type in cells of diverse origin (Laakko, King et al. 2002; Ozgen, Savasan et al. 
2000). 
 
 
3.1.1 Effects of GCS-100 in DOHH2 cells 
 
DOHH2 is a mature B cell line which expresses high levels of Bcl-2 and is 
resistant to many chemotherapeutic drugs (Kluin-Nelemans, Limpens et al. 
1991). These cells were treated with GCS-100 and stained with DiOC6(3) 
and MC540. An increase in the MC540 staining detected on FL-2 channel, 
consistent with perturbation in plasma membrane, and a decrease in the 
DiOC6(3) staining detected on FL-1 channel, consistent with changes in 
mitochondrial inner membrane potential (DeltaPsi(m)), were seen in GCS-
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100-treated cells. Data from an individual experiment are illustrated in Figure 
3.1, by way of exemplification. Complete data for this cell line, based on a 
minimum of 3 experiments, are presented in Figure 3.2 and Figure 3.3. Here, 
MC540 positive and DiOC6(3) negative cells were quantified using WinMDI 
software, and were found to be significantly increased (p<0.01) after GCS-
100 treatment. 
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Figure 3.1 Flow analysis of the pro-apoptotic effects of GCS-100 in DOHH2 cells. Cells 
were treated with or without (control) 40 µg/ml GCS-100 for 24 hours and then stained with 
either MC540 or DiOC6(3) before flow analysis. (A) Cell debris was gated out on the FS/SS 
plot. (i) non-treated cells stained with MC540; (ii) GCS-100-treated cells stained with MC540, 
showing a marked positive shift on FL-2 channel; (iii) non-treated cells stained with DiOC6(3); 
(iv) GCS-100-treated cells stained with DiOC6(3), showing a marked negative shift on FL-1 
channel. R1, region 1; FS, forward scatter; SS, side scatter. 
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Figure 3.2 Flow analysis of the effect of GCS-100 on membrane integrity in DOHH2 
cells. Cells  were treated with or without 20 or 40 µg/ml GCS-100 for 24 hours and then 
stained with MC540 before flow analysis. Data were quantified and analysed as described in 
Chapter 2. GCS-100 treatment with both doses increased the MC540 positive population 
significantly. *, p<0.01 (n=3). 
 
 
 
 
 
 
* * 
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Figure 3.3 Flow analysis of mitochondrial DeltaPsi(m) dissipation induced by GCS-100 
in DOHH2 cells. Cells were treated with or without 20 or 40 µg/ml GCS-100 for 24 hours and 
then stained with DiOC6(3) before flow analysis. Data were quantified and analysed as 
described in Chapter 2. GCS-100 treatment with both doses increased the DiOC6(3) 
negative population significantly. *, p<0.01 (n=3). 
 
 
 
3.1.2 Effects of GCS-100 in primary CLL cells. 
 
While GCS-100 clearly induces apoptosis in human primary multiple 
myeloma cells and B cell lines, the effect of the agent in primary chronic 
lymphocytic leukaemia (CLL) cells has not been reported. Data on the 
lymphocytes of CLL patients studied are summarised in Appendix I. Thus, 
using freshly isolated lymphocytes from whole blood samples of CLL patients 
* 
* 
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with white cell counts in excess of 100x109/L, the pro-apoptotic effects of 
GCS-100 were investigated by DiOC6(3) and MC540 staining and flow 
cytometry.  As with the cell line DOHH2, CLL cells were treated with 
increasing doses of GCS-100 for 24 hours prior to MC540 and DiOC6(3) 
staining and flow analysis. By contrast with the cell lines, there was much 
greater variability in the numbers of cells undergoing apoptosis in the 
untreated (control) population shown, for clarity, as individual values in Figure 
3.5(A) and correspondingly reflected in the values for the treated CLL 
samples. Nevertheless, a right-shift on FL-2 channel was demonstrated in 
MC540-stained cells after GCS-100 treatment which was clearly dose-related 
as exemplified in Figure 3.4. Regardless of the level of pretreatment 
apoptosis (i.e. that observed in the controls), all samples were characterised 
by an increase in the MC540-positive population on GCS-100 exposure. Data 
from CLL cells (from 8 patients), collectively quantified, are summarised and 
statistically analysed in Figure 3.5(B). Significant differences in the MC540-
positive population were found between treated and non-treated cells, 
confirming the pattern of findings exemplified in Figure 3.4. 
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Figure 3.4 Flow analysis of the effects of GCS-100 in primary CLL cells using MC540 
staining. Freshly isolated CLL cells were treated with or without different doses of GCS-100 
for 24 hours prior to MC540 staining and flow analysis. A marked right-shift on FL-2 channel 
was detected in GCS-100-treated cells. (A) non-treated; (B) 10 µg/ml GCS-100-treated; (C) 
30 µg/ml GCS-100-treated; (D) 50 µg/ml GCS-100 treated. 
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Figure 3.5 Summary of GCS-100 effects in primary CLL cells using MC540 staining and 
flow cytometry. Lymphocytes from eight samples of CLL patients (see Appendix I) were 
treated with or without different doses of GCS-100 for 24 hours prior to MC540 staining and 
flow analysis. Significant changes in the MC540-positive population between treated and 
non-treated cells were observed. (A) Summarised data from eight CLL samples; (B) Means 
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and standard errors for these data. Data were analysed as previously described in Chapter 2. 
*, p<0.05; **, p<0.01; n=8. 
 
Similar effects of GCS-100 were seen in DiOC6(3)-stained cells where a 
marked left-shift on FL-1 channel was detected after GCS-100 treatment as 
exemplified in Figure 3.6. Data quantification and statistical analysis revealed 
significant differences in the DiOC6(3)-negative population between treated 
and non-treated cells at all doses with the exception of 30 µg/ml (Figure 3.7). 
Notwithstanding this unexplained result, there was a statistically significant 
trend for GCS-100-treated CLL cells to exhibit a greater degree of apoptosis 
than untreated controls. 
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Figure 3.6 Flow analysis of the effects of GCS-100 in primary CLL cells using DiOC6(3) 
staining. Freshly isolated CLL cells were treated with or without different doses of GCS-100 
for 24 hours prior to DiOC6(3) staining and flow analysis. A marked left-shift on FL-1 channel 
was detected in GCS-100-treated cells. (A) non-treated; (B) 10 µg/ml GCS-100-treated; (C) 
30 µg/ml GCS-100-treated; (D) 50 µg/ml GCS-100-treated. 
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Figure 3.7 Summary of GCS-100 effects in primary CLL cells using DiOC6(3) staining 
and flow cytometry. Lymphocytes from five CLL patients (see Appendix I) were treated with 
or without different doses of GCS-100 for 24 hours prior to DiOC6(3) staining and flow 
analysis. Significant changes in the DiOC6(3)-negative population between treated and non-
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treated cells were shown with the exception of the 30 µg/ml dose. (A) Summarised data from 
five CLL patients; (B) Means and standard errors for these data. *, p<0.05; **, p<0.01; n=5. 
 
Notwithstanding the demonstration of apoptosis induction by GCS-100 in vitro 
in CLL cells in the foregoing experiments, the number of CLL samples 
examined for this property was too small to make any correlations with 
immunological and genetic parameters or treatment status of the patients 
listed in Appendix I. 
 
 
3.1.3 Effects of GCS-100 in human normal lymphocytes. 
 
The cytotoxic effects of GCS-100 in human normal lymphocytes were studied 
previously using cell viability assays (Chauhan, Li et al. 2005). However, any 
potential pro-apoptotic effect of the agent in these cells has not been 
reported. Therefore, using freshly isolated lymphocytes from three normal 
donors, the effects of GCS-100 on mitochondrial transmembrane potential 
were investigated. Ideally, for comparison with transformed B cells (as in 
CLL), such experiments should have been conducted with purified B cells or 
at least populations enriched for the B cell compartment. However, due to the 
limited availability of samples, it was impossible to recover sufficient pure B 
cells for this study. Any potential effect of GCS-100 on normal B cells was 
thus inferential and based on the following reasoning: It is known that typically 
5-10% of normal peripheral blood mononuclear cells are B cells (Splawski, 
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Lipsky et al. 1997). If GCS-100 had the same pro-apoptotic effects on normal 
B cells as on CLL cells, which showed an approximately 10% difference in 
DeltaPsi(m) collapse between control and treated cells at the highest dose 
(60 µg/ml, see Figure 3.7), only a 0.5-1% (5-10%x10%) difference between 
control and treated cells might have been expected, a difference outside the 
capacity of the assay for reliable detection. However, in the event, at all 
doses the trend was toward a decrease in the DiOC6(3)-negative population, 
i.e. the number of apoptotic cells decreased. This was particularly marked at 
the highest dose of 200 µg/ml for 48 hours where the population in 
DeltaPsi(m) collapse was lower even than the controls. On these grounds it is 
concluded that induction of an apoptotic effect in normal B cells by GCS-100 
is unlikely, and that the effect of the agent on transformed B cells is selective 
to that extent. 
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Figure 3.8  Flow analysis of the pro-apoptotic effects of GCS-100 in unfractionated 
human normal lymphocytes. Lymphocytes were freshly isolated from three normal 
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peripheral blood samples and incubated with 0-200 µg/ml GCS-100 for 24 or 48 hours prior 
to flow cytometry analysis with DiOC6(3) staining. Statistical analysis was undertaken as 
previously described (see legend in Figure 3.2). No significant differences (p>0.05, n=3) were 
found between control and treated cells. By contrast with CLL cells, there was a downward 
trend in the DiOC6(3)-negative population. 
 
 
3.2 Effects of VP-16 in GCS-100-treated cell lines. 
 
VP-16, or etoposide, is a semi-synthetic derivative of podophyllotoxin that 
exhibits anti-tumour activity. VP-16 inhibits DNA synthesis by forming a 
complex with topoisomerase II and DNA and has been used for the treatment 
of haematopoietic malignancies (Martins, Mesner et al. 1997). However, the 
cytotoxic effects of the drug have restricted its use at high doses for treatment 
of these neoplasms. It was pertinent therefore to ask the question whether 
GCS-100 might facilitate the pro-apoptotic effects of VP-16 as a potential 
basis for its use in a lower dose regimen. The effect of combined treatment 
with the drugs in human haemapoietic cell lines was therefore investigated 
using the methodologies previously applied. 
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3.2.1 Effects of GCS-100 and VP-16 in DOHH2 cells. 
 
Dose-response curves for VP-16 were derived with or without (control) pre-
incubation with GCS-100. VP-16 alone induced apoptosis in DOHH2 cells in 
a dose-dependent manner (Figure 3.9, red). As anticipated from earlier 
experiments, pre-incubation for 24 hours with GCS-100 at both doses 
induced a level of apoptosis which exceeded that in the untreated controls. 
However, this was enhanced by subsequent exposure to VP-16 in a dose-
dependent manner, especially at concentrations higher than 1 µM. Thus, pre-
incubation with GCS-100 shifted the dose-response curve of VP-16 to the left, 
significantly (p<0.05, n=3) enhancing the pro-apoptotic effects of VP-16 
(Figure 3.9, blue and green). EC50 values were calculated by GraphPad 
Prizm software and statistically analysed, as shown in Table 3.1. 
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Figure 3.9 Flow analysis of effects of combined treatment of DOHH2 cells with GCS-
100 and VP-16. Cells were treated with or without (control) GCS-100 for 24 hours prior to 
incubation with different doses of VP-16 for 20 hours. Cells were then stained with (A) 
MC540 and (B) DiOC6(3) and analysed by flow cytometry. GCS-100 reduced the EC50 value 
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for VP-16 and therefore facilitated the pro-apoptotic effects of VP-16 (see Table 3.1, 
statistical analysis was undertaken as described in Chapter 2, n=3). 
 
 
Table 3.1 EC50s of GCS-100/VP-16 treatment in DOHH2 cells. 
Cell 
Line 
GCS-100 
(µg/ml) 
EC50 (µM, 
MC540) 
P 
value 
EC50 (µM, 
DiOC6(3)) 
P 
value 
DOHH2 
0 >10 
<0.05 
>10 
<0.01 20 0.8 0.1 
40 0.05 0.007 
 
 
 
3.2.2 Effects of GCS-100 and VP-16 in RAMOS cells. 
 
RAMOS is a B lymphoma cell line which expresses a p53 mutation (see 
2.2.2). As DOHH2 cells have wild type p53, the question whether p53 
mutations could alter the cell response to GCS-100/VP-16 was addressed, 
using the same methodology to determine pro-apoptotic effects. RAMOS 
cells differed from DOHH2 cells in their greater sensitivity to apoptosis 
induction by GCS-100 alone, a factor which appeared to contribute to their 
much enhanced sensitivity, relative to DOHH2, to the combination of drugs 
(Figure 3.10), as evident from the EC50 calculations (Table 3.2). Greater 
sensitivity to apoptosis induction in a cell line containing a p53 mutation could 
be argued as counter-intuitive, but caution needs to be exercised about such 
limited data. 
Bo Su, 2010. Chapter 3: Apoptosis induction by GCS-100           
 
- 135 -
Effects of VP-16/GCS-100 in RAMOS cells
10-4 10-3 10-2 10-1 100 101 102
0
1000
2000
3000
4000
5000
6000 No GCS-100
20ug/ml
40ug/ml
VP-16, mM
C
el
l C
ou
nt
, M
C
54
0+
 
Effects of VP-16/GCS-100 in RAMOS cells
10-4 10-3 10-2 10-1 100 101 102
0
1000
2000
3000
4000
5000
No GCS-100
20ug/ml
40ug/ml
VP-16, mM
C
el
l C
ou
nt
, D
iO
C
6(
3)
-
 
Figure 3.10 Flow analysis of effects of combined treatment of RAMOS cells with GCS-
100 and VP-16. Cells were treated with or without GCS-100 for 24 hours before incubation 
with different doses of VP-16 for 20 hours. Cells were then stained with (A) MC540 and (B) 
DiOC6(3) and analysed by flow cytometry. GCS-100 reduced the EC50 value for VP-16 and 
therefore facilitated the pro-apoptotic effects of VP-16 (see Table 3.2, statistical analysis was 
undertaken as described in Chapter 2, n=3). 
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Table 3.2 EC50s of GCS-100/VP-16 treatment in RAMOS cells 
Cell 
Line 
GCS-100 
(µg/ml) 
EC50 (µM, 
MC540) 
P 
value 
EC50 (µM, 
DiOC6(3)) 
P 
value 
RAMOS 
0 >10 
<0.01 
3.2 
<0.01 20 0.008 0.005 
40 0.004 0.003 
 
  
 
 
3.2.3 Effects of GCS-100 and VP-16 in K562 cells. 
 
The K562 cell line is derived from myeloid leukaemia (see 2.2.2) and, by 
contrast with DOHH2 and RAMOS cells, showed greater resistance to both 
VP-16 and GCS-100 treatment alone (Figure 3.11). However, GCS-100 at 40 
µg/ml still reduced the EC50 of VP-16, exhibiting greater pro-apoptotic effects 
for the drugs in combination, even in this relatively resistant cell line.  
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Figure 3.11 Flow analysis of effects of combined treatment of K562 cells with GCS-100 
and VP-16. Cells were treated with or without (control) GCS-100 for 24 hours prior to 
incubation with different doses of VP-16 for 20 hours. Cells were then stained with (A) 
MC540 and (B) DiOC6(3) and analysed by flow cytometry. GCS-100 reduced the EC50 value 
for VP-16 and therefore facilitated the pro-apoptotic effects of VP-16 (see Table 3.3, 
statisitcal analysis was undertaken as described in Chapter 2, n=3). 
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Table 3.3 EC50s of GCS-100/VP-16 treatment in K562 cells. 
Cell 
Line 
GCS-100 
(µg/ml) 
EC50 (µM, 
MC540) 
P 
value 
EC50 (µM, 
DiOC6(3)) 
P 
value 
K562 
0 >10 
<0.01 
>10 
<0.05 20 >10 >10 
40 1.5 6.8 
 
 
The above data from 3.2.1 to 3.2.3 showed that apoptosis could be induced 
by GCS-100/VP-16 in human haematopoietic malignant cells, with differential 
potency depending on the cell line. Relatively speaking, DOHH2 and RAMOS 
cells appeared to be more sensitive to apoptosis induction by GCS-100/VP-
16 than K562 cells. In VP-16 treated cell lines, pre-treatment with GCS-100 
enhanced the induction of apoptosis to different degrees, depending on the 
cell type. 
 
 
3.3 GCS-100 and the mitochondrial apoptotic pathway. 
 
It has been established herein that GCS-100 induces apoptosis either alone 
or in combination with VP-16 in human malignant B cells (see 3.1 & 3.2). The 
next part of this project set out to determine the effect of the agent on the 
apoptotic pathway. As most apoptosis inducers act via either caspase-8 or 
caspase-9, immunoblotting analysis was performed (see 2.5) to determine 
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which of these two enzymes was involved in the effect of GCS-100. Such an 
experiment would also confirm the pro-apoptotic effects of GCS-100 shown in 
3.1 and 3.2, as distinct from an artefact of flow cytometric methodology, since 
activation of either caspase is one of the major defining events in the 
apoptotic cascade (see 1.2). 
 
Caspase-8 activation is involved in the extrinsic apoptotic pathway (see 1.2) 
and was first analysed in GCS-100/VP-16-treated DOHH2 cells. This enzyme 
must become cleaved in order to produce its effects (see 1.2.1). However, 
cleavage of caspase-8 was not detected in DOHH2 cells after 24-hour 
incubation with GCS-100 at a dose of up to 100 µg/ml (Figure 3.12(A)). By 
contrast, cleavage of caspase-9, the enzyme involved in the intrinsic 
apoptotic pathway (see 1.2), was clearly seen in cells treated with either 
GCS-100 alone or in combination with VP-16 (Figure 3.12(B)). 
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Figure 3.12  Western analysis of caspase-8 and -9 activities in DOHH2 cells after 
incubation with GCS-100, either alone or in combination with VP16. Western blotting 
was performed as stated above (see 2.5). Whole cell lysates were prepared from 10x106 
cells incubated with medium alone, GCS-100 at various concentrations from 40 to 100 µg/ml, 
VP-16 1 µM, or GCS-100 and VP-16 together, and analysed by Western blotting for 
activation of (A) caspase-8 and (B) caspase-9. (A) The anti-caspase-8 antibody is directed 
against the p18 subunit which detects pro-caspase 8 (p55/54) and the intermediate cleavage 
products of 43 kD and 41 kD (p43/41). No cleavage products were detected after incubation 
with GCS-100, VP-16 or the two in combination. Lane 1, control with no treatment; Lane 2, 
VP16 1 µM for 16 hours; Lane 3, GCS-100 40 µg/ml; Lane 4, GCS-100 80 µg/ml; Lane 5, 
GCS-100 100 µg/ml, all for 24 hours; Lane 6, GCS-100 40 µg/ml 6 hours + VP16 1 µM for 16 
hours; Lane 7, anti-FAS 100 ng/ml for 4 hours, as a positive control for caspase-8 activation. 
(B) The anti-caspase-9 antibody detects the inactive pro-caspase-9 (approximately 46 kD) 
and following activation cleaved caspase-9 of approximately 35 and 37 kD. Although GCS-
Pro-caspase-9 
Cleaved caspase-9 
Beta-actin 
Bo Su, 2010. Chapter 3: Apoptosis induction by GCS-100           
 
- 141 -
100 and VP-16 alone both induced caspase-9 cleavage, this effect was enhanced when the 
two were used in combination. Lane 1, control with no treatment; Lane 2, VP16 1 µM for 16 
hours; Lane 3, GCS-100 40 µg/ml; Lane 4, GCS-100 80 µg/ml; Lane 5, GCS-100 100 µg/ml, 
all for 24 hours; Lane 6, GCS-100 40 µg/ml 6 hours + VP16 1 µM for 16 hours. 
 
 
3.4 GCS-100 and ROS generation. 
 
ROS generation is an important mechanism for apoptosis induction, in 
particular when the mitochondrial apoptotic pathway was involved (see 1.2.2). 
To further investigate the possible mechanism of apoptosis induction by 
GCS-100, the question whether this agent has ROS-generating effect was 
explored. To address this question, DOHH2 cells, among the most 
susceptible of all the cell lines studied for the apoptosis-inducing effect of 
GCS-100, were treated with various doses of GCS-100 and ROS production 
was measured by dihydroethidium (DHE) staining and flow cytometry (see 
2.3). No significant enhancement (p>0.05, n=3) of intracellular ROS was 
detected at doses of up to 160 µg/ml for 24 hours (Figure 3.13), conditions 
under which apoptosis was readily induced in this cell line (see 3.1.1). 
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Figure 3.13  Flow analysis of the ROS-inducing effect of GCS-100 in DOHH2 cells. Cells 
were incubated with 0 (control) – 160 µg/ml GCS-100 for 1, 2, 4 or 24 hours. ROS generation 
was measured by flow cytometry with DHE staining (see 2.3). 100 µM PK11195-treated cells 
were used as positive control for ROS. No significant (p>0.05, n=3) ROS production was 
detected in GCS-100-treated cells. MFI, mean of fluorescence intensity; DHE, 
dihydroethidium; ROS, reactive oxygen species. 
 
 
Summary 
 
DiOC6(3) and MC540 staining are commonly used as surrogate measures of 
apoptosis (Laakko, King et al. 2002; Ozgen, Savasan et al. 2000). DiOC6(3) 
probes mitochondrial inner membrane potential (DeltaPsi(m)) changes by 
staining non-apoptotic mitochondrial membrane. When DeltaPsi(m) collapses 
– which happens during early apoptosis – the uptake of DiOC6(3) by a cell is 
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reduced which can be detected by flow cytometry. MC540 measures cell 
membrane integrity and lipid asymmetry, alterations which are associated 
with the membrane blebbing during apoptosis (see 2.3). These approaches 
have been successfully adopted to measure, in reproducible fashion, the 
apoptosis-inducing effects of GCS-100. 
 
In addition, the effect of GCS-100 on apoptosis has been demonstrated by 
immunoblotting studies on the mitochondrial apoptotic pathway. Thus two 
independent methodologies have established the pro-apoptotic properties of 
GCS-100 in cell types beyond that of multiple myeloma originally described in 
the literature. 
 
In this chapter, data have been presented which have shown unequivocally 
that the modified citrus pectin, GCS-100, is capable of inducing apoptosis in a 
dose-dependent manner in a variety of malignant cell lines of B cell 
provenance, as well as primary CLL cells. To the extent that apoptosis is not 
observed under similar conditions in normal lymphocytes, the effect would 
also appear to be selective for cells of the transformed state. GCS-100 also 
significantly (p<0.05, n=3) enhanced the pro-apoptotic effect of VP-16 in 
these cells, acting via the mitochondrial apoptotic pathway as evidenced by 
activation of caspase-9. The above findings suggest a basis for a novel, 
effective and putatively selective way to approach the treatment of 
haemotopoietic malignancies with GCS-100 per se, or more likely through 
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lowering the thresholds for apoptosis induction with established anti-tumour 
agents such as VP-16. 
 
In conclusion,  
 
i) GCS-100 induces apoptosis in human malignant B cells, including primary 
CLL cells, though it was not possible to relate this property to any of the 
patients’ laboratory parameters or clinical status (see Appendix I). DOHH2 
and RAMOS, the human malignant B-cell lines, showed the greatest 
sensitivity to GCS-100 in comparison with another cell line, K562, used in 
this study. The sensitivity of the RAMOS cells, which carries a p53 
mutation, could be considered counter-intuitive since p53 mutant tumour 
cells might generally be considered to be more resistant to apoptosis 
induction. 
ii) GCS-100 does not readily induce apoptosis in normal human 
lymphocytes. 
iii) GCS-100 significantly (p<0.05, n=3) enhances the pro-apoptotic effect of 
VP-16 in malignant cell lines. 
iv) GCS-100 acts via the mitochondrial caspase-9 pathway but not the 
caspase-8 pathway. 
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GCS-100 is theoretically an inhibitor of galectin-3 (see 1.7), thus the role that 
galectin-3 plays in the apoptosis-inducing effect of GCS-100 became of intrin-
sic interest and was investigated in Chapters 4 and 5.
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Chapter 4  Interaction of galectin-3 and Bcl-2 
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Having shown that GCS-100 induces apoptosis in malignant cells via the 
mitochondria-caspase-9 pathway, this chapter aims to investigate whether or 
not galectin-3 is a direct target for GCS-100 and  how galectin-3 interacts with 
Bcl-2 proteins in order to exert its effects on the caspase-9 pathway. Bcl-2 
proteins exert their effects through the mitochondrial permeability transition 
pore, controlling the release of apoptogenic factors (see 1.2.3 & 1.3.1). It has 
been shown in vitro that galectin-3 and Bcl-2 physically bind and co-
immunoprecipitate, possibly through their homologous NWGR motif in the 
carbohydrate-binding domain and the BH1 domain, respectively (Yang, Hsu 
et al. 1996). Here the interaction of galectin-3 and Bcl-2 and the possible 
influence of GCS-100 on this interaction were investigated in human cell 
lines. 
 
GCS-100 is suggested to function by binding to galectin-3 across its 
carbohydrate-binding domain and acts as an antagonist due to its abundance 
of galactoside residues (see 1.7). The carbohydrate-binding domain of 
galectin-3 contains the NWGR motif of the BH1 domain, which it shares with 
some members of the Bcl-2 family proteins including Bcl-2 itself (see 1.3). 
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4.1 Expression of galectin-3 and Bcl-2 family proteins in 
tumour cells 
 
For an interaction to occur between two molecules and be amenable to study, 
they must exist, either naturally or reconstitutively, at a detectable level and 
be accessible to each other within the cell. The expression levels of galectin-3 
and Bcl-2 proteins were therefore determined in all studied cell lines and 
primary CLL cells by immunoblotting analysis (see 2.5). The intracellular 
localization of Bcl-2 and galectin-3 was studied by immunofluorescent 
imaging (see 2.7). 
 
 
4.1.1 Galectin-3 and Bcl-2 protein expression  
 
Bcl-2 was highly expressed in DOHH2, JURKAT, SUD4, U266, RPMI8226 
cell lines and primary CLL cells (Figure 4.1). Galectin-3 was highly expressed 
in U266 and CLL cells and at lower levels in RPMI8226 and HEK293, but was 
not seen in DOHH2, JURKAT, K562, RAMOS and SUD4 cells (Figure 4.1). 
Bax was generally expressed at high levels in all cells tested, except JURKAT 
cells which showed a relatively low level of expression (Figure 4.1). Bcl-xl 
expression was detected at higher levels in U266, K562, RAMOS and SUD4 
cells and at lower levels in JURKAT, DOHH2 and RPMI8226 cells (Figure 
4.1). Primary CLL cells from a single patient and HEK293 cells did not show 
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any expression of Bcl-xl (Figure 4.1). Beta-actin was used as a control to 
determine protein loading in each of the lanes. 
 
 
 
 
 
Figure 4.1  Western analysis of Bcl-2, galectin-3, Bax and Bcl-xl in human cell lines and 
primary CLL cells. Whole cell lysates were analysed by immunoblotting (for details see 2.5) 
for cellular expression of Bcl-2, galectin-3, Bax and Bcl-xl. Beta-actin was used as the loading 
control. 
 
These findings do not support the theory that GCS-100 must bind galectin-3 
to induce pro-apoptotic effects, as in DOHH2, RAMOS and, to a lesser 
extent, K562 cells where GCS-100 was found to be an effective apoptosis-
inducer, galectin-3 was not detectable by immunoblotting (Figure 4.1).  
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This experiment revealed that U266 and RPMI8226 are the only two 
haematopoietic cell lines which naturally co-express galectin-3 and Bcl-2. 
Therefore, despite their resistance to GCS-100, U266 cells were used in the 
following study to determine the cellular localisation of galectin-3 and Bcl-2. 
 
 
4.1.2 Galectin-3 expression in primary CLL cells. 
 
Galectin-3 expression in CLL was further investigated using primary 
lymphocytes isolated from 8 CLL patients. The result (Figure 4.2) indicated 
that galectin-3 expression was heterogeneous amongst CLL patients, ranging 
from intense staining (patient 8) to being virtually indetectable (patient 6). 
 
 
  
 
Figure 4.2  Western blotting analysis of galectin-3 expression in primary CLL cells. 
Lymphocytes were isolated (see 2.2) from fresh peripheral blood samples of eight CLL 
patients (Lane 1 – 8, see Appendix I). Whole cell lysates were analysed for galectin-3 
expression by Western blotting (see 2.5). 
 
kD 
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4.1.3  Intracellular distribution of galectin-3 in RPMI8226 cells. 
 
RPMI8226 is a human myeloma cell line with constitutive expression of both 
galectin-3 and Bcl-2 (see Figure 4.1). The intracellular localisation of galectin-
3 was analysed in these cells using an immunofluorescent imaging technique 
(see 2.7). Galectin-3 was detected mainly as diffuse staining in the 
cytoplasm. No nuclear staining was observed (Figure 4.3).  
 
(A)                                                             (B) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Fluorescent imaging of intracellular distribution of galectin-3 in RPMI8226 
cells. Cells were stained with a mouse mononuclear anti-galectin-3 antibody and then a PE-
conjugated goat-anti-mouse antibody (red, see 2.7). Cell nuclei were stained with DAPI 
(blue). (A) Diffuse staining of intracellular galectin-3; (B) Control image showing cells stained 
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with secondary antibody only. 100X magnification. PE, phycoerythrin; DAPI, 4,6-diamino-2-
phenylindole. 
 
 
4.1.4 Intracellular distribution of Bcl-2 in RPMI8226 cells. 
 
A further question was whether Bcl-2 was also a cytoplasmic protein 
accessible for interaction with galectin-3. Bcl-2 was expressed in RPMI8226 
cells (see Figure 4.1), and its intracellular distribution was investigated by 
immunofluorescent imaging (see 2.7). Bcl-2 was also found mainly in the 
cytoplasm. As with galectin-3, no nuclear localisation of Bcl-2 was observed 
(Figure 4.4). 
 
 
 
(A)                                                             (B) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4  Fluorescent imaging of intracellular distribution of Bcl-2 in RPMI8226 cells. 
Cells were stained with a polyclonal rabbit anti-Bcl-2 antibody and then PE-conjugated goat-
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anti-rabbit antibody (see 2.7). Cell nuclei were stained with DAPI (blue). (A) Intracellular 
distribution of Bcl-2; (B) Control image with secondary antibody staining only. 100X 
magnification. PE, phycoerythrin; DAPI, 4,6-diamino-2-phenylindole. 
 
 
4.2 Interaction of galectin-3 and Bcl-2. 
 
Following the demonstration that in some cell types (e.g. RPMI8226) at least, 
galectin-3 and Bcl-2 appear to be constitutively co-expressed (see Figure 4.1) 
and that these two molecules are both cytoplasmic (see Figures 4.3 & 4.4), 
the direct physical interaction between Bcl-2 and galectin-3 was investigated. 
To maximise the opportunity for interaction, cell transfection was selected as 
the methodology of choice. For this purpose, a cell model with high 
expression of both galectin-3 and Bcl-2 was artificially established. The 
interaction between these two molecules was then investigated by 
immunoprecipitation. This was further confirmed by immunofluorescence 
imaging.  
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4.2.1 Galectin-3 and Bcl-2 co-transfection and immuno-
precipitation. 
 
Galectin-3 and Bcl-2 expression vectors were cloned and transfected in 
HEK293 cells, chosen for their normally high transfection efficiency and, 
coincidentally, their low level of constitutive expression of each protein of 
interest. Thus the expression of these two molecules was elevated artificially 
in the same cell so as to raise the heteroligomer level of galectin-3 and Bcl-2, 
assuming that they bound interactively. Human galectin-3 and bcl-2 genes 
were cloned into the pCMV.Tag 4A expression vector with or without the 
6×His Tag (see 2.6). HEK293 cells were then transfected with the cloned 
galectin-3 or bcl-2 vectors (see 2.6). A GFP-vector control was included in 
each transfection to determine the transfection efficiency (>80% as positive) 
by flow cytometry (see 2.6 & Figure 4.5). Expression levels of the transfected 
genes was further confirmed by immunoblotting analysis (see 2.5 & Figure 
4.6) before immunoprecipitation was performed. 
 
 
 
 
                                              Bo Su, 2010. Chapter 4: Interaction of galectin-3 and Bcl-2 
 
- 155 -
 
 
 
Figure 4.5  Flow cytometry analysis of the transfection efficiency in HEK293 cells. For 
each experiment, cells were transfected with pEGFP-N3 vector (Clontech) (see 2.6) and 
analysed by flow cytometry to check the transfection efficiency. (A) Cell debris was gated out. 
(B) Vector-control: cells transfected with empty vector had no GFP expression. (C) GFP-
control: cells transfected with pEGFP-N3 vector showed strong GFP expression. Data 
analysis indicated that the transfection efficiency was >80%. 
 
HEK293 cells express relatively low levels of galectin-3 and Bcl-2 
constitutively (see Figure 4.1), as detected in vector control cells (Figure 4.6, 
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Lane 1). Galectin-3-transfected cells showed greatly increased galectin-3 
expression (Figure 4.6, Lanes 2 & 3). Similarly, Bcl-2 expression level was 
also highly elevated in bcl-2-transfected cells (Figure 4.6, Lane 4 & 5). Some 
of the vectors were tagged with the 6xHis sequence and detected by the 
Penta-His antibody (Figure 4.6, Lanes 2 & 4). 
 
 
 
 
Figure 4.6  Western blotting analysis of galectin-3 and Bcl-2 transfection in HEK293 
cells. Cells were transfected using the PEI method (see 2.6) with different expression vectors 
as indicated and collected at 72 hours post-transfection. Whole cell lysates were analysed by 
immunoblotting (see 2.5) for galectin-3 and Bcl-2 expression. Lane 1, empty pCMV vector-
control; Lane 2, galectin-3-6xHis-tagged; Lane 3, galectin-3 without tag; Lane 4, bcl-2-6xHis-
tagged; Lane 5, bcl-2 without tag. PEI, polyethyleneimine. 
 
After HEK293 cells were successfully co-transfected with both galectin-3 and 
bcl-2 vectors, immunoprecipitation was performed on whole cell lysates using 
monoclonal antibodies against galectin-3 and Bcl-2 separately. 
32kD 
26kD 
30kD 
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Immunoblotting was then performed with anti-Bcl-2 and anti-galectin-3 
antibodies respectively.  
 
Galectin-3 was detected in the anti-Bcl-2-precipitated product (Figure 4.7A, 
Lane 4). Treatment with GCS-100 at an extremely high dose of 500 µg/ml for 
24 hours did not significantly alter this co-immunoprecipitation (Figure 4.7A, 
Lane 5). This suggests that an interaction between galectin-3 and Bcl-2 exists 
but that GCS-100 does not appear to affect it. 
 
Reciprocally, Bcl-2 was detected in the anti-galectin-3-precipitated product 
(Figure 4.7B, Lane 4). Treatment with 500 µg/ml GCS-100 for 24 hours again 
did not affect this interaction (Figure 4.7B, Lane 5). The quantity of Bcl-2 
detected on the blot was much less than the galectin-3 detected in the anti-
Bcl-2-precipitated product. This was attributable to the different affinity of 
antibodies used in the immunoprecipitation. 
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Figure 4.7  Co-immunoprecipitation of galectin-3 and Bcl-2 in transfected HEK293 
cells. Immunoprecipitation and subsequent immunoblotting (see 2.4 & 2.5) were performed 
in whole cell lysate with different sets of antibodies as indicated. (A) Two monoclonal anti-
bodies, anti-Bcl-2 and anti-galectin-3; (B) Two antibodies from different species, i.e. 
monoclonal anti-galectin-3 and rabbit polyclonal anti-Bcl-2. Lane 1, Vector-control whole cell 
lysate; Lane 2, galectin-3-6xHis-tagged and bcl-2 co-transfected whole cell lysate control; 
Lane 3, galectin-3-6xHis-tagged and bcl-2 co-transfected whole cell lysate with 500 µg/ml 
GCS-100 treatment for 24 hours; Lane 4 & 5, samples as Lane 2 & 3 after immuno-
precipitation, respectively; Lane 6, antibody-control: the antibody used in the immuno-
precipitation. Galectin-3 antibody was purchased from BD Bioscience, Bcl-2 monoclonal from 
Santa Cruz, Bcl-2 polyclonal from Abcam (see Chapter 2). M, monoclonal; R, rabbit 
polyclonal; IP, immunoprecipitation. 
 
 
4.2.2  Co-localization of galectin-3 and Bcl-2 in RPMI8226 
cells. 
 
RPMI8226 constitutively expresses both galectin-3 and Bcl-2 (see Figure 4.1) 
and, based on previous experiments (see 4.1.3 & 4.1.4), immunofluorescent 
imaging (see 2.7) was performed in order to further investigate the interaction 
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between galectin-3 and Bcl-2 in the constitutive setting with RPMI8226 cells, 
on account of the technical limitations imposed with adherent HEK293 cells in 
fluorescent studies (see Chapter 7). Cells were co-stained with galectin-3 and 
Bcl-2 antibodies from different species as previously described (see 4.1.3 & 
4.1.4), and then with species-specific secondary antibodies conjugated with 
different fluorochromes (see 2.7). In most cells there appeared to be overlap 
(Figure 4.8), which was most obvious in regions of the cytoplasm where 
individual expression was greatest. Such co-localisation is consistent with an 
interaction between Bcl-2 and galectin-3, as demonstrated in 4.2.1 and 
previously in the literature (Yang, Hsu et al. 1996). However, not all cellular 
co-expressed galectin-3 and Bcl-2 proteins may be mutually bound. 
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Figure 4.8  Fluorescent imaging of galectin-3 and Bcl-2 in RPMI8226 cells. Cells were 
stained with both anti-galectin-3 (mouse, monoclonal) and anti-Bcl-2 (rabbit, polyclonal) 
followed by secondary antibodies staining, i.e. Alexa Fluor 488 donkey anti-mouse (green) for 
galectin-3 and  PE-conjugated goat anti-rabbit (red) for Bcl-2 (see 2.7). (A) intracellular 
distribution of Bcl-2; (B) intracellular distribution of galectin-3; (C) galectin-3 and Bcl-2 co-
localization. 100X magnification. PE, polyethyleneimine. 
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Summary 
 
The aim of this chapter was to explore the interplay between galectin-3 and 
Bcl-2, and whether any interaction was influenced by GCS-100. The following 
is a summary of the conclusions. 
 
i) Galectin-3 and Bcl-2 interact intracellularly, as demonstrated by 
immunoprecipitation  in transfected adherent cell lines with elevated 
expression of these two proteins, and  by immunofluorescent imaging in 
human malignant B-lineage cell lines. Due to the technical difficulties 
experienced when using these two different techniques, two distinct cell 
lines were selected to perform these experiments. Therefore the data 
presented herein cannot be extrapolated to other B cell types. 
ii) Notwithstanding the shared NWGR motif in the carbohydrate-binding 
domain and BH1 domain of galectin-3 and Bcl-2, respectively, GCS-100 
does not significantly affect the interaction between the two proteins at a 
dose of up to 500 µg/ml for 24 hours.  
 
If GCS-100 does not act on the oligomerisation of galectin-3 and Bcl-2, other 
mechanisms for its apoptosis-inducing effect must exist. The next chapter 
explores the action of GCS-100 on other survival mechanisms in malignant B 
cells. 
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Chapter 5  PI3K/Akt/NF-?B signalling pathway  
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The PI3K/Akt/NF-?B signalling transduction pathway is another survival 
mechanism operative in tumour cells (see 1.3). This chapter aims to 
investigate the involvement of the pathway in apoptosis and how it 
contributes to the mechanism of the pro-apoptotic action of GCS-100 in 
human haematopoietic cell lines. 
 
 
5.1 Effects of GCS-100/VP-16 on Akt activity. 
 
Akt is an important protein kinase involved in cell proliferation, survival and 
the apoptotic pathway (see 1.3.3). It is phosphorylated and activated 
downstream of phosphoinositide 3-kinase (PI3K). Hyperactivity of Akt 
correlates with tumour progression and inhibition of its activation induces 
apoptosis in tumour cells (see 1.3.3). The involvement of Akt activity in the 
apoptotic pathway was investigated in DOHH2 cells by immunoblotting 
analysis using an antibody specific for the phosphorylated (activated) form of 
Akt (see 2.5). Significant downregulation of phosphorylated Akt was observed 
following treatment with GCS-100 (Figure 5.1). This downregulation was 
detected following 6-hour GCS-100 treatment at 500 µg/ml (Figure 5.1, Lane 
3) and increased significantly after 24-hour treatment (Figure 5.1, Lane 5). 
Interestingly, 1 µM VP-16 alone did not reduce the Akt activity even after 24 
hours of exposure (Figure 5.1, Lane 6). However, combined treatment with 
both VP-16 and GCS-100 caused  a much greater decrease in Akt activity 
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(Figure 5.1, Lane 7). Beta-actin confirmed consistent protein loading apart 
from Lane 6 which had slightly higher protein levels, which was also reflected 
in the pAkt band. However, this was probably insufficient to obscure any 
inhibitory effect of VP16 alone. 
 
 
 
 
Figure 5.1 Western analysis of Akt downregulation by GCS-100 in DOHH2 cells. Cells 
were treated with or without (as control) 500 µg/ml GCS-100 (Batch.6527) or 1 µM VP-16 and 
collected at the time point indicated. Whole cell lysates were analysed by Western blotting 
(see 2.5) for phosphorylated Akt. Lane 1, Time-0 control; Lane 2, 6-hour control; Lane 3, 
GCS-100-treated, 6 hours; Lane 4, 24-hour control; Lane 5, GCS-100-treated, 24 hours; 
Lane 6, VP-16-treated, 24 hours; Lane 7, VP-16- and GCS-100-treated, 24 hours. 
 
Akt knockdown by GCS-100 in DOHH2 cells was seen only at high doses 
relative to those needed to induce apoptosis as measured by flow cytometry. 
This new action of GCS-100, which has not been described elsewhere in the 
literature, appears to contribute to the pro-apoptotic effect of GCS-100. 
However, the extent of this contribution is difficult to quantify because 
differences in assay sensitivity could account, at least in part, for the 
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differential GCS-100 activity. It is beyond the scope of this thesis to 
investigate independently. However, another factor may also be implicated. 
Hitherto, all experiments in this thesis were conducted on a single batch of 
GCS-100 (viz. 876284-HO1, supplied by GlycoGenesys, see 2.1). The 
experiments on the Akt pathway were conducted with a new batch (viz. 
6527), the activity of which was less by a factor of approximately 5-fold than 
876284-HO1. Any effects on the Akt pathway will thus have been 
underestimated. 
 
To investigate the effect of GCS-100 on this pathway further, experiments 
were conducted in additional cell lines and effects on markers downstream of 
Akt were also analysed. 
 
 
5.2 GCS-100 and NF-(kappa)B pathway. 
 
Akt is an activator of the NF-(kappa)B pathway, downstream of PI3K 
activation (see 1.3.3). The effects of GCS-100 on the NF-(kappa)B pathway 
were therefore investigated. 
 
Various cell lines as well as a single sample of primary CLL cells were 
screened for Akt phosphorylation by immunoblotting (see 2.5). The JURKAT 
cell line (derived from human T-leukaemia cells, see 2.2) showed the highest 
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constitutive activation of Akt (Figure 5.2, Lane 1) and was therefore selected 
for this experiment. The other cell line with significant phosphorylated Akt 
expression was HEK293 (Figure 5.2, Lane 7). SUD4 cells also showed some 
constitutive Akt activity (Figure 5.2, Lane 4). No Akt activity was detected in 
the single sample of CLL cells tested (Figure 5.2, Lane 8). 
 
 
 
 
 
Figure 5.2  Western analysis of constitutive Akt phosphorylation in cell lines and 
primary CLL cells. Whole cell lysates were analysed by Western blotting (see 2.5) for 
phosphorylated Akt level in each cell type. Beta-actin control was used to ensure equal 
protein loading. Lane 1, JURKAT cells; Lane 2, K562 cells; Lane 3, RAMOS cells; Lane 4, 
SUD4 cells; Lane 5, U266 cells; Lane 6, RPMI8226 cells; Lane 7, HEK293 cells; Lane 8, 
primary CLL cells from the patient whose data are exhibited in Appendix I. 
 
JURKAT cells were treated with 500 µg/ml GCS-100 for 24 or 48 hours and 
the intracellular level of phosphorylated Akt and the 65 kD subunit (p65) of 
NF-(kappa)B were analysed by immunoblotting (see 2.5). Downregulation of 
Akt activity was observed after 24-hour treatment with 500 µg/ml GCS-100 
(Figure 5.3, Lane 2), in a similar manner to DOHH2 cells (Figure 5.1, Lane 5) 
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although the effect did not appear to be so marked. Longer incubation (48 
hours) with GCS-100 did not further reduce the level of Akt phosphorylation 
(Figure 5.3, Lane 3). No significant effect of GCS-100 on NF-(kappa)B-p65 
protein level was seen in this experiment (Figure 5.3, Land 2 & 3). 
 
 
Figure 5.3  Western analysis of GCS-100 effect on Akt/NF-(kappa)B pathway in 
JURKAT cells. Cells were treated with or without (as control) 500 µg/ml (Batch.6527) GCS-
100 for 24 or 48 hours. Whole cell lysates were analysed by Western blotting (see 2.5) for 
Akt activity and the 65 kD subunit (p65) of NF-(kappa)B. Lane 1, control; Lane 2, GCS-100-
treated, 24 hours; Lane 3, GCS-100-treated, 48 hours.  
 
The effect of GCS-100 on I(kappa)B, the negative regulator of NF-(kappa)B 
pathway, was analysed by immunoblotting (see 2.5) for I(kappa)B-alpha and 
its phosphorylation. The level of phosphorylated I(kappa)B-alpha appeared to 
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be moderately upregulated following 24-hour treatment with 300 µg/ml GCS-
100 in DOHH2 cells (Figure 5.4, Lane 2). 
 
 
 
 
Figure 5.4 Western analysis of GCS-100 effect on I(kappa)B-alpha and its 
phosphorylation in DOHH2 cells. Cells were treated with or without (as control) 300 µg/ml 
GCS-100 (Batch.6527) for 24 hours. Whole cell lysates were analysed by Western blotting 
(see 2.5) for I(kappa)B-alpha and its phosphorylation. Lane 1, control; Lane 2, GCS-100-
treated, 24 hours. 
 
 
5.3 Galectin-3/Bcl-2 expression and Akt activity. 
 
It has been shown in a breast cancer cell line that dephosphorylation of Akt 
occurs when galectin-3 is transfected (Lee, Song et al. 2003). In contrast, 
overexpression of galectin-3 increases the level of phosphorylated Akt in a 
bladder carcinoma cell line (Oka, Nakahara et al. 2005). These controversial 
Bo Su, 2010. Chapter 5: PI3K/Akt/NF-?B 
 
- 169 -
findings led to the following investigation of the effect of intracellular galectin-
3 as well as Bcl-2 levels on Akt phosphorylation in HEK293 cells, a human 
embryonic kidney cell line, when transfected with galectin-3 or Bcl-2 
expression vectors, i.e. the same transfected cell systems used in earlier 
experiments (see 4.2.1. especially Figure 4.6). Immunoblotting was 
performed to compare the level of Akt phosphorylation in cells transfected 
with empty vector (Figure 5.5, Lane 2), galectin-3 vectors (Figure 5.5, Lanes 
3 & 4) and bcl-2 vectors (Figure 5.5, Lanes 5 & 6). No significant difference of 
Akt activity was seen between cells with wild-type (Figure 5.5, Lanes 1 & 2) 
and overexpressed galectin-3 (Figure 5.5, Lanes 3 & 4). The Bcl-2 expression 
level did not appear to be related to Akt activity either (Figure 5.5, Lanes 5 & 
6). 
 
 
 
 
 
Figure 5.5  Western analysis of intracellular galectin-3/Bcl-2 levels and Akt activity in 
transfected HEK293 cells. Cells were transfected with GFP vector, empty pCMV vector, 
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galectin-3 or bcl-2 vectors using PEI method (see 2.6). The GFP transfection efficiency was 
above 80% as a result of flow cytometry analysis (see 4.2.2). Whole cell lysates were then 
analysed by immunoblotting (see 2.5) for galectin-3, Bcl-2 and phosphorylated Akt levels, i.e. 
the same samples in Figure 4.6 were probed for Akt activity. Lane 1, GFP vector control; 
Lane 2, empty pCMV vector control; Lane 3, galectin-3-6xHis-transfected; Lane 4, galectin-3-
transfected; Lane 5, bcl-2-6xHis-transfected; Lane 6, bcl-2-transfected. PEI, polyethyl-
eneimine. 
 
 
Summary   
 
i) Akt phosphorylation is significantly downregulated by a relatively high 
dose of GCS-100, but not by VP-16 in DOHH2 cells. JURKAT cells with 
high constitutive expression of pAkt were also responsive to GCS-100 but 
to an apparently lesser extent than DOHH2 cells.  
ii) The p65 unit of NF-(kappa)B was not affected by GCS-100 treatment at a 
dose up to 500 µg/ml for 48 hours. 
 
The Akt knockdown effect of GCS-100 explains in part its pro-apoptotic effect, 
but the contribution of this component relative to other mechanisms is difficult 
to quantify on account of differential assay sensitivity and the use of a 
different batch of GCS-100 for reasons beyond the investigators’ control. The 
data as described may thus have underestimated the role of pAkt 
downregulation. Akt has been suggested to be a significant factor in survival 
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pathways for tumour cells (see 1.3.3). The findings of this study (i.e. 
downregulation of Akt leading to induction of apoptosis) add weight to this 
hypothesis. This effect was apparently more significant in DOHH2 than 
JURKAT cells, suggesting that DOHH2 cells are relatively more sensitive to 
GCS-100.  
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This thesis aims to analyse the underlying mechanisms for tumour cell 
survival in human B lymphoid malignancies by studying apoptosis in the 
context of two disparate apoptosis-inducing agents which have been subject 
of clinical investigation. As has been reported above, GCS-100 targets the 
mitochondrial apoptotic pathway and downregulates Akt phosphorylation (see 
Chapters 3, 4 and 5). By contrast, PK11195 induces apoptosis via induction 
of reactive oxygen species (ROS). 
 
ROS are natural products from mitochondria during cell respiration. They can 
induce cell apoptosis if not converted to other non-toxic products by the 
natural defence mechanisms of the cell. Many drugs that generate ROS can 
also induce apoptosis. PK11195 induces apoptosis in many haematopoietic 
malignant cells (see 1.8), but the link between its pro-apoptotic effects and its 
role in intracellular ROS production has not been investigated. In this chapter 
the mechanism of the pro-apoptotic effect of PK11195 was examined in 
depth, with a focus on its ROS-generating role and expression level of Nox-5, 
the enzyme which catalyses the generation of ROS in lymphoid tissues.  
 
PK11195 is a small synthetic molecule that induces apoptosis in many types 
of tumour cells with low toxicity for their normal counterparts. Both in vitro and 
in vivo it has the ability to increase the sensitivity of tumour cells to 
chemotherapy-induced apoptosis (Banker, Cooper et al. 2002; Chauhan, Li et 
al. 2004; Fennell, Corbo et al. 2001; Gonzalez- Polo, Carvalho et al. 2005; 
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Okaro, Fennell et al. 2002). It has been described as a high-affinity ligand for 
the mitochondrial peripheral benzodiazepine receptor (mPBR, see 1.2.2.a). 
However, its mechanism of action in the apoptotic pathway has not been fully 
clarified and is the aim of this chapter. As in previous studies, the effect of 
PK11195 on apoptosis was investigated, together with the role of ROS 
generation in its mechanism in human haematopoietic cell lines. 
 
 
6.1 PK11195 and apoptosis induction. 
 
The effect of PK11195 was studied in the DOHH2 cell line with high levels of 
Bcl-2 protein and consequent resistance to apoptosis. 75 µM PK11195 
treatment for 24 hours induced significant mitochondrial transmembrane 
potential (DeltaPsi(m)) collapse which was partially reversed by MnTBAP, a 
ROS scavenger. MnTBAP alone did not induce DeltaPsi(m) collapse (Figure 
6.1). This indicates that ROS generation was a key mechanism for the pro-
apoptotic effects of PK11195. 
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Figure 6.1  Flow analysis of the pro-apoptotic effects of PK11195 in DOHH2 cells. Cells 
were treated with or without (control) 75 µM PK11195 for 24 hours in the presence/absence 
of 100 µM MnTBAP, prior to DiOC6(3) staining and flow cytometry analysis. PK11195 alone 
caused a significant increase (*, p<0.01, n=3) in the DiOC6(3)-negative population, which 
was partially reversed by MnTBAP (·, p<0.05, n=3),. MnTBAP alone did not induce 
DeltaPsi(m) collapse (D, p>0.05, n=3). PK, PK11195; MNT, MnTBAP. 
 
 
6.2 PK11195 and ROS induction. 
 
ROS generation has been implicated in the mechanism of apoptosis induction 
by PK11195 in multiple myeloma cells (Chauhan, Li, et al. 2004). Thus the 
role of intracellular ROS in the pro-apoptotic effects of PK11195 was studied 
by DHE staining and flow cytometry analysis (see 2.3) in DOHH2 cells.  
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PK11195 treatment alone (75 µM) caused an increase of DHE fluorescence 
which was visualised on the FL-3 channel by flow cytometry, suggesting 
generation of ROS (Figure 6.2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 DHE staining and flow analysis of the ROS-generating effects of PK11195 in 
DOHH2 cells. Cells were treated with 75 µM PK11195 for 24 hours before DHE staining and 
flow analysis. PK11195 treatment caused an increase of fluorescence on the FL-3 channel, 
which indicates ROS generation. DHE, dihydroethidium; ROS, reactive oxygen species. 
 
 
It has been shown that PK11195 induced apoptosis in DOHH2 cells (see 6.1). 
Whether or not ROS induction was involved in this process was investigated 
in the same cell type. The enhancement of intracellular ROS by PK11195 
was observed with the same dose (75 µM) and time course (24 hours). These 
FL-3 
PK11195-treated 
Control 
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cells showed a significantly increased level of ROS following 24-hour 
treatment with PK11195 (Figure 6.3).  
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Figure 6.3  Flow analysis of the ROS-generating effects of PK11195 in DOHH2 cells. 
Cells were treated with or without (control) 75 µM PK11195 for 24 hours in the 
presence/absence of 100 µM MnTBAP, before DHE staining and flow cytometry analysis 
were performed. PK11195 alone caused a significant increase (*, p<0.01, n=3) of DHE 
fluorescence, which was partially reversed by MnTBAP (·, p<0.05, n=3). MnTBAP alone did 
not induce ROS generation (D, p>0.05, n=3). PK, PK11195; MNT, MnTBAP; MFI, mean of 
fluorescent intensity; DHE, dihydroethidium. 
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6.3 Nox-5 expression in a PK11195-resistant cell line. 
 
It is understood that the reaction of intracellular ROS production in lymphoid 
tissues is mainly catalysed by Nox-5, a member of the NADPH oxidase family 
(see 1.2.2.b). As PK11195 raised the intracellular ROS level in various cell 
lines with different sensitivity, whether or not this was related to cell 
resistance to PK11195 was examined by comparing Nox-5 levels in 
PK11195-sensitive and -resistant cell lines. A PK11195-resistant cell line was 
established by culturing RAMOS cells with increasing doses of PK11195 over 
time (see 2.2.6). These cells were used to study the effect of PK11195 on 
Nox-5 expression in comparison with its sensitive counterpart. The Nox-5 
mRNA level in the PK11195-resistant cells was significantly lower than in the 
sensitive cells (Figure 6.4), suggesting that Nox-5 level could be related to 
cell sensitivity to PK11195. 
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Figure 6.4  Different Nox-5 levels in PK11195-sensitive and -resistant cells. Three 
independent experiments were performed in PK11195-sensitive and -resistant cells to 
compare their Nox-5 mRNA levels by real-time PCR (see 2.8). The Nox-5 expression was 
significantly lower (*, p<0.01, n=3)  in resistant cells than in sensitive cells.  
 
 
6.4 PK11195 and Nox-5 expression. 
 
The previous experiments suggested that ROS generation plays an important 
part in the mechanism of PK11195 (see 6.2). Since it had previously been 
hypothesised that PK11195 functioned as a mPBR ligand, this study resolved 
the mPBR role by investigating the effect of PK11195 in JURKAT cells which 
lack the mPBR (Canat, Carayon et al. 1993; Carayon, Portier et al. 1996; 
Hans, Wislet-Gendebien et al. 2005) . The response was as strong as that for 
other cell lines which possessed the mPBR (see 6.2). Therefore, ROS 
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generation would appear to be the major factor for the apoptosis induction by 
PK11195. This was further studied by comparing Nox-5 expression before 
and after PK11195 treatment in JURKAT cells using real-time PCR (see 2.8). 
A dose of 75 µM PK11195 for 24 hours enhanced the Nox-5 level significantly 
in comparison with the non-treated cells (Figure 6.5). This suggests that 
PK11195 interferes with the Nox-5 level and thus ROS generation. Taken 
together, the above data (6.3 & 6.4) imply that the NADPH oxidase pathway 
is important for PK11195-induced apoptosis in tumour cells. 
0
10
20
30
40
50
60
70
80
90
Time 0 Control PK11195(75uM)
N
ox
-5
 e
xp
re
ss
io
n
 
Figure 6.5  Effects of PK11195 on Nox-5 expression in JURKAT cells. Cells were treated 
with  or without (control) 75 µM PK11195 for 24 hours before the intracellular Nox-5 level was 
analysed by real-time PCR (see 2.8). Time 0 was cells before the 24-hour treatment was 
performed. The control level of Nox-5 was set as 1. In non-treated cells, the 24-hour 
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incubation reduced the Nox-5 expression, i.e. the difference between Time 0 and control. 
PK11195 treatment significantly enhanced the Nox-5 level (*, p<0.01, n=3).  
 
 
Summary   
 
This chapter has demonstrated that the synthetic compound PK11195 has 
three effects on haematopoietic malignant cells: apoptosis induction via the 
mitochondrial pathway, ROS generation, and enhancement of Nox-5 
expression. Apoptosis induction by PK11195 can be inhibited by MnTBAP, a 
ROS antagonist. Taken together, these data support the essential role of 
intracellular ROS, generated by NADPH oxidase, in the apoptosis-inducing 
effects of PK11195, suggesting a new mechanism of apoptosis induction in 
tumour cells. The mechanism would appear to be differentiated from that of 
GCS-100, notwithstanding the fact that the mechanism of action of the latter 
agent has not been fully elucidated. The mitochondrial NADPH oxidase 
pathway is a potential target for cancer therapy. 
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Galectin-3, Bcl-2 and the PI3K/Akt/NF-?B pathway are implicated in three 
major survival mechanisms in tumour cells amongst others, often resulting in 
defective apopotic pathways as well as abnormal cellular proliferation. 
Interference with these mechanisms can result in the induction of apoptosis 
and thereby point to potential strategies for cancer treatment. Other 
mechanisms of apoptosis induction include reactive oxygen species (ROS) 
generation. This  thesis has studied two structurally different anti-cancer drug 
candidates, GCS-100 and PK11195, for their role in surmounting the anti-
apoptotic mechanisms in human malignant B cells, and the possible 
molecular mechanisms underlying their apoptosis-inducing effects. 
 
GCS-100 is a type of modified citrus pectin derived by acid/base hydrolysis of 
citrus pectin isolated from the skin and pulp of citrus fruits (GlycoGenesys, 
Inc, Boston, MA). A series of clinical trials on this drug candidate have been 
carried out in different types of cancer patients in the U.S.A. (Cotter 2004; 
Daliani, Pratt et al. 1999; Grous, Redfern et al. 2006; Gunzburg and Salmons 
2001; Springgate, Cartwright et al. 2001; Staddon, Bonnem et al. 1999; 
Stuart, Kindler et al. 2001). It induces apoptosis in human multiple myeloma 
cells and is currently in Phase II clinical trial in multiple myeloma, colorectal 
and pancreatic cancers (see 1.7). Its pro-apoptotic effects are thought to be 
connected with its ability to bind and inhibit galectin-3, the anti-apoptotic 
molecule frequently overexpressed in tumour cells. In this project, it is shown 
for the first time that GCS-100 induced apoptosis in a number of human 
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malignant B cells which express high levels of Bcl-2 but do not have 
detectable galectin-3 expression, indicating that GCS-100 can overcome the 
apoptosis-resistant survival mechanisms induced by Bcl-2 overexpression, 
but also that galectin-3 may not be instrumental in apoptosis induction by this 
agent. Further investigation has shown that GCS-100 targets the 
mitochondrial apoptotic pathway by inducing cleavage of caspase-9, the key 
enzyme activated by apoptogenic factors released from mitochondria. 
Another important mechanism of GCS-100 action provisionally shown herein 
is downregulation of Akt activity, the crucial molecule in the PI3K signalling 
pathway, suggesting that, notwithstanding the need to establish the relative 
role of different mechanisms more quantitatively, GCS-100 has multi-faceted 
mechanisms for its apoptosis-inducing effects, with the ability to target a 
broad range of pathways leading to programmed cell death. 
 
By contrast with GCS-100, PK11195 is a synthetic ligand (isoquinoline 
carboxamide) for the peripheral benzodiazepine receptor (PBR) with high 
affinity (KD<20 nM) (Casellas, Galiegue et al. 2002). It induces apoptosis in 
human acute promyelocytic leukaemia cells which is thought to be irrelevant 
to its PBR-binding capacity, as the doses required for apoptosis induction are 
much higher than  those required for receptor engagement (Fennell, Corbo et 
al. 2001). In parallel with the GCS-100 study, this part of the project examined 
the pro-apoptotic effect of PK11195 and its ROS-generating role, as well as 
any potential link between these two mechanisms. The data showed that 
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PK11195 induced apoptosis in human malignant B cell lines and intracellular 
ROS levels were involved in this process. In addition, Nox-5, the enzyme that 
catalyses production of ROS intracellularly, was found to be related to 
PK11195’s apoptosis-inducing effect, confirming the involvement of ROS 
generation in the mechanism underlying the action of  PK11195. 
 
 
7.1 GCS-100 is pro-apoptotic 
 
GCS-100 consistently induced apoptosis in a variety of human cell lines, 
alone or in combination with VP-16, one of the most potent chemotherapeutic 
drugs used in clinical cancer therapy (Montecucco and Biamonti 2007), 
although the sensitivity (EC50) varied between cell types.  GCS-100 
treatment (20 or 40 µg/ml) shifted the dose-response curve of VP-16 to the 
left, reducing the EC50 values by 2-4 logfold in DOHH2 and RAMOS cells 
(see 3.1 & 3.2), indicating that GCS-100 can act synergistically with VP-16 for 
apoptosis induction in human malignant B cell lines. 
 
To address the same issue in primary B cells, blood samples from a panel of 
up to 8 patients with chronic lymphocytic leukaemia (CLL) were used. In 
common with B cell lines, GCS-100 caused significant mitochondrial inner 
membrane potential (DeltaPsi(m)) collapse and cell membrane perturbation in 
CLL cells, both typical events in the apoptotic cascade. Although a significant 
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amount of haematological and other data were available on the CLL patients 
(courtesy of Heartlands Hospital), the scope of this study was insufficient to 
seek any potential correlations between parameters associated with 
apoptosis, e.g. ZAP-70 expression (see 1.6), or prognosis, e.g. VH mutation 
status (see 1.6), and sensitivity to apoptosis induction in vitro by GCS-100. 
Any such correlations would require a dedicated study in a much larger 
patient population and more extensive in vitro studies, including GCS-100 in 
combination with drugs routinely used in the management of CLL.  
 
Notwithstanding the relatively small size of the B cell compartment in normal 
unfractionated lymphocytes, it was possible to conclude that a pro-apoptotic 
effect in the latter, with concomitant implications for unwanted toxicities, was 
unlikely on the grounds that on treatment with a much higher dose (up to 200 
µg/ml) and for a longer incubation time (up to 48 hours), a contrary trend in 
the DiOC6(3)-negative population was observed. These results are consistent 
with published data on the selectivity of GCS-100 for multiple myeloma 
(Chauhan, Li et al. 2005). 
 
Two types of technique were used as widely-accepted and well-established 
measurements of apoptosis: (i) DiOC6(3) and MC540 staining with flow 
cytometry measuring DeltaPsi(m) collapse and cell membrane integrity, 
respectively (Laakko, King et al. 2002; Ozgen, Savasan et al. 2000); and (ii) 
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immunoblotting analysis for caspase activation, which defines apoptosis at 
the molecular level (see 1.2). 
 
DOHH2 cells are known to overexpress Bcl-2 which renders certain cancer 
cells drug resistant (see 1.3.1). These cells showed high sensitivity to GCS-
100 and only 20 µg/ml treatment for 24 hours was required to observe a 
significant increase in DeltaPsi(m) collapse and membrane blebbing (Figures 
3.2 & 3.3). Thus, GCS-100 has the potential to overcome Bcl-2-
overexpression-mediated anti-apoptosis, at least in some cell lines. 
 
In comparison with DOHH2 cells which express wild type p53, the tumour 
suppressor protein, RAMOS cells have mutated p53 which contributes to 
tumour progression and chemo-resistance (see 2.2.2). If GCS-100/VP-16 
acted through p53 to induce apoptosis, the expectation would be that 
RAMOS cells might be more resistant to GCS-100/VP-16 than DOHH2 cells. 
In fact, the EC50s for concurrent treatment with GCS-100 and VP-16 were 
lower in RAMOS cells than in DOHH2 cells under the same treatment 
conditions (Tables 3.1 & 3.2). This implies that RAMOS cells are inherently 
more sensitive to GCS-100/VP-16 treatment and  that p53 status is not critical 
for their action. 
 
It has been reported that GCS-100 (formerly designated GBC-590), as a type 
of modified citrus pectin, binds and inhibits galectin-3, the anti-apoptotic 
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carbohydrate-binding protein widely believed to be overexpressed in tumour 
cells (see 1.3.2), and that this is the key mechanism for its pro-apoptotic 
effects. This hypothesis was not supported by the data presented herein, as 
DOHH2 and RAMOS cells did not reveal any detectable galectin-3 
expression (Figure 4.1), which is consistent with published data on the non-
detectable level of galectin-3 expression in Burkitt lymphoma and follicular 
lymphoma cell lines and patient samples (Hoyer, Pang et al. 2004). However, 
they still responded to GCS-100 (see Chapter 3). This leads to the important 
conclusion, hitherto not described, that galectin-3 at least was not the only 
mechanism for the apoptosis-inducing action of GCS-100. 
 
 
7.2 GCS-100 acts via mitochondria. 
 
It is known that VP-16 induces apoptosis in cancer cells via the mitochondrial 
apoptotic pathway (Montecucco and Biamonti 2007). As shown in 3.2, GCS-
100 acted synergistically with VP-16 to exert its pro-apoptotic effects. 
Therefore it was pertinent to ask whether GCS-100 might also work via the 
mitochondrial apoptotic pathway. DiOC6(3) staining already established that 
mitochondrial inner membrane potential (DeltaPsi(m)) collapsed due to the 
effect of GCS-100 (see 3.1 & 3.2), indicating that mitochondria were involved 
in its apoptosis-inducing effect. This was further confirmed by showing that 
caspase-9, but not caspase-8, was activated in GCS-100-treated cells (Figure 
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3.12), as caspase-9 acts downstream of mitochondria and is cleaved by 
apoptogenic factors released from mitochondria (see 1.2.2). 
 
Combined treatment of GCS-100 and VP-16 caused caspase-9 activation to 
a much greater extent than either agent alone (Figure 3.12), which was 
consistent with previous data showing that these two drugs were more 
effective for apoptosis induction if applied concurrently to malignant cells (see 
3.2). These data support the conclusion that GCS-100 induces apoptosis via 
the intrinsic apoptotic pathway, activating caspase-9 as the downstream 
target. 
 
 
7.3 Galectin-3 interacts with Bcl-2. 
 
Galectin-3 and Bcl-2 are both anti-apoptotic proteins overexpressed in cancer 
cells, structurally sharing the NWGR motif within the carbohydrate-binding 
domain of galectin-3, where GCS-100 binds, and the BH1 domain of Bcl-2. 
Point mutation studies have shown that this sequence is crucial for the anti-
apoptotic effect of both Bcl-2 and galectin-3 (see 1.3). Physical binding 
between these two molecules has been demonstrated previously in vitro 
(Yang, Hsu et al. 1996). Using an immunofluorescence technique, data 
presented herein showed that both molecules were detectable in the 
cytoplasm (see 4.1.3 and 4.1.4). Based on the above observations, the 
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possible interaction between galectin-3 and Bcl-2 was investigated using two 
techniques, immunoprecipitation and immunofluorescence.  
 
For immunoprecipitation, HEK293 cells were co-transfected with expression 
vectors of galectin-3 and Bcl-2. Transfection of this adherent cell line ensured 
that conditions were optimal for detection of the respective proteins and any 
interaction between them, especially by the relatively insensitive technique of 
immunoprecipitation. Flow cytometry for GFP expression (see 4.2.1) and 
immunoblotting showed that expression of both molecules was indeed highly 
elevated after transfection. Whole cell lysates were prepared and galectin-3 
or Bcl-2 were precipitated using specific antibodies prior to immunoblotting 
analysis for the other molecule. In the anti-Bcl-2-precipitated products, 
galectin-3 was detected. Reciprocally, Bcl-2 was detected in the anti-galectin-
3-precipitated products. However, the interaction between galectin-3 and Bcl-
2 was not affected by GCS-100 treatment (500 µg/ml, 24 hours, see 4.2.1).  
 
Immunofluorescence is another well-established technique widely used for 
co-localisation studies with the advantage of greater inherent sensitivity than 
immunoprecipitation and immunoblotting. However, in our experience, this 
technique was less reliable when applied to adherent cells (HEK293) than to 
cytospin preparations of RPMI8226 cells, in which co-expression of galectin-3 
and Bcl-2 is constitutive, albeit at a lower level than in transfectants. Thus, in 
the immunofluorescence experiments, RPMI8226 cells were co-stained with 
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anti-Bcl-2 (rabbit) and anti-galectin-3 (mouse). Secondary antibodies with 
different fluorescent labels, anti-rabbit-PE (red) and anti-mouse-Alexa Fluor 
488 (green) were then applied. The microscopic images showed that, where 
Bcl-2 (red) and galectin-3 (green) co-localised, the emission wavelength of 
fluorescence changed to orange. These findings further confirmed the data 
obtained by immunoprecipitation. 
 
The above data provide strong evidence that interaction between galectin-3 
and Bcl-2 exists in tumour cells. However, as no marked effect of GCS-100 
on this interaction could be demonstrated, it is concluded that this may not be 
the main mechanism of its action on the apoptotic pathway. 
 
 
7.4 Akt knockdown by GCS-100. 
 
A number of studies have validated the association between increased Akt 
activity and cell survival (see 1.3.3). However, the underlying molecular basis 
for this has been poorly defined. It has been reported that galectin-3 
overexpression inactivates Akt by dephosphorylation in a breast cancer cell 
line (Lee, Song et al. 2003), while in contrast, high levels of galectin-3 
promote Akt activation in a bladder carcinoma cell line (Oka, Nakahara et al. 
2005). GCS-100 has the ability to downregulate the galectin-3 level in 
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multiple myeloma cells (Chauhan, Li et al. 2005). These findings show that 
the link between GCS-100, galectin-3 and Akt is still unclear.  
 
In this study, the intracellular level of phosphorylated Akt was significantly 
reduced after GCS-100 treatment in DOHH2 and JURKAT cells (Figures 5.1 
& 5.3). DOHH2 cells, the more sensitive cell line to GCS-100, showed clear 
inhibition of Akt activity following 6-hour treatment. The Akt level continued to 
fall up to 24 hours of incubation (Figure 5.1). In contrast, JURKAT cells did 
not show significant Akt downregulation until 48 hours after treatment (Figure 
5.3). VP-16 treatment alone of DOHH2 cells did not alter Akt phosphorylation. 
Thus the effectiveness of GCS-100 against malignant cells appears to be 
related to its action on Akt. As expected, combined treatment with both GCS-
100 and VP-16 induced a more profound reduction of Akt phosphorylation, 
which correlates with the effectiveness of the apoptosis-inducing role of the 
combination.  
 
Both DOHH2 and JURKAT cells showed reduced Akt activity following GCS-
100 treatment although they did not express detectable levels of galectin-3 
(Figure 4.1), which suggests that galectin-3 alone did not appear to mediate 
the effect of GCS-100 on Akt. In addition, HEK293 cells with elevated levels 
of galectin-3 failed to show any altered Akt activity (Figure 5.5), further 
supporting this hypothesis. The above data all indicate that GCS-100 can 
interfere with Akt phosphorylation, but that much of this effect is not mediated 
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by galectin-3. PI3K, a lipid kinase upstream of Akt that can be activated by 
various cell surface receptors, is a possible target of GCS-100. More studies 
are needed to investigate this possibility. The PI3K/Akt pathway is more 
commonly activated in tumour cells (Samuels and Ericson 2006) than 
expression of galectin-3. If the former is a major target for GCS-100, a 
broader application might be expected for this agent in cancer therapy. 
 
A caveat to the above data on Akt downregulation discussed in 5.1 is that a 
different batch of GCS-100 had to be deployed for these experiments. The 
potency of the second batch was approximately 5-fold less than that used for 
the vast majority of experiments described in this thesis. Data on Akt 
downregulation must therefore be interpreted in the awareness that the extent 
of the phenomenon is underestimated. The fact that Akt downregulation was 
observed at all, strongly supports the conclusion that this is a real event. The 
issue that the weaker batch of GCS-100 therefore raises, is that of the 
relative contribution of Akt downregulation to the overall mechanisms of 
action of GCS-100, not whether it occurs. 
 
 
7.5 Akt and the apoptotic pathway. 
 
GCS-100 downregulates Akt phosphorylation and also interferes with the 
mitochondrial apoptotic pathway. It is thus not unreasonable to consider that 
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connections between Akt and the mitochondrial pathway may contribute to 
GCS-100’s apoptosis-inducing effects. 
 
Akt can act as an inhibitor of apoptosis and block mitochondrial apoptotic 
events, e.g. cytochrome c release (Kennedy, Kandel et al. 1999). This protein 
kinase exerts influence intracellularly at multiple levels and its substrates are 
involved in a wide range of signal transduction pathways, including that of 
apoptosis. The Bad protein, a pro-apoptotic member of the Bcl-2 family, is 
one of its direct targets and phosphorylation of Bad by Akt releases Bcl-xl, an 
anti-apoptotic Bcl-2 family protein. Bcl-xl then dimerizes with Bax to promote 
cell survival (see 1.3.3). GCS-100 mediates dephosphorylation and 
inactivation of Akt, possibly reducing Bad phosphorylation indirectly. 
Dephosphorylated Bad oligomerizes with Bcl-xl and frees Bax to form 
homodimers which cause the subsequent DeltaPsi(m) collapse, apoptogenic 
factor release and activation of caspases.  
 
Caspase-9 is another direct substrate of Akt. Activated Akt phosphorylates 
and inactivates caspase-9 and interrupts the mitochondrial amplification loop 
(see 1.3.3). This suggests that Akt can block the apoptotic cascade even 
downstream of cychrome c release. GCS-100 treatment in DOHH2 cells 
caused activation of caspase-9 (Figure 3.12), which may in part be due to Akt 
inactivation by GCS-100 with subsequent dephosphorylation of caspase-9. 
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The third direct target of Akt that may be related to the effect of GCS-100 is 
I(kappa)B kinase (IKK). IKK catalyses the phosphorylation and degradation of 
Inhibitor of NF-(kappa)B (I(kappa)B),  the negative regulator of NF-(kappa)B. 
Akt phosphorylates and activates IKK, which in turn upregulates the NF-
(kappa)B activity (see 1.3.3). Bcl-2, IAP and FLIP are among the pro-survival 
genes under NF-(kappa)B regulation (see 1.3.3). GCS-100 promotes 
dephosphorylation and inactivation of Akt and therefore inhibits NF-(kappa)B 
activity as well as the subsequent transcription of the pro-survival genes. 
Although this is theoretically possible, the NF-(kappa)B activity did not show 
significant changes following GCS-100 treatment in JURKAT cells (Figure 
5.3). The I(kappa)B-alpha phosphorylation level was found to be only slightly 
increased in DOHH2 cells (Figure 5.4). In addition, it has been reported that 
GCS-100 decreases cell viability in an I(kappa)B-mutated lymphoma cell line 
(Chauhan, Li et al. 2005), suggesting that I(kappa)B is not predominantly 
involved in the pro-apoptotic effect of GCS-100.  
 
Akt can prevent Forkhead transcription factors from entering the nucleus and 
the subsequent transcription of FasL gene (Datta, Brunet et al. 1999). It is 
therefore possible that GCS-100 inhibits Akt activity and thus enhances the 
expression of FasL and Fas-related apoptosis. However, caspase-8 
activation was not observed (Figure 3.12) and would have been expected if 
this were the case.  
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Akt may also influence mitochondrial energy production and the electron 
transduction chain (Gottlob, Majewski et al. 2001) where alterations in ROS 
generation would be expected. No significant elevation of intracellular ROS 
level could be detected following GCS-100 treatment in DOHH2 cells (Figure 
3.13), suggesting that this is not a viable explanation. 
 
It is concluded that GCS-100 has a multi-faceted role in the apoptotic 
pathway. The mechanism of its pro-apoptotic effect involves several signal 
transduction pathways activated directly or indirectly by GCS-100.  Akt can 
prevent apoptosis upstream of mitochondria, bypassing mitochondria via 
direct phosphorylation of caspase-9, or through regulation of other 
transcriptional pathways. The data presented here support the involvement of 
Akt activity and caspase-9 activation in the mechanism of GCS-100 and 
provide some understanding for the complex and intriguing role of GCS-100 
and further insights for future experiments. 
 
 
7.6 PK11195, ROS and apoptosis 
 
ROS generation is a physiological process that inevitably occurs during cell 
respiration (see 1.2.2.b). The association between ROS and apoptosis has 
been studied extensively. It is believed that tumour cells experience more 
oxidative stress than normal cells and have generally enhanced intracellular 
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ROS levels, a key feature involved in transformation, proliferation and 
tumourigenesis (Pelicano, Carney et al. 2004). However, excessive ROS also 
kill malignant cells, as it is often a concomitant phenomenon with apoptosis 
when collapse of mitochondrial inner membrane potential (DeltaPsi(m)) and 
the demise of energy production and electron transduction chain occur. 
Mitochondria are the major source of intracellular ROS (Paradies, Petrosillo 
et al. 2001; Pelicano, Carney et al. 2004). Such significant enhancement of 
intracellular ROS by PK11195 is likely to be due to its effects on 
mitochondria. Data herein have clearly demonstrated induction of ROS 
generation by PK11195 in DOHH2 cells and concomitant DeltaPsi(m) 
collapse (Figures 6.1 & 6.3). The two apoptotic events are tightly linked and, 
based on previous studies in the literature as stated above, they can be both 
cause and consequence of each other. This is also suggested by data 
presented here showing that enhancement of intracellular ROS level was 
detected at the same dose and time point after PK11195 treatment as 
DeltaPsi(m) collapse. 
 
The effects of PK11195 shown here appear to be independent of the 
mitochondrial peripheral benzodiazepine receptor (mPBR) based on the 
following findings. 
 
i) PBR gene knockout by specific antisense does not abolish the effects of 
PK11195 (Gonzalez-Polo, Carvalho et al. 2005). 
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ii) JURKAT cells, naturally lacking the mPBR expression, responded to 
PK11195 (Figure 6.5). 
iii) The dose of PK11195 (µM) required to induce apoptosis or ROS 
generation is several orders of magnitude higher than its KD for the PBR 
(nM) (Casellas, Galiegue et al. 2002). 
 
Nox-5 is a possible downstream target for PK11195. 24-hour treatment with 
75 µM PK11195 raised the Nox-5 mRNA expression level over eight fold in 
JURKAT cells (Figure 6.5), consistent with the extent of ROS-level 
enhancement by the same dose of PK11195 in the same cell type (see 1.8). 
Repeated treatment of RAMOS cells with increasing doses of PK11195 
reduced Nox-5 expression and caused resistance to PK11195 in these cells 
(Figure 6.4), indicating the existence of a negative feedback loop that 
downregulates Nox-5 after long exposure to PK11195.  
 
Nox-5 acts as a sensor of intracellular [Ca2+] through its N-terminal EF-hand 
domains (see 1.2.2.b). It could be suggested that PK11195 interferes with the 
intracellular [Ca2+] balance, a key factor in the apoptotic pathway. This 
subsequently alters the Nox-5 function as well as induces apoptosis. The 
relationship between Nox-5/intracellular [Ca2+] and PK11195/ROS/apoptosis 
remains to be fully clarified. 
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MnTBAP is a synthetic manganese superoxide dismutase (MnSOD) mimetic 
and has comparable SOD activity (Gauuan, Trova et al. 2002). It scavenges 
intracellular ROS potently and can inhibit Fas-induced apoptosis in liver cells 
(Malassagne, Ferret et al. 2001). Thus, its effect on PK11195-induced ROS 
generation and apoptosis was studied. Without inducing ROS or apoptosis on 
its own, MnTBAP significantly reduced ROS as well as apoptosis induced by 
PK11195 in DOHH2 cells (Figures 6.1 & 6.3). This further provides evidence 
that the intracellular ROS level is crucial for the apoptosis inducing effect of 
PK11195. 
 
 
Summary: Implications for cancer therapy 
 
It is axiomatic that tumour cells have survival advantages over normal cells. 
Two widely disparate synthetic molecules, GCS-100 and PK11195, can each 
overcome these advantages at least in vitro, and induce apoptosis in certain 
malignant cells, via different mechanisms. GCS-100, the putative galectin-3 
inhibitor currently in Phase II clinical trial for the treatment of various 
malignant diseases (see 1.7), selectively induces apoptosis in B-lineage 
tumour cells without appearing to affect normal lymphocytes. It also 
significantly enhances the pro-apoptotic effect of the chemotherapeutic agent 
VP-16. GCS-100 mediates two major mitochondrial apoptotic events: 
mitochondrial inner membrane potential (DeltaPsi(m)) collapse and caspase-
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9 activation. Further investigations reveal that GCS-100 causes 
dephosphorylation and inactivation of Akt, a serine/threonine kinase that 
promotes cell survival by regulating transcriptiton factors and proteins that 
control apoptosis. PK11195, a small synthetic molecule with high affinity for 
mPBR (see 1.8), induces intracellular ROS generation and subsequent 
apoptosis in malignant B cells. This appears to be due to its effect on Nox-5, 
the member of NADPH oxidase family in lymphocytes which catalyses 
intracellular ROS production. As such, the mechanisms of action of the 
respective agents are fundamentally different.  
 
Interference with cell signal transduction has been extensively explored for 
potential therapeutic strategies for the treatment of malignant disease. A 
number of anti-cancer drugs with the ability to induce apoptosis have 
exhibited sucessful clinical utility, e.g. imatinib in the treatment of chronic 
myeloid leukaemia (CML) (Ohno 2006). However, as more drugs enter the 
clinical arena, intrinsic drug resistance, due to a plethora of apoptosis-
resistant mechanisms pre-existing in cancer cells, and/or acquired drug 
resistance to the original molecular target, remain a major issue (Frame 
2007). Therefore, superior drugs that work via novel mechanisms on selective 
targets to overcome cell survival, alone or in combination with existing 
chemotherapeutic drugs, will be required for as long as cytotoxic agents are 
the mainstay of the oncologists’ armoury. 
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The data presented here in the context of agents GCS-100 and PK11195 
have revealed the complexity of the underlying mechanisms of cell survival 
and apoptosis induction in B cell malignancies. They have also provided 
some new insights which might be harnessed to help further define anti-
apoptotic strategies in cancer therapy.  
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Appendix I  CLL patients data (from Birmingham Heartlands Hospital) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient CD38 ZAP70 Mutat status 1st Treat Chlor Pred Flud Cyclo CHOP Alem Ritux Nº Treat 
  (% of  (% of  0 Unmut 0 CLB 0 No 0 No 0 No 0 No 0 No 0 No 0 No   
   positive  positive 1 Mut 1 Flud 1 Yes 1 Yes 1 Yes 1 Yes 1 Yes 1 Yes 1 Yes   
   cells)*  cells)*   2 FludCy                 
        3 CHOP                 
Fig3.5-1** 11.3 26.9 1          
Fig3.5-2 25.5 18.0 1 0 1 0 0 0 0 0 0 2 
Fig3.5-3 11.3 26.9 1          
Fig3.5-4 25.5 18.0 1 0 1 0 0 0 0 0 0 2 
Fig3.5-5 64.9 68.2 0 0 1 1 0 0 0 0 0 6 
Fig3.5-6 82.6 14.2 1 0 1 1 0 0 0 0 0 2 
Fig3.5-7 8.2 23.0  0 1 1 0 0 0 0 0 1 
Fig3.5-8 41.1 50.9 0 1 0 0 1 1 0 1 0 3 
Fig3.7-1 11.3 26.9 1          
Fig3.7-2 25.5 18.0 1 0 1 0 0 0 0 0 0 2 
Fig3.7-3 11.3 26.9 1          
Fig3.7-4 25.5 18.0 1 0 1 0 0 0 0 0 0 2 
Fig3.7-5 64.9 68.2 0 0 1 1 0 0 0 0 0 6 
Fig4.2-1 3.7 2.6 1 0 1 0 0 0 0 0 0 1 
Fig4.2-2 47.1 76.3 0 0 1 0 0 0 0 0 0 3 
Fig4.2-3 3 29.3 0 0 1 0 0 0 0 0 0 2 
Fig4.2-4 2.7 5.5 1          
Fig4.2-5 5 14.0 0 0 1 1 1 0 0 0 0 3 
Fig4.2-6 3.1 6.9 1 0 1 0 0 0 0 0 0 2 
Fig4.2-7 21.5 10.8 1 0 1 1 1 1 0 0 0 6 
Fig4.2-8 49.4 69.7 1 0 1 1 1 1 1 1 0 6 
Fig5.2 51.2 28.1 1 0 1 1 0 0 0 0 0 3 
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* Cytoplasmic ZAP-70 expression was determined by using a modification of a previously published flow cytometry 
method. Crespo, M., F. Bosch, et al. (2003). “ZAP-70 expression as a surrogate for immunoglobulin-variable-region 
mutations in chronic lymphocytic leukemia.” N Engl J Med 348(18): 1764-75. 
 
 
**Figures refer to samples from individual patients. Patients’ identities are omitted to preserve anonymity . 
 
